Compound
Compounds that modulate ERAP1 activity enhance immune recognition of cancer cells and viral antigens, addressing limitations in current treatments by increasing antigen presentation and immune response efficacy.
Patent Information
- Application Number
- JP2021528835
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-11-14
- Filing Date
- 2019-11-22
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2039-11-22
AI Technical Summary
Current treatments for diseases such as cancer, autoimmune disorders, and viral infections are limited in their ability to modulate the antigen presentation pathway, particularly the role of ERAP1, which affects the visibility of cancer cells to the immune system and the recognition of viral antigens.
Development of compounds that modulate ERAP1 activity, altering the repertoire of antigens and neoantigens presented on cancer cells and viral-infected cells, enhancing immune recognition and response.
The compounds increase the visibility of cancer cells to the immune system, leading to enhanced CD8+ T cell responses and immune-mediated tumor clearance, and improve recognition and destruction of virus-infected cells, potentially combining with existing cancer therapeutics for improved treatment outcomes.
Smart Images

Figure 0007595355000345 
Figure 0007595355000346 
Figure 0007595355000347
Abstract
Description
[Technical Field]
[0001] The present invention relates to a compound capable of modulating ERAP1. The compound has potential therapeutic applications in the treatment of various diseases including proliferative, viral, immune and inflammatory diseases. [Background technology]
[0002] ERAP1 (endoplasmic reticulum aminopeptidase 1; also known as APPILS or ARTS1) is an aminopeptidase important for the production of a proportion of antigens and neoantigens as part of the antigen presentation pathway. 1 The antigen presentation pathway begins with proteolysis into peptides by the proteasome. These peptides are transported to the endoplasmic reticulum, where a proportion are processed by ERAP1 before binding to the major histocompatibility complex class I (MHC class I). 1 The antigen bound to MHC class I is then transported to the cell surface and bound to CD8 + Neoantigens are presented to T cells and recognized as self or non-self. Neoantigens are antigens specific to cancer and can be recognized as foreign by the immune system, leading to the destruction of cancer cells. Neoantigens arise as a direct result of somatic mutations in the DNA of cancer cells, leading to the production of mutant proteins, or as an indirect consequence of somatic mutations on protein processing and expression. Those cancers with higher mutation rates, and correspondingly higher neoantigen levels, have much higher response rates to checkpoint inhibitor immunotherapies anti-PD-1 (e.g., pembrolizumab, nivolumab), anti-PD-L1 (e.g., atezolizumab, avelumab, durvalumab), and anti-CTLA4 antibodies (e.g., ipilimumab, tremelimumab) compared to cancers with fewer neoantigens. 2,3 .
[0003] The role of ERAP1 in the antigen presentation pathway is to trim a certain proportion of peptides by its aminopeptidase activity to form antigens and neoantigens of optimal length for binding to MHC class I. ERAP1 also excessively trims some neoantigens, preventing their binding to MHC class I and presentation on the cell surface. 4 It has been shown that removal of ERAP1 activity changes the antigen and neoantigen repertoire, resulting in increased presentation of certain antigens / neoantigens and completely new antigens / neoantigens. 5 Furthermore, ERAP1 deletion inhibited CD8 + Induces T cell-dependent tumor rejection 4 Therefore, modulators of ERAP1 activity may be useful in cancer treatment, either alone or in combination with current cancer immunotherapy agents including checkpoint inhibitors, to change the antigens and neoantigens presented on the surface of cancer cells, making them more visible to the immune system and leading to tumor attack and destruction.
[0004] Knockdown of ERAP1 has also been shown to reduce the levels of regulatory T cells and enhance cancer cell killing by natural killer cells. 6,7 This suggests that modulators of ERAP1 activity may be effective cancer therapeutic agents by modulating the visibility of cancer cells and generating a stronger anti-tumorigenic immune response. The role of ERAP1 in peptide processing in antigen presentation is also applicable to infectious viral diseases. Summary of the Invention [Problem to be solved by the invention]
[0005] An object of the present invention is to provide a compound capable of modulating ERAP1. Such a compound has potential therapeutic applications in the treatment of various diseases including proliferative diseases, immune diseases, and inflammatory diseases. [Means for solving the problem]
[0006] A first aspect of the present invention is a compound of formula (Ia)
[0007] [ka]
[0008] (In the formula, The XY group is -NHSO2- or -SO2NH-; R1 is H or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is selected from H, Cl and alkyl; R4 is selected from H, Cl and F; R5 is selected from H, alkyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, alkynyl, alkenyl, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R6 is H; R7 is H, CN, haloalkyl, Cl, F, SO2-alkyl, SO2NR 13 R 14 , heteroaryl and alkyl, wherein the heteroaryl group is optionally substituted with one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; R8 is selected from H, alkyl, haloalkyl, and halo; R9 is H, C1-C3-alkyl or halo; R 10 and R 11taken together with the nitrogen to which they are attached form an azepanyl group, (a) the azepanyl group is substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, which may in turn be further substituted with one or more groups selected from halo and alkyl, or (b) one or two carbons in the azepanyl group are replaced with a group selected from O, NH, S, and CO, and the azepanyl group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, which may in turn be further substituted with one or more groups selected from halo and alkyl; or R 10 and R 11 taken together with the nitrogen to which they are attached form an azetidinyl, pyrrolidinyl, or piperidinyl group, (a) the azetidinyl, pyrrolidinyl, or piperidinyl group is substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, which heteroaryl groups may in turn be further substituted with one or more groups selected from halo and alkyl, or (b) one or two carbons in the azetidinyl, pyrrolidinyl, or piperidinyl group are replaced with a group selected from NH, S, and CO; or R 10 and R 11 together with the nitrogen to which they are attached form an 8-, 9-, or 10-membered bicyclic heterocycloalkyl group, wherein one or two carbons in the bicyclic heterocycloalkyl ring are optionally replaced with groups selected from O, NH, S, and CO, and said bicyclic heterocycloalkyl group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl; or R 10 and R 11together with the nitrogen to which they are attached form a 6-12 membered bicyclic group containing spiro ring carbon atoms, in which one or two carbons in the bicyclic group are optionally replaced with a group selected from O, NH, S and CO, and in which the bicyclic group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, or in which the bicyclic group is optionally fused to a 5- or 6-membered aryl or heteroaryl group; R 13 and R 14 and R are each independently H or alkyl, or a pharmaceutically acceptable salt or hydrate thereof.
[0009] A second aspect of the present invention is a compound of formula (Ib)
[0010] [ka]
[0011] (In the formula, The XY group is -NHSO2- or -SO2NH-; R1 is H or alkyl; R2 is a tetrazolyl group; R3 is selected from H, Cl and alkyl; R4 is selected from H, Cl and F; R5 is selected from H, alkyl, alkynyl, alkenyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R6 is H; R7 is H, CN, haloalkyl, Cl, F, SO2-alkyl, SO2NR 13 R 14 , heteroaryl and alkyl, wherein the heteroaryl group is optionally substituted with one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; R8 is selected from H, alkyl, haloalkyl, and halo; R9 is H, C1-C3-alkyl or halo; R 10 is H or alkyl; R 11 are NH2, OH, and NHC02R 12 (In the formula, R 12 is alkyl); or R 10 and R 11 together with the nitrogen to which they are attached form a 4-, 5-, 6-, or 7-membered monocyclic heterocycloalkyl group, in which one or two carbons are optionally replaced with groups selected from O, NH, S, and CO, said monocyclic heterocycloalkyl group being optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, which heteroaryl groups may in turn be further substituted with one or more groups selected from halo and alkyl; or R 10 and R 11 together with the nitrogen to which they are attached form an 8-, 9-, or 10-membered bicyclic heterocycloalkyl group, wherein one or two carbons in the bicyclic heterocycloalkyl ring are optionally replaced with groups selected from O, NH, S, and CO, and said bicyclic heterocycloalkyl group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl; or R 10 and R 11together with the nitrogen to which they are attached form a 6-12 membered bicyclic group containing spiro ring carbon atoms, in which one or two carbons in the bicyclic group are optionally replaced with a group selected from O, NH, S and CO, and in which the bicyclic group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, or in which the bicyclic group is optionally fused to a 5- or 6-membered aryl or heteroaryl group; R 13 and R 14 and R are each independently H or alkyl, or a pharmaceutically acceptable salt or hydrate thereof.
[0012] A third aspect of the present invention is a compound of formula (Ic)
[0013] [ka]
[0014] (In the formula, X is SO2; Y is NH; R1 is H or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is selected from H, Cl and alkyl; R4 is selected from H, Cl and F; R5 is selected from H, alkyl, alkynyl, alkenyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R6 is H; R7 is H, CN, haloalkyl, Cl, F, SO2-alkyl, SO2NR 13 R 14 , heteroaryl and alkyl, wherein the heteroaryl group is optionally substituted with one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; R8 is selected from H, alkyl, haloalkyl, and halo; R9 is H, C1-C3-alkyl or halo; R 10 is H or alkyl; R 11 are NH2, OH, and NHC02R 12 (In the formula, R 12 is alkyl); or R 10 and R 11 together with the nitrogen to which they are attached form a 4-, 5-, 6-, or 7-membered monocyclic heterocycloalkyl group, in which one or two carbons are optionally replaced with groups selected from O, NH, S, and CO, said monocyclic heterocycloalkyl group being optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, which heteroaryl groups may in turn be further substituted with one or more groups selected from halo and alkyl; or R 10 and R 11 together with the nitrogen to which they are attached form an 8-, 9-, or 10-membered bicyclic heterocycloalkyl group, wherein one or two carbons in the bicyclic heterocycloalkyl ring are optionally replaced with groups selected from O, NH, S, and CO, and said bicyclic heterocycloalkyl group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl; or R 10 and R 11together with the nitrogen to which they are attached form a 6-12 membered bicyclic group containing spiro ring carbon atoms, in which one or two carbons in the bicyclic group are optionally replaced with a group selected from O, NH, S and CO, and in which the bicyclic group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, or in which the bicyclic group is optionally fused to a 5- or 6-membered aryl or heteroaryl group; R 13 and R 14 and R are each independently H or alkyl, or a pharmaceutically acceptable salt or hydrate thereof.
[0015] A fourth aspect of the present invention is a compound of formula (Id)
[0016] [ka]
[0017] (In the formula, The XY group is -NHSO2- or -SO2NH-; R1 is H or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is selected from H, Cl and alkyl; R4 is selected from H, Cl and F; R5 is selected from H, alkyl, alkynyl, alkenyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R6 is H; R7 is CN, SO2-alkyl, SO2NR 13 R 14 or a heteroaryl group, said heteroaryl group being optionally substituted with one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl, and OH; R8 is selected from H, alkyl, haloalkyl, and halo; R9 is H, C1-C3-alkyl or halo; R 10 is H or alkyl; R 11 are NH2, OH, and NHC02R 12 (In the formula, R 12 is alkyl); or R 10 and R 11 together with the nitrogen to which they are attached form a 4-, 5-, 6-, or 7-membered monocyclic heterocycloalkyl group, in which one or two carbons are optionally replaced with groups selected from O, NH, S, and CO, said monocyclic heterocycloalkyl group being optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, which heteroaryl groups may in turn be further substituted with one or more groups selected from halo and alkyl; or R 10 and R 11 together with the nitrogen to which they are attached form an 8-, 9-, or 10-membered bicyclic heterocycloalkyl group, wherein one or two carbons in the bicyclic heterocycloalkyl ring are optionally replaced with groups selected from O, NH, S, and CO, and said bicyclic heterocycloalkyl group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl; or R 10 and R 11together with the nitrogen to which they are attached form a 6-12 membered bicyclic group containing spiro ring carbon atoms, in which one or two carbons in the bicyclic group are optionally replaced with a group selected from O, NH, S and CO, and in which the bicyclic group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, or in which the bicyclic group is optionally fused to a 5- or 6-membered aryl or heteroaryl group; R 13 and R 14 and R are each independently H or alkyl, or a pharmaceutically acceptable salt or hydrate thereof.
[0018] Advantageously, the compounds claimed in the present application can modulate ERAP1, which makes the compounds therapeutically interesting in the treatment of various diseases, for example, in the fields of oncology and immuno-oncology.
[0019] A fifth aspect of the present invention relates to a pharmaceutical composition comprising at least one compound as described above and a pharmaceutically acceptable carrier, diluent or excipient.
[0020] A sixth aspect of the invention relates to a compound as described above for use in medicine.
[0021] A seventh aspect of the present invention relates to a compound as described above for use in the treatment or prevention of a disease selected from a proliferative disease, an immune disease, a viral disease and an inflammatory disease.
[0022] An eighth aspect of the present invention relates to the use of a compound as described above in the preparation of a medicament for the treatment or prevention of a disease selected from a proliferative disease, an immune disease, a viral disease and an inflammatory disease.
[0023] The ninth aspect of the present invention relates to the above-mentioned compound for use in the prevention or treatment of a disease caused by, related to, or accompanied by any abnormal ERAP1 activity.
[0024] The tenth aspect of the present invention relates to use of the above-mentioned compound in preparing a medicament for preventing or treating a disease caused by, related to, or accompanied by abnormal ERAP1 activity.
[0025] An eleventh aspect of the present invention relates to a method for treating a mammal having a disease condition that is alleviated by modulating ERAP1, the method comprising the step of administering a therapeutically effective amount of the above-mentioned compound to the mammal.
[0026] A twelfth aspect of the present invention relates to the above-mentioned compound for use in the treatment or prevention of a disease state that is alleviated by modulating ERAP1.
[0027] A thirteenth aspect of the present invention relates to use of the above-mentioned compound in preparing a medicament for treating or preventing a disease state that is alleviated by modulating ERAP1.
[0028] A fourteenth aspect of the present invention relates to a method of treating or preventing a disease selected from a proliferative disease, an immune disease, a viral disease and an inflammatory disease in a subject, the method comprising the step of administering to the subject a therapeutically effective amount of a compound as described above.
[0029] A fifteenth aspect of the present invention relates to a compound of formula (I) for use in the treatment or prevention of a disease selected from a proliferative disease, an immune disease, a viral disease and an inflammatory disease.
[0030] [ka]
[0031] (In the formula, The XY group is -NHSO2- or -SO2NH-; R1 is H or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is selected from H, Cl and alkyl; R4 is selected from H, Cl and F; R5 is selected from H, alkyl, alkynyl, alkenyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R6 is H; R7 is H, CN, haloalkyl, Cl, F, SO2-alkyl, SO2NR 13 R 14 , heteroaryl and alkyl, wherein the heteroaryl group is optionally substituted with one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; R8 is selected from H, alkyl, haloalkyl, and halo; R9 is H, C1-C3-alkyl or halo; R 10 is H or alkyl; R 11 are NH2, OH, and NHC02R 12 (In the formula, R 12 is alkyl); or R 10 and R 11 together with the nitrogen to which they are attached form a 4-, 5-, 6-, or 7-membered monocyclic heterocycloalkyl group, in which one or two carbons are optionally replaced with groups selected from O, NH, S, and CO, said monocyclic heterocycloalkyl group being optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, which heteroaryl groups may in turn be further substituted with one or more groups selected from halo and alkyl; or R 10 and R 11together with the nitrogen to which they are attached form an 8-, 9-, or 10-membered bicyclic heterocycloalkyl group, wherein one or two carbons in the bicyclic heterocycloalkyl ring are optionally replaced with groups selected from O, NH, S, and CO, and said bicyclic heterocycloalkyl group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl; or R 10 and R 11 together with the nitrogen to which they are attached form a 6-12 membered bicyclic group containing spiro ring carbon atoms, in which one or two carbons in the bicyclic group are optionally replaced with a group selected from O, NH, S and CO, and in which the bicyclic group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, or in which the bicyclic group is optionally fused to a 5- or 6-membered aryl or heteroaryl group; R 13 and R 14 and R are each independently H or alkyl, or a pharmaceutically acceptable salt or hydrate thereof. DETAILED DESCRIPTION OF THE INVENTION
[0032] The present invention relates to a bis-arylsulfonamide compound capable of modulating ERAP1. Preferably, the compound selectively modulates ERAP1.
[0033] "Alkyl" as used herein refers to a linear or branched alkyl radical, preferably C 1-20 Alkyl, more preferably C 1-12 Alkyl, even more preferably C 1-10 Alkyl or C 1-6 Alkyl or C 1-3 -alkyl. Examples of suitable alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, and hexyl.
[0034] "Cycloalkyl" as used herein refers to a monocyclic alkyl ring, preferably C 3-7 -cycloalkyl, more preferably C 3-6 -cycloalkyl. Preferred examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, or fused bicyclic ring systems such as norbornane.
[0035] "Halogen" is defined herein as chloro, fluoro, bromo, or iodo.
[0036] As used herein, the term "aryl" refers to an optionally benzo-fused C 6-12 It refers to an aromatic group such as phenyl or naphthyl.
[0037] "Heteroaryl" as used herein refers to a monocyclic or bicyclic C alkyl group containing one or more heteroatoms (which may be the same or different), such as oxygen, nitrogen, or sulfur. 2-12Examples of suitable heteroaryl groups include thienyl, furanyl, pyrrolyl, pyridinyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, and the like, and benzo derivatives thereof, such as benzofuranyl, benzothienyl, benzimidazolyl, indolyl, isoindolyl, indazolyl, and the like; or pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, and the like, and benzo derivatives thereof, such as quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and the like.Particularly preferred heteroaryl groups are 1H-imidazol-5-yl, 1H-imidazol-4-yl, 1H-imidazol-2-yl, 1H-pyrrol-1-yl, 1H-pyrrol-2-yl, 1H-pyrrol-3-yl, 1H-pyrrol-4-yl, 1H-pyrrol-5-yl, 1H-pyrazol-1-yl, 1H-pyrazol-5-yl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, oxazol-2-yl , oxazol-4-yl, oxazol-5-yl, 1H-1,2,4-triazol-3-yl, 1H-1,2,4-triazol-5-yl, 1H-1,2,4-triazol-1-yl, 1H-1,2,3-triazol-4-yl, 1H-1,2,3-triazol-5-yl, 1H-1,2,3-triazol-1-yl, thiazol-5-yl, thiazol-4-yl, thiazol-2-yl, 1H-1,2,3,4 -tetrazol-4-yl, 2H-1,2,3,4-tetrazol-5-yl, oxazol-5-yl, oxazol-4-yl, oxazol-2-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, pyrazidin-3-yl, pyrazidin-4-yl, pyrazinyl, 1,3,4-oxadiazo Examples of oxadiazol-2-yl include 1,3,4-oxadiazol-5-yl, 1,2,5-oxadiazol-3-yl, 1,2,5-oxadiazol-4-yl, 1,2,3-oxadiazol-4-yl, 1,2,3-oxadiazol-5-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, isoxazol-5-yl, isoxazol-4-yl and isoxazol-3-yl.
[0038] "Heterocycloalkyl" refers to a cyclic aliphatic group containing one or more heteroatoms selected from nitrogen, oxygen, and sulfur, which may be interrupted by one or more -(CO)- groups within the ring and / or may contain one or more double bonds within the ring. Preferably, heterocycloalkyl groups are monocyclic or bicyclic. Preferably, heterocycloalkyl groups are C 3-7-heterocycloalkyl, more preferably C 3-6 Alternatively, the heterocycloalkyl group is C 4-7 -heterocycloalkyl, more preferably C 4-6 -heterocycloalkyl. Preferred heterocycloalkyl groups include, but are not limited to, piperazinyl, piperidinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, tetrahydrofuranyl, and tetrahydropyranyl. Preferably, the heterocycloalkyl group is fully saturated.
[0039] "Azepanyl" refers to a 7-membered saturated heterocyclic ring containing 6 carbon atoms and 1 nitrogen atom. "Piperidinyl" refers to a 6-membered saturated heterocyclic ring containing 5 carbon atoms and 1 nitrogen atom. "Pyrrolidinyl" refers to a 5-membered saturated heterocyclic ring containing 4 carbon atoms and 1 nitrogen atom. "Azetidinyl" refers to a 4-membered saturated heterocyclic ring containing 3 carbon atoms and 1 nitrogen atom.
[0040] Compounds of formula (Ia) One aspect of the present invention relates to compounds of formula (Ia) as described above.
[0041] In one preferred embodiment, R1 is H or Me, more preferably H.
[0042] In one preferred embodiment, R2 is COOH.
[0043] In one preferred embodiment, XY is NH—SO.
[0044] In one preferred embodiment, R5 is selected from alkyl, alkenyl, alkynyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl, and haloalkoxy.
[0045] In one preferred embodiment, R5 is selected from H, Me, CF3, CHF2, SO2-Me, Cl, ethynyl, MeO, OH, CH2OH, SMe, cyclopropyl, triazolyl, oxetanyl, and CN. More preferably, R5 is selected from H, CN, Me, SO2-Me, CF3, CHF2, CH2OH, SMe, cyclopropyl, 3,4-triazol-1-yl, and oxetan-3-yl. More preferably, R5 is selected from H, CN, Me, SO2-Me, CF3, and CHF2.
[0046] In another preferred embodiment, R5 is selected from OMe, Me, Et, Pr, ethynyl and Cl, more preferably OMe, Me, Et, Pr and Cl, more preferably OMe or Et.
[0047] In one preferred embodiment, R7 is H, CN, haloalkyl, Cl, F, SO2-alkyl, SO2NR 13 R 14 , heteroaryl and alkyl.
[0048] In one preferred embodiment, R7 is selected from H, CN, CF3, CHF2, Cl, F, SO2-Me, SO2NH2, heteroaryl, and Me. More preferably, R7 is selected from H, CN, Me, SO2-Me, tetrazolyl, CF3, and CHF2.
[0049] In one preferred embodiment, R7 is CF3.
[0050] In one preferred embodiment, R7 is CN.
[0051] In another preferred embodiment, R7 is SO2-alkyl, more preferably SO2-Me.
[0052] In one preferred embodiment, R7 is SO2NR 13 R 14 , more preferably SO2NH2.
[0053] In one preferred embodiment, R7 is a heteroaryl group optionally substituted with one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl, and OH.
[0054] In one preferred embodiment, R 7 is a heteroaryl group selected from pyridinyl, thienyl, imidazolyl, pyrimidinyl, pyrazolyl, pyrazinyl, pyrazidinyl, thiazolyl, isothiazolyl, triazinyl, pyrrolyl, furanyl, oxazolyl, isoxazolyl, oxadiazolyl, tetrazolyl, and triazolyl, each of which is optionally substituted with one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl, and OH.
[0055] In one preferred embodiment, R 7 is a heteroaryl group selected from imidazolyl, pyrazolyl, pyrazinyl, pyrazidinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, tetrazolyl, and triazolyl, each of which is optionally substituted with one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl, and OH.
[0056] In one preferred embodiment, R 7are 1H-imidazol-5-yl, 1H-imidazol-4-yl, 1H-imidazol-2-yl, 1H-pyrrol-1-yl, 1H-pyrrol-2-yl, 1H-pyrrol-3-yl, 1H-pyrrol-4-yl, 1H-pyrrol-5-yl, 1H-pyrazol-1-yl, 1H-pyrazol-5-yl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, 1H-1,2 ,4-triazol-3-yl, 1H-1,2,4-triazol-5-yl, 1H-1,2,4-triazol-1-yl, 1H-1,2,3-triazol-4-yl, 1H-1,2,3-triazol-5-yl, 1H-1,2,3-triazol-1-yl, thiazol-5-yl, thiazol-4-yl, thiazol-2-yl, 1H-1,2,3,4-tetrazol-4-yl, 2H-1,2,3,4-tetrazol-5-yl, oxazol-5-yl , oxazol-4-yl, oxazol-2-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, pyrazidin-3-yl, pyrazidin-4-yl, pyrazinyl, 1,3,4-oxadiazol-2-yl, 1,3,4-oxadiazol-5-yl, 1,2,5-oxadiazol-3-yl, 1,2,5-oxadiazol-4-yl and heteroaryl groups selected from 1,2,3-oxadiazol-4-yl, 1,2,3-oxadiazol-5-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, isoxazol-5-yl, isoxazol-4-yl and isoxazol-3-yl, each of which may be substituted by one or more substituents selected from alkyl, halo, CN, alkoxy, haloalkyl and OH.
[0057] In one highly preferred embodiment, R 7is a heteroaryl group selected from 1H-pyrazol-5-yl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, oxazol-2-yl, 1H-1,2,3-triazol-4-yl, 1H-1,2,3-triazol-5-yl, thiazol-5-yl, 1H-1,2,3,4-tetrazol-4-yl, 2H-1,2,3,4-tetrazol-5-yl, isoxazol-4-yl, isoxazol-5-yl, isothiazol-5-yl, pyrazidin-3-yl, pyrazidin-4-yl, pyrazinyl, and 1,3,4-oxadiazol-2-yl, each of which is optionally substituted with one or more substituents selected from Me, F, Cl, CN, and MeO.
[0058] In one preferred embodiment, R 7 is a heteroaryl group optionally substituted with one or more alkyl groups, preferably one or more Me groups.
[0059] In one preferred embodiment, R7 is haloalkyl or heteroaryl, more preferably tetrazolyl.
[0060] In one preferred embodiment, R7 is haloalkyl, more preferably CF3.
[0061] In one preferred embodiment, R8 is H or haloalkyl, more preferably H or CF3, and even more preferably H.
[0062] In one preferred embodiment, R8 is selected from H, Me, CF3, Cl, Br and F.
[0063] In another preferred embodiment, R8 is selected from H, haloalkyl, and Cl.
[0064] In one preferred embodiment, R9 is H, Me or F, more preferably H or F, more preferably H.
[0065] In one preferred embodiment, R1, R3, R4, R6, R8 and R9 are all H.
[0066] In one preferred embodiment, R2 is COOH; XY is NH-SO2; R5 is selected from OMe, Me, Et, Pr and Cl, more preferably OMe; R1, R3, R4, R6, R8 and R9 are all H; R7 is haloalkyl, more preferably CF3.
[0067] In one preferred embodiment, R 10 and R 11 taken together with the nitrogen to which they are attached form an azepanyl group, wherein (a) the azepanyl group is substituted with one or more (more preferably one or two) groups selected from alkyl, CN, halo, and heteroaryl, which may in turn be further substituted with one or more (more preferably one or two) groups selected from halo and alkyl, or (b) one or two carbons in the azepanyl group are replaced with a group selected from O, NH, S, and CO, and the azepanyl group is optionally substituted with one or more (more preferably one or two) groups selected from alkyl, CN, halo, and heteroaryl, which may in turn be further substituted with one or more (more preferably one or two) groups selected from halo and alkyl.
[0068] In one preferred embodiment, R 10 and R 11taken together with the nitrogen to which they are attached form an azetidinyl, pyrrolidinyl, or piperidinyl group, wherein (a) the azetidinyl, pyrrolidinyl, or piperidinyl group is substituted with one or more groups (more preferably one or two groups) selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, which heteroaryl groups may in turn be further substituted with one or more groups (more preferably one or two groups) selected from halo and alkyl, or (b) one or two carbons in the azetidinyl, pyrrolidinyl, or piperidinyl group are replaced with groups selected from NH, S, and CO.
[0069] In one preferred embodiment, R 10 and R 11 together with the nitrogen to which they are attached form an azetidinyl, pyrrolidinyl, or piperidinyl group, which is substituted with one or more groups (more preferably one or two groups) selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, which heteroaryl groups may in turn be further substituted with one or more groups (more preferably one or two groups) selected from halo and alkyl.
[0070] In one preferred embodiment, R 10 and R 11 together with the nitrogen to which they are attached, C 1-3 -Alkyl, CN, C 3-6 -cycloalkyl, OH, C 1-3 - forms an azetidinyl group substituted with one or more groups (more preferably one or two groups) selected from alkoxy, halo and CF3.
[0071] In one preferred embodiment, R 10 and R 11 together with the nitrogen to which they are attached, C 1-3 -Alkyl, CN, C 3-6 -cycloalkyl, OH, C1-3 -forming a pyrrolidinyl group substituted by one or more groups (more preferably one or two groups) selected from alkoxy, halo and CF3.
[0072] In one preferred embodiment, R 10 and R 11 together with the nitrogen to which they are attached, C 1-3 -Alkyl, CN, C 3-6 -cycloalkyl, OH, C 1-3 -forming a piperidinyl group substituted by one or more groups (more preferably one or two groups) selected from alkoxy, halo and CF3.
[0073] In one preferred embodiment, R 10 and R 11 taken together with the nitrogen to which they are attached form an 8-, 9-, or 10-membered bicyclic heterocycloalkyl group, wherein one or two carbons in the bicyclic heterocycloalkyl ring are optionally replaced with groups selected from O, NH, S, and CO, and wherein the bicyclic heterocycloalkyl group is optionally substituted with one or more groups (more preferably one or two groups) selected from alkyl, CN, OH, and halo.
[0074] In one preferred embodiment, R 10 and R 11 together with the nitrogen to which they are attached form an 8-, 9-, or 10-membered bridged bicyclic heterocycloalkyl group, wherein one or two carbons in the bridged bicyclic heterocycloalkyl ring are optionally replaced with groups selected from O, NH, S, and CO, and wherein the bicyclic heterocycloalkyl group is optionally substituted with one or more groups (more preferably one or two groups) selected from alkyl, CN, OH, and halo.
[0075] In one preferred embodiment, R 10 and R 11together with the nitrogen to which they are attached form a piperidinyl group optionally substituted with one or more groups (more preferably one or two groups) selected from alkyl, CN, OH and halo, wherein two non-adjacent ring carbons in said piperidinyl group are linked to each other via a two-carbon or three-carbon alkylene bridge.
[0076] In one preferred embodiment, R 10 and R 11 together with the nitrogen to which they are attached form a 6-12 membered bicyclic group containing spiro ring carbon atoms, one carbon in the bicyclic group optionally being replaced by O, the bicyclic group optionally being substituted with one or more groups (more preferably one or two groups) selected from alkyl, CN, halo and heteroaryl, or the bicyclic group optionally being fused to a 5 or 6 membered aryl or heteroaryl group. Preferably, R 10 and R 11 taken together with the nitrogen to which they are attached form a 7- to 12-membered bicyclic group containing a spiro ring carbon atom.
[0077] In one preferred embodiment, R 10 and R 11 together with the nitrogen to which they are attached form a bicyclic group containing a spiro ring carbon atom, which group has the following formula (Z):
[0078] [ka]
[0079] (In the formula, m is 1 or 2; n is 1, 2 or 3; Ring A is a 3-, 4-, 5-, or 6-membered cycloalkyl or heterocycloalkyl group.
[0080] In one preferred embodiment, ring A is a 3-membered cycloalkyl or heterocycloalkyl group.
[0081] In one preferred embodiment, ring A is a 4-membered cycloalkyl or heterocycloalkyl group.
[0082] In one preferred embodiment, ring A is a 5-membered cycloalkyl or heterocycloalkyl group.
[0083] In one preferred embodiment, ring A is a 6-membered cycloalkyl or heterocycloalkyl group.
[0084] In one preferred embodiment, m is 1 and n is 1.
[0085] In one preferred embodiment, m is 1 and n is 2.
[0086] In one preferred embodiment, m is 2 and n is 2.
[0087] In one preferred embodiment, m is 2 and n is 3.
[0088] In one preferred embodiment, R 10 and R 11 together with the nitrogen to which they are attached form a 7-membered bicyclic group containing spiro ring carbon atoms, one carbon in the bicyclic group being replaced with O, and the bicyclic group being optionally substituted with one or more groups (more preferably one or two groups) selected from alkyl, halo, and heteroaryl.
[0089] In one preferred embodiment, R 10 and R 11 together with the nitrogen to which they are attached form an 8-membered bicyclic group containing spiro ring carbon atoms, one carbon in the bicyclic group being replaced with O, and the bicyclic group being optionally substituted with one or more groups selected from alkyl, halo, and heteroaryl.
[0090] In one preferred embodiment, R 10 and R11 together with the nitrogen to which they are attached form a 9-membered bicyclic group containing spiro ring carbon atoms, one carbon in the bicyclic group being replaced with O, and the bicyclic group being optionally substituted with one or more groups (more preferably one or two groups) selected from alkyl, halo, and heteroaryl.
[0091] In one preferred embodiment, R 10 and R 11 together with the nitrogen to which they are attached form a 10-membered bicyclic group containing spiro ring carbon atoms, one carbon in the bicyclic group being replaced with O, and the bicyclic group being optionally substituted with one or more groups (more preferably one or two groups) selected from alkyl, halo, and heteroaryl.
[0092] In one preferred embodiment, R 10 and R 11 together with the nitrogen to which they are attached form an 11-membered bicyclic group containing spiro ring carbon atoms, one carbon in the bicyclic group being replaced with O, and the bicyclic group being optionally substituted with one or more groups (more preferably one or two groups) selected from alkyl, halo, and heteroaryl.
[0093] In one preferred embodiment, R 10 and R 11 together with the nitrogen to which they are attached form a 12-membered bicyclic group containing spiro ring carbon atoms, one carbon in the bicyclic group being replaced with O, and the bicyclic group being optionally substituted with one or more groups (more preferably one or two groups) selected from alkyl, halo, and heteroaryl.
[0094] In one preferred embodiment, R 10 and R 11together with the nitrogen to which they are attached form a bicyclic group containing a ring system selected from the spiro[3.3]heptane, spiro[3.4]octane, spiro[3.5]nonane, spiro[4.4]nonane, spiro[4,5]decane, spiro[3.6]decane, spiro[5.5]undecane, and spiro[5,6]dodecane configurations, and in each of the above bicyclic groups, NR 10 R 11 The nitrogen of the group forms a member of a ring system, and other carbons in the ring system may be replaced with O, and the bicyclic group may be optionally substituted with one or more groups (more preferably one or two groups) selected from alkyl, halo, and heteroaryl.
[0095] In one preferred embodiment, NR 10 R 11 teeth,
[0096] [ka]
[0097] is selected from.
[0098] In one preferred embodiment, NR 10 R 11 teeth,
[0099] [ka]
[0100] is selected from.
[0101] In one preferred embodiment, NR 10 R 11 teeth,
[0102] [ka]
[0103] is selected from.
[0104] In one preferred embodiment, R2 is COOH; XY is NH-SO2; R5 is cyclopropyl; R1, R3, R4, R6, R8 and R9 are all H; R7 is selected from CN, haloalkyl, heteroaryl and SO2-alkyl; NR 10 R 11 teeth,
[0105] [ka]
[0106] is selected from.
[0107] In one preferred embodiment, R2 is COOH; XY is NH-SO2; R5 is cyclopropyl; R1, R3, R4, R6, R8 and R9 are all H; R7 is selected from CN, CF3, tetrazoyl and SO2-Me, more preferably CN and SO2-Me; NR 10 R 11 teeth,
[0108] [ka]
[0109] is selected from.
[0110] In one preferred embodiment, R2 is COOH; XY is NH-SO2; R5 is ethyl; R1, R3, R4, R6, R8 and R9 are all H; R7 is selected from CN, haloalkyl, heteroaryl and SO2-alkyl; NR 10 R 11 teeth,
[0111] [ka]
[0112] is selected from.
[0113] In one preferred embodiment, R2 is COOH; XY is NH-SO2; R5 is ethyl; R1, R3, R4, R6, R8 and R9 are all H; R7 is selected from CN and CF3; NR 10 R 11 teeth,
[0114] [ka]
[0115] is.
[0116] In one preferred embodiment, R2 is COOH; XY is NH-SO2; R5 is OMe; R1, R3, R4, R6, R8 and R9 are all H; R7 is selected from CN, haloalkyl, heteroaryl and SO2-alkyl; NR 10 R 11 teeth,
[0117] [ka]
[0118] is selected from.
[0119] In one preferred embodiment, R2 is COOH; XY is NH-SO2; R5 is OMe; R1, R3, R4, R6, R8 and R9 are all H; R7 is selected from CF3 and SO2-Me; NR 10 R 11 teeth,
[0120] [ka]
[0121] is selected from.
[0122] In one preferred embodiment, the compound of formula (Ia) is
[0123] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka]
[0124] and pharmaceutically acceptable salts and hydrates thereof.
[0125] Compound of formula (Ib) Another aspect of the present invention is a compound of formula (Ib)
[0126] [ka]
[0127] (In the formula, The XY group is -NHSO2- or -SO2NH-; R1 is H or alkyl; R2 is a tetrazolyl group; R3 is selected from H, Cl and alkyl; R4 is selected from H, Cl and F; R5 is selected from H, alkyl, alkynyl, alkenyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R6 is H; R7 is H, CN, haloalkyl, Cl, F, SO2-alkyl, SO2NR 13 R 14 , heteroaryl and alkyl, wherein the heteroaryl group is optionally substituted with one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; R8 is selected from H, alkyl, haloalkyl, and halo; R9 is H; R9 is H, C1-C3-alkyl or halo; R11 are NH2, OH, and NHC02R 12 (In the formula, R 12 is alkyl); or R 10 and R 11 together with the nitrogen to which they are attached form a 4-, 5-, 6-, or 7-membered monocyclic heterocycloalkyl group, in which one or two carbons are optionally replaced with groups selected from O, NH, S, and CO, said monocyclic heterocycloalkyl group being optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, which heteroaryl groups may in turn be further substituted with one or more groups selected from halo and alkyl; or R 10 and R 11 together with the nitrogen to which they are attached form an 8-, 9-, or 10-membered bicyclic heterocycloalkyl group, wherein one or two carbons in the bicyclic heterocycloalkyl ring are optionally replaced with groups selected from O, NH, S, and CO, and said bicyclic heterocycloalkyl group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl; or R 10 and R 11 together with the nitrogen to which they are attached form a 6-12 membered bicyclic group containing spiro ring carbon atoms, in which one or two carbons in the bicyclic group are optionally replaced with a group selected from O, NH, S and CO, and in which the bicyclic group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, or in which the bicyclic group is optionally fused to a 5- or 6-membered aryl or heteroaryl group; R 13 and R 14and R are each independently H or alkyl, or a pharmaceutically acceptable salt or hydrate thereof.
[0128] In one preferred embodiment, R 10 and R 11 together with the nitrogen to which they are attached form a 4-, 5-, 6-, or 7-membered monocyclic heterocycloalkyl group, in which one or two carbons are optionally replaced with a group selected from O, NH, S, and CO, and the monocyclic heterocycloalkyl group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, which in turn may be further substituted with one or more groups selected from halo and alkyl. More preferably, R 10 and R 11 taken together with the nitrogen to which they are attached form a piperidinyl, pyrrolidinyl, azepanyl, or azetidinyl group, each of which is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, and haloalkyl.
[0129] In one preferred embodiment, R 10 and R 11 together with the nitrogen to which they are attached form a 6-membered monocyclic heterocycloalkyl group selected from piperidinyl, morpholinyl, thiomorpholinyl, and piperazinyl, each of which is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, which in turn may be further substituted with one or more groups selected from halo and alkyl. More preferably, R 10 and R 11together with the nitrogen to which they are attached form a 6-membered monocyclic heterocycloalkyl group selected from piperidinyl, morpholinyl, thiomorpholinyl, and piperazinyl, each of which is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, and haloalkyl.
[0130] In one preferred embodiment, R 10 and R 11 taken together with the nitrogen to which they are attached form a piperidinyl group, wherein one or two carbons in the monocyclic heterocycloalkyl group are optionally replaced with groups selected from O, NH, S, and CO, and the piperidinyl group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, which in turn may be further substituted with one or more groups selected from halo and alkyl. In one highly preferred embodiment, R 10 and R 11 taken together with the nitrogen to which they are attached form an unsubstituted piperidinyl or pyrrolidinyl group, more preferably an unsubstituted piperidinyl.
[0131] R1, R 3-11 Other preferred definitions for the groups X and Y are as given above for compounds of formula (Ia) and apply mutatis mutandis to compounds of formula (Ib).
[0132] In one preferred embodiment, the compound of formula (Ib) is
[0133] [ka]
[0134] or a pharmaceutically acceptable salt or hydrate thereof.
[0135] Compound of formula (Ic) Another aspect of the present invention is a compound of formula (Ic)
[0136] [ka]
[0137] (In the formula, X is SO2; Y is NH; R1 is H or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is selected from H, Cl and alkyl; R4 is selected from H, Cl and F; R5 is selected from H, alkyl, alkynyl, alkenyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R6 is H; R7 is H, CN, haloalkyl, Cl, F, SO2-alkyl, SO2NR 13 R 14 , heteroaryl and alkyl, wherein the heteroaryl group is optionally substituted with one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; R8 is selected from H, alkyl, haloalkyl, and halo; R9 is H, C1-C3-alkyl or halo; R 10 is H or alkyl; R 11 are NH2, OH, and NHC02R 12 (In the formula, R 12 is alkyl); or R 10 and R 11together with the nitrogen to which they are attached form a 4-, 5-, 6-, or 7-membered monocyclic heterocycloalkyl group, in which one or two carbons are optionally replaced with groups selected from O, NH, S, and CO, said monocyclic heterocycloalkyl group being optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, which heteroaryl groups may in turn be further substituted with one or more groups selected from halo and alkyl; or R 10 and R 11 together with the nitrogen to which they are attached form an 8-, 9-, or 10-membered bicyclic heterocycloalkyl group, wherein one or two carbons in the bicyclic heterocycloalkyl ring are optionally replaced with groups selected from O, NH, S, and CO, and said bicyclic heterocycloalkyl group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl; or R 10 and R 11 together with the nitrogen to which they are attached form a 6-12 membered bicyclic group containing spiro ring carbon atoms, in which one or two carbons in the bicyclic group are optionally replaced with a group selected from O, NH, S and CO, and in which the bicyclic group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, or in which the bicyclic group is optionally fused to a 5- or 6-membered aryl or heteroaryl group; R 13 and R 14 and R are each independently H or alkyl, or a pharmaceutically acceptable salt or hydrate thereof.
[0138] In one preferred embodiment, R 10 and R 11together with the nitrogen to which they are attached form a 4-, 5-, 6-, or 7-membered monocyclic heterocycloalkyl group, in which one or two carbons are optionally replaced with a group selected from O, NH, S, and CO, and the monocyclic heterocycloalkyl group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, which in turn may be further substituted with one or more groups selected from halo and alkyl. More preferably, R 10 and R 11 taken together with the nitrogen to which they are attached form a piperidinyl, pyrrolidinyl, azepanyl, or azetidinyl group, each of which is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, and haloalkyl.
[0139] In one preferred embodiment, R 10 and R 11 together with the nitrogen to which they are attached form a 6-membered monocyclic heterocycloalkyl group selected from piperidinyl, morpholinyl, thiomorpholinyl, and piperazinyl, each of which is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, which in turn may be further substituted with one or more groups selected from halo and alkyl. More preferably, R 10 and R 11 together with the nitrogen to which they are attached form a 6-membered monocyclic heterocycloalkyl group selected from piperidinyl, morpholinyl, thiomorpholinyl, and piperazinyl, each of which is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, and haloalkyl.
[0140] In one preferred embodiment, R 10 and R 11taken together with the nitrogen to which they are attached form a piperidinyl group, wherein one or two carbons in the monocyclic heterocycloalkyl group are optionally replaced with groups selected from O, NH, S, and CO, and the piperidinyl group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, which in turn may be further substituted with one or more groups selected from halo and alkyl. In one highly preferred embodiment, R 10 and R 11 taken together with the nitrogen to which they are attached form an unsubstituted piperidinyl or pyrrolidinyl group, more preferably an unsubstituted piperidinyl.
[0141] R 1-11 Other preferred definitions for groups are as given above for compounds of formula (Ia) and apply mutatis mutandis to compounds of formula (Ic).
[0142] In one embodiment, the compound of formula (Ic) is
[0143] [ka]
[0144] and pharmaceutically acceptable salts and hydrates thereof.
[0145] Compounds of formula (Id) A further aspect of the present invention is a compound of formula (Id)
[0146] [ka]
[0147] (In the formula, The XY group is -NHSO2- or -SO2NH-; R1 is H or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is selected from H, Cl and alkyl; R4 is selected from H, Cl and F; R5 is selected from H, alkyl, alkynyl, alkenyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R6 is H; R7 is CN, SO2-alkyl, SO2NR 13 R 14 or a heteroaryl group, said heteroaryl group being optionally substituted with one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl, and OH; R8 is selected from H, alkyl, haloalkyl, and halo; R9 is H, C1-C3-alkyl or halo; R 10 is H or alkyl; R 11 are NH2, OH, and NHC02R 12 (In the formula, R 12 is alkyl); or R 10 and R 11 together with the nitrogen to which they are attached form a 4-, 5-, 6-, or 7-membered monocyclic heterocycloalkyl group, in which one or two carbons are optionally replaced with groups selected from O, NH, S, and CO, said monocyclic heterocycloalkyl group being optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, which heteroaryl groups may in turn be further substituted with one or more groups selected from halo and alkyl; or R 10 and R 11together with the nitrogen to which they are attached form an 8-, 9-, or 10-membered bicyclic heterocycloalkyl group, wherein one or two carbons in the bicyclic heterocycloalkyl ring are optionally replaced with groups selected from O, NH, S, and CO, and said bicyclic heterocycloalkyl group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl; or R 10 and R 11 together with the nitrogen to which they are attached form a 6-12 membered bicyclic group containing spiro ring carbon atoms, in which one or two carbons in the bicyclic group are optionally replaced with a group selected from O, NH, S and CO, and in which the bicyclic group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, or in which the bicyclic group is optionally fused to a 5- or 6-membered aryl or heteroaryl group; R 13 and R 14 and R are each independently H or alkyl, or a pharmaceutically acceptable salt or hydrate thereof.
[0148] Substituents X, Y, R 1-6 and R 8-11 Preferred definitions for are as given above for compounds of formula (Ia) and apply mutatis mutandis to compounds of formula (Id).
[0149] In one preferred embodiment, R 10 and R 11together with the nitrogen to which they are attached form a 4-, 5-, 6-, or 7-membered monocyclic heterocycloalkyl group, in which one or two carbons in the monocyclic heterocycloalkyl group are optionally replaced with groups selected from O, NH, S, and CO, and the monocyclic heterocycloalkyl group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, which in turn are optionally further substituted with one or more groups selected from halo and alkyl. More preferably, R 10 and R 11 taken together with the nitrogen to which they are attached form a piperidinyl, pyrrolidinyl, azepanyl, or azetidinyl group, each of which is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, and haloalkyl.
[0150] In one preferred embodiment, R 10 and R 11 together with the nitrogen to which they are attached form a 6-membered monocyclic heterocycloalkyl group, in which one or two carbons are optionally replaced with groups selected from O, NH, S and CO, and the monocyclic heterocycloalkyl group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, which in turn may be further substituted with one or more groups selected from halo and alkyl.
[0151] In one preferred embodiment, R 10 and R 11together with the nitrogen to which they are attached form a 6-membered monocyclic heterocycloalkyl group selected from piperidinyl, morpholinyl, thiomorpholinyl, and piperazinyl, each of which is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, which in turn may be further substituted with one or more groups selected from halo and alkyl. More preferably, R 10 and R 11 together with the nitrogen to which they are attached form a 6-membered monocyclic heterocycloalkyl group selected from piperidinyl, morpholinyl, thiomorpholinyl, and piperazinyl, each of which is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, and haloalkyl.
[0152] In one preferred embodiment, R 10 and R 11 together with the nitrogen to which they are attached form a piperidinyl group optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, which in turn may be further substituted with one or more groups selected from halo and alkyl. More preferably, R 10 and R 11 taken together with the nitrogen to which they are attached form an unsubstituted piperidinyl group.
[0153] In one preferred embodiment, R7 is CN.
[0154] In another preferred embodiment, R7 is SO2-alkyl, more preferably SO2-Me.
[0155] In one preferred embodiment, R7 is SO2NR 13 R 14 , more preferably SO2NH2.
[0156] In one preferred embodiment, R7 is a heteroaryl group optionally substituted with one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl, and OH.
[0157] In one preferred embodiment, R7 is a heteroaryl group selected from pyridinyl, thienyl, imidazolyl, pyrimidinyl, pyrazolyl, pyrazinyl, pyrazidinyl, thiazolyl, isothiazolyl, triazinyl, pyrrolyl, furanyl, oxazolyl, isoxazolyl, oxadiazolyl, tetrazolyl, and triazolyl, each of which is optionally substituted with one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl, and OH.
[0158] In one preferred embodiment, R7 is a heteroaryl group selected from imidazolyl, pyrazolyl, pyrazinyl, pyrazidinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, tetrazolyl, and triazolyl, each of which is optionally substituted with one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl, and OH.
[0159] In one preferred embodiment, R7 is 1H-imidazol-5-yl, 1H-imidazol-4-yl, 1H-imidazol-2-yl, 1H-pyrrol-1-yl, 1H-pyrrol-2-yl, 1H-pyrrol-3-yl, 1H-pyrrol-4-yl, 1H-pyrrol-5-yl, 1H-pyrazol-1-yl, 1H-pyrazol-5-yl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, oxazol-2-yl, oxazol-4-yl, oxazoline, 1H-1,2,4-triazol-3-yl, 1H-1,2,4-triazol-5-yl, 1H-1,2,4-triazol-1-yl, 1H-1,2,3-triazol-4-yl, 1H-1,2,3-triazol-5-yl, 1H-1,2,3-triazol-1-yl, thiazol-5-yl, thiazol-4-yl, thiazol-2-yl, 1H-1,2,3,4-tetrazol-4-yl, 2H-1,2,3,4-tetrazol-5-yl, oxazol-3-yl, oxazol-5-yl, oxazol-5-yl, oxazol-5-yl, oxazol-4-yl, oxazol-2 ... 5-oxazolyl, 4-oxazolyl, 2-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl, 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl, 3-pyrazinyl, 4-pyrazinyl, 1,3,4-oxadiazol-2-yl, 1,3,4-oxadiazol-5-yl, 1,2,5-oxadiazol-3-yl, 1,2,5-oxadiazol-5-yl and heteroaryl groups selected from 1,2,3-oxadiazol-4-yl, 1,2,3-oxadiazol-5-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, isoxazol-5-yl, isoxazol-4-yl and isoxazol-3-yl, each of which may be substituted by one or more substituents selected from alkyl, halo, CN, alkoxy, haloalkyl and OH.
[0160] In one highly preferred embodiment, R7 is a heteroaryl group selected from 1H-pyrazol-5-yl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, oxazol-2-yl, 1H-1,2,3-triazol-4-yl, 1H-1,2,3-triazol-5-yl, thiazol-5-yl, 1H-1,2,3,4-tetrazol-4-yl, 2H-1,2,3,4-tetrazol-5-yl, isoxazol-4-yl, isoxazol-5-yl, isothiazol-5-yl, pyrazidin-3-yl, pyrazidin-4-yl, pyrazinyl, and 1,3,4-oxadiazol-2-yl, each of which may be substituted with one or more substituents selected from Me, F, Cl, CN, and MeO.
[0161] In one preferred embodiment, R7 is a heteroaryl group optionally substituted with one or more alkyl groups, preferably one or more Me groups.
[0162] In one highly preferred embodiment, the compound of formula (Id) is
[0163] [ka] [ka] [ka] [ka] [ka]
[0164] and pharmaceutically acceptable salts and hydrates thereof.
[0165] A further aspect of the present invention is
[0166] [ka] [ka] [ka]
[0167] and pharmaceutically acceptable salts and hydrates thereof.
[0168] therapeutic use A further aspect of the present invention relates to the compounds described herein for use in medicine. The compounds have particular application in the fields of oncology and immuno-oncology, as described in more detail below.
[0169] Yet another aspect of the present invention pertains to a compound as described herein for use in the treatment or prevention of a disease selected from a proliferative disease, an immune disease, an inflammatory disease, and a viral disease.
[0170] In a preferred embodiment, the compound of the present invention modulates ERAP1. More preferably, the compound modulates the cell antigen processing activity of ERAP1.
[0171] In one embodiment, the compound inhibits the activity of ERAP1. More preferably, the compound inhibits the cell antigen processing activity of ERAP1.
[0172] In an alternative embodiment, the compound increases the activity of ERAP1.
[0173] In one embodiment, the compounds of the invention may alter the repertoire of antigens presented.
[0174] One aspect of the present invention pertains to compounds, as described herein, for use in the treatment of a proliferative disorder. Preferably, the proliferative disorder is cancer or leukemia.
[0175] Cancers include basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; cancer of the peritoneum; cervical cancer; choriocarcinoma; colon and rectal cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; head and neck cancer; gastrointestinal cancer (including gastrointestinal cancer); glioblastoma; liver cancer; hepatocellular carcinoma; intraepithelial neoplasia; kidney or renal cancer; laryngeal cancer; leukemia; liver cancer; lung cancer (e.g., small cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous cell carcinoma of the lung); melanoma; myeloma; neuroblastoma; oral cancer (lip, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer ; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of the respiratory system; salivary gland cancer; sarcoma; skin cancer; squamous cell carcinoma; stomach cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulvar cancer; lymphomas, including Hodgkin's and non-Hodgkin's lymphomas and B-cell lymphomas, such as low-grade / follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate-grade / follicular NHL; intermediate-grade diffuse NHL; high-grade immunoblastic NHL; high-grade immunoblastic NHL; high-grade small non-cleaved cell NHL; bulky disease and Waldenstrom's macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); hairy cell leukemia; chronic myeloblastic leukemia; and other carcinomas and sarcomas; and post-transplant lymphoproliferative disorder (PTLD), and abnormal blood vessel proliferation associated with phacomatosis, edema (e.g., associated with brain tumors), and Meigs' syndrome.
[0176] Without wishing to be bound by theory, it is understood that ERAP1 modulators can change at least 10% of the antigen and neoantigen repertoire of cancer cells, as measured using immunopeptidomics and mass spectrometry. Approximately 50% of this change is the upregulation of the presentation of certain antigens and neoantigens, while the remaining 50% is the presentation of completely new antigens and neoantigens. Both changes increase the visibility of tumors to the immune system and increase the CD8 + T cell repertoire and CD8+ This results in a measurable change in T cell activation status. + Altered T cell responses result in immune-mediated tumor clearance and can potentially be enhanced by combining them with cancer therapeutics such as antibody checkpoint inhibitors (e.g., anti-PD-1).
[0177] Without wishing to be bound by theory, it is understood that a modulator of ERAP1 causes natural killer (NK) cells to kill cancer cells by disrupting the interaction between a killer cell Ig-like receptor (KIR) or a lectin-like receptor CD94-NKG2A on NK cells and a classical or non-classical MHC-I-peptide (pMHC-I) complex on cancer cells.
[0178] In one preferred embodiment, the disease is cancer and the compound increases the visibility of cancer cells to the immune system by altering the repertoire of antigens and neoantigens presented to the immune system.
[0179] A further aspect of the present invention relates to a method for increasing the visibility of cancer cells to the immune system in a subject by modifying the repertoire of antigens and neoantigens presented to the immune system, said method comprising the step of administering to the subject a compound of Formula (I), (Ia), (Ib), (Ic) or (Id).
[0180] In one preferred embodiment, the compound increases the CD8+ T cell response against cancer cells.
[0181] In one preferred embodiment, the compound of the present invention is for use in the treatment of a disease of uncontrolled cell proliferation, proliferation and / or survival, an inappropriate cellular immune response, or an inappropriate cellular inflammatory response, in particular, the uncontrolled cell proliferation, proliferation and / or survival, an inappropriate cellular immune response, or an inappropriate cellular inflammatory response is modulated by the ERAP1 pathway.
[0182] In one preferred embodiment, the disease of uncontrolled cell proliferation, growth and / or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is selected from hematological tumors, solid tumors and / or metastases thereof.
[0183] More preferably, the compounds are for use in the treatment of diseases selected from leukemia and myelodysplastic syndromes, malignant lymphomas, head and neck tumors including brain tumors and brain metastases, breast tumors including non-small cell and small cell lung tumors, gastrointestinal tumors, endocrine tumors, breast tumors and other gynecological tumors, urinary tumors including kidney, bladder and prostate tumors, skin tumors, and sarcomas, and / or metastases thereof.
[0184] The compounds can kill cancer cells, reduce the number of proliferating cells in the cancer, and / or reduce the volume or size of a tumor containing the cancer cells. The compounds can reduce the number of metastatic cancer cells.
[0185] In one embodiment, the compounds can be used to treat cancer in subjects who have previously had cancer. The compounds can be used to reduce the likelihood of cancer recurrence or the development of additional cancers. In recurrent or additional cancers, the compounds can induce neoantigens to which the subject already has a pre-existing immune response. Thus, the compounds can increase or enhance the immune response against cancer.
[0186] In one embodiment, the compound is for use in the prevention of cancer. The compound can be used to prevent the onset of cancer. That is, the compound can stimulate an immune response, such as a vaccine response, against future cancers. The compound can stimulate an immune response against neoantigens in a subject. Once cancer develops in a subject, the subject can be treated again with the compound (or a different compound) to stimulate the development of the same neoantigen, thereby eliciting the subject's existing immune response against the neoantigen and treating or preventing cancer.
[0187] The same or different compounds may be used before and after cancer develops in the subject.
[0188] In one embodiment, the compounds may be used for the prevention of cancer.
[0189] In one embodiment, the subject may have previously had cancer, may have a family history of cancer, may be at high risk of developing cancer, may have a genetic predisposition to developing cancer, or may have been exposed to a carcinogen, hi one embodiment, the subject may be in remission from cancer.
[0190] One embodiment provides ex vivo-produced antigen-presenting cells, such as dendritic cells (DCs). Antigen-presenting cells can be produced ex vivo to present neoantigens, such as those produced by the compounds of the present invention. The compounds can be used in methods for producing ex vivo antigen-presenting cells that present neoantigens, and the cells can be used as a vaccine against cancer.
[0191] Antigen-presenting cells, such as dendritic cells, may be pulsed or loaded with neoantigens or genetically modified (via DNA or RNA transfer) to express one, two, or more neoantigens. Methods for preparing dendritic cell vaccines are known in the art.
[0192] Neoantigens can be produced from normal tissues of a subject, and ERAP1 is modulated with the compound according to the present invention. The source of normal tissue may be fibroblasts or B cells, which can be easily expanded in vitro, for example. Alternatively, RNA from cancer, total or mRNA-enriched polyA+RNA may be used. PolyA+RNA can also be amplified to produce sufficient antigens for DC loading, thereby limiting the ex vivo culture step.
[0193] In one embodiment, dendritic cells treated with the above-described compounds can be used to treat a subject. Dendritic cells can be contacted with the compounds ex vivo, and then the dendritic cells can be administered to a subject. Thus, the compounds can be used in vitro or in vivo, e.g., either in situ or ex vivo treatment, followed by administration of the treated cells to a subject.
[0194] Another aspect of the invention relates to the compounds described above for use in the treatment of an immune disease or for modulating an immune response. In one preferred embodiment, the immune disease is an autoimmune disease, such as a T-cell mediated autoimmune disease.
[0195] Examples of autoimmune diseases include, but are not limited to, rheumatoid arthritis (RA), myasthenia gravis (MG), multiple sclerosis (MS), systemic lupus erythematosus (SLE), autoimmune thyroiditis (Hashimoto's thyroiditis), Graves' disease, inflammatory bowel disease, autoimmune uveoretinitis, polymyositis and certain types of diabetes, systemic vasculitis, polymyositis-dermatomyositis, systemic sclerosis (scleroderma), Sjogren's syndrome, ankylosing spondylitis and related spinal joint diseases, rheumatic fever, hypersensitivity pneumonitis, allergic bronchopulmonary aspergillosis, inorganic pneumoconiosis, sarcoidosis, autoimmune hemolytic anemia, immunological platelet disorders, cryopathies such as cryofibrinogenemia, psoriasis, Behcet's disease, shatter-like chorioretinopathy, and autoimmune polyendocrinopathy.
[0196] Polymorphisms in the ERAP1 gene that affect ERAP1 enzyme activity are strongly associated with increased risk of autoimmune diseases, including ankylosing spondylitis, psoriasis, Behçet's disease, and shatter-like chorioretinopathy 11 ERAP1 variants that reduce ERAP1 enzyme activity protect against disease, while those that have been reported to increase activity are associated with an increased disease risk. 12 This suggests that modulating ERAP1 activity may be an effective treatment for autoimmune diseases.
[0197] Thus, in one preferred embodiment, the immune disorder is selected from ankylosing spondylitis, psoriasis, Behcet's disease and shotcretic chorioretinopathy.
[0198] In one preferred embodiment, the immune disease is ankylosing spondylitis. Ankylosing spondylitis (AS) is a type of arthritis characterized by long-term inflammation in the joints of the spine. Typically, the joints where the spine connects to the pelvis are also affected. Other joints, such as the shoulder or hip, may also be involved. It affects 0.1% to 1.8% of the population, typically affecting young adults. The cause of ankylosing spondylitis is unknown, but a combination of genetic and environmental factors is involved. Over 90% of affected individuals have a specific human leukocyte antigen known as the HLA-B27 antigen. 13 Furthermore, certain variants of ERAP1, in conjunction with HLA-B27, are clearly associated with either an increased or decreased risk of disease, providing evidence for a clear role of modulated antigen presentation in disease. 18 There is no cure for ankylosing spondylitis, and current treatments only provide symptomatic improvement and prevention of worsening. Medications used to date include NSAIDs, steroids, DMARDs such as sulfasalazine, and biologic agents such as infliximab.
[0199] In one preferred embodiment, the immune disease is Behçet's disease (BD). Behçet's disease (BD) is a type of inflammatory disease that affects multiple parts of the body. The most common symptoms include painful mouth sores, genital pain, inflammation of parts of the eyes, and arthritis. The cause is unclear and environmental factors are involved, but genetic studies have shown an increased risk of the disease in patients with HLA-B51 in combination with specific variants of ERAP1. 19The disease is primarily characterized by autoinflammation of blood vessels and may therefore be characterized as an autoinflammatory disease. While there is currently no cure for Behçet's disease, symptoms can be controlled with medications that reduce inflammation in affected areas of the body, such as corticosteroids, immunosuppressants, or biologic therapies that target biological processes involved in the inflammatory process. In one preferred embodiment, the immune disease is scattershot chorioretinopathy. Also known as birdshot uveitis or HLA-A29 uveitis, scattershot chorioretinopathy is a rare form of bilateral posterior uveitis affecting the eyes. It causes severe, progressive inflammation of both the choroid and retina. Symptoms include floaters, blurred vision, photopsias (flashing lights in the eye), loss of color vision, and night blindness. Scattershot chorioretinopathy is considered an autoimmune disease. The disease is strongly associated with human leukocyte antigen haplotype (HLA)-A29. This indicates a role for T lymphocytes in the pathogenesis. Shottiglottic chorioretinopathy is associated with IL-17, a cytokine characteristic of T lymphocytes (TH17) that plays an important role in autoimmunity. 15,16 Genome-wide association studies have identified HLA-A29:02 as a major risk factor and both ERAP1 and ERAP2 as associated with shatter-like chorioretinopathy. 17,20 Genetic variants in the ERAP1 and ERAP2 loci modulate enzyme activity and also mRNA and protein expression. ERAP2, together with ERAP1, is an aminopeptidase that trims peptides in the endoplasmic reticulum and loads these peptides onto HLA molecules for presentation to T cells of the immune system.
[0200] In one preferred embodiment, the immune disease is psoriasis.Psoriasis is a chronic skin disease in which skin cells rapidly accumulate on the surface of the skin, forming itchy and sometimes painful scales and red patches.The cause is unclear, but includes both environmental and genetic factors.HLA-C06 is strongly associated with the risk of the disease, and ERAP1 variants are also strongly associated with the disease, possibly in conjunction with HLA-C06. 21There is no cure for psoriasis, and current treatments only provide improvement of symptoms and prevention of exacerbations. Medications used in treatment include steroids, methotrexate, sulfasalazine, and biologic agents such as etanercept.
[0201] Another aspect of the present invention relates to the above-mentioned compound for use in the treatment or prevention of viral diseases. Modulators of ERAP1, for example, compounds described herein, can change the antigen repertoire of multiple viruses, which results in the recognition and destruction of virus-infected cells. Therefore, ERAP1 modulators have potential therapeutic applications in the treatment of viral infections and diseases. ERAP1 modulates certain viral antigens, including those from human papillomavirus (HPV), human cytomegalovirus (CMV), hepatitis C (HCV), and human immunodeficiency virus (HIV). 8,9,10 Furthermore, knockdown of ERAP1 in HPV-infected cells altered the repertoire of presented HPV antigens and upregulated CD8 + resulting in greater recognition by T cells 8 .
[0202] In one preferred embodiment, the viral disease is a viral disease or infection selected from HIV, HPV, CMV and HCV.
[0203] In one preferred embodiment, the viral disease is HIV.
[0204] In one preferred embodiment, the viral disease is HPV.
[0205] In one preferred embodiment, the viral disease is CMV.
[0206] In one preferred embodiment, the viral disease is HCV.
[0207] Another aspect of the present invention relates to the compounds described above for use in the treatment or prevention of hypertension.
[0208] Another aspect relates to the compound described herein for use in the prevention or treatment of a disease caused by, related to, or accompanied by abnormal activity against ERAP1.
[0209] Another aspect relates to the compound described herein for use in the prevention or treatment of an ERAP1-associated disease or disorder.
[0210] Yet another embodiment relates to use of a compound described herein in the preparation of a medicament for preventing or treating a disease caused by, related to, or accompanied by any abnormal activity against ERAP1.
[0211] As used herein, the phrase "preparation of a medicament" includes the use of a component of the present invention in any stage of the preparation of a medicament, as well as the use of a component of the present invention directly as such a medicament.
[0212] Another aspect relates to the use of a compound as described above in the preparation of a medicament for the treatment or prevention of a disease selected from a proliferative disease, an immune disease, a viral disease and an inflammatory disease.
[0213] Yet another embodiment relates to use of a compound described herein in the preparation of a medicament for the prevention or treatment of an ERAP1-associated disease or disorder.
[0214] Another aspect of the present invention relates to a method for treating an ERAP1-related disease or disorder in a subject. The method according to this aspect of the present invention, as described herein above, is achieved by administering a therapeutically effective amount of the compound of the present invention to a subject in need thereof, either by itself or, more preferably, as described hereinafter in detail, as part of a pharmaceutical composition mixed with, for example, a pharmaceutically acceptable carrier.
[0215] Yet another aspect of the present invention relates to a method for treating a subject having a disease condition that is alleviated by modulating ERAP1, the method comprising the step of administering a therapeutically effective amount of the compound according to the present invention to the subject.
[0216] Another aspect relates to a method for treating a disease state alleviated by modulating ERAP1, the method comprising the step of administering a therapeutically effective amount of the compound according to the present invention to a subject.
[0217] Preferably, the subject is a mammal, more preferably a human.
[0218] The term "method" refers to ways, means, techniques, and procedures for accomplishing a given task, and includes, but is not limited to, ways, means, techniques, and procedures known to those of ordinary skill in the chemical, pharmacological, biological, biochemical, and medical arts, or that can be readily developed from known ways, means, techniques, and procedures by such skilled artisans.
[0219] As used herein, the term "treating" includes negating, substantially inhibiting, slowing, or reversing the progression of a disease or disorder, substantially ameliorating a disease or clinical symptoms of a disorder, or substantially preventing the onset of a disease or clinical symptoms of a disorder.
[0220] As used herein, the term "preventing" refers to a method for barring an organism from acquiring a disease or disorder in the first place.
[0221] The term "therapeutically effective amount" refers to that amount of the compound being administered which will relieve to some extent one or more of the symptoms of the disease or disorder being treated.
[0222] For any compound used in the present invention, the therapeutically effective amount, also referred to herein as the therapeutically effective dose, can be estimated initially from cell culture assays. For example, a dose can be estimated based on the IC 50 or IC 100The dosage can be formulated to achieve a circulating concentration range including the range of circulating concentrations of the active ingredient. Using such information, the useful dose in humans can be more accurately determined. The initial dosage can also be estimated from in vivo data. Using these initial guidelines, those skilled in the art can determine the effective dosage in humans.
[0223] Furthermore, the toxicity and therapeutic efficacy of the compounds described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., by LD 50 and ED 50 The dose ratio between toxic and therapeutic effect is the therapeutic index, and the LD 50 and ED 50 Therapeutic indices can be expressed as a ratio between ED and ED . Compounds that exhibit large therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used to formulate a dosage range that is non-toxic for use in humans. The dosage of such compounds is preferably within the ED range that produces little or no toxicity. 50 The dosage may vary within this range depending on the dosage form employed and the route of administration utilized. The exact formulation, route of administration, and dosage can be chosen by the individual physician in view of the patient's condition (see, e.g., Fingl et al., 1975, The Pharmacological Basis of Therapeutics, chapter 1, page 1).
[0224] The dosage and interval can be individually adjusted to provide a plasma level of the active compound sufficient to maintain the therapeutic effect. The dosage for oral administration to a typical patient is in the range of about 50 to 2000 mg / kg / day, generally about 100 to 1000 mg / kg / day, preferably about 150 to 700 mg / kg / day, and most preferably about 250 to 500 mg / kg / day. Preferably, a therapeutically effective serum level is achieved by administering multiple doses daily. In the case of local administration or selective uptake, the effective local concentration of the drug may not be related to the plasma concentration. Those skilled in the art can optimize the therapeutically effective local dosage without undue experimentation. As used herein, "ERAP1-related disease or disorder" refers to a disease or disorder characterized by inappropriate ERAP1 activity. Inappropriate activity refers to either an increase or decrease in ERAP1 activity compared to wild-type ERAP1 (Uniprot ID Q9NZ08) caused by variations in the ERAP1 protein sequence, as measured by enzyme or cellular assays. The inappropriate activity may also be due to overexpression of ERAP1 in diseased tissues compared with healthy adjacent tissues.
[0225] Preferred diseases or disorders that the compounds described herein may be useful in preventing include the proliferative, viral, immune and inflammatory disorders described herein above.
[0226] Therefore, the present invention further provides use of the compound defined in the present specification for the manufacture of a medicament for the treatment of a disease in which it is desirable to modulate ERAP1. Such diseases include the proliferative diseases, viral diseases, immune diseases and inflammatory diseases described herein above.
[0227] In one preferred embodiment, the compound activates the conversion of (L)-leucine-7-amido-4-methylcoumarin (L-AMC) to (L)-leucine and the fluorescent molecule 7-amino-4-methylcoumarin by ERAP1. Although the same assay can also identify inhibitors of the cleavage of the amide bond in L-AMC by ERAP1, for the purposes of this application, this assay is referred to as "L-AMC activator assay." The efficacy of any activator can be determined by measuring the concentration of the activator required to increase the enzymatic activity of ERAP1 by 50% from its baseline level (i.e., EC 50 )
[0228] In one preferred embodiment, the compound has an EC of less than about 25 μM in the L-AMC activator assay. 50 More preferably, the compounds have an EC value in the L-AMC activator assay of less than about 10 μM, more preferably less than about 5 μM, even more preferably less than about 1 μM, even more preferably less than about 0.1 μM, and even more preferably less than about 0.01 μM. 50 Indicates the value.
[0229] In one preferred embodiment, the compound inhibits the ability of ERAP1 to hydrolyze the decapeptide substrate WRVYEKCdnpALK. This peptide has minimal fluorescence because the fluorescence of the N-terminal tryptophan residue is quenched by a dinitrophenol (DNP) residue within the peptide. However, as ERAP1 hydrolyzes the N-terminal amide bond and tryptophan is released, this internal quenching is lost, and the reaction is monitored by an increase in tryptophan fluorescence during the assay. For the purposes of this application, this assay is referred to as a "10-mer inhibition assay," and the potency of a compound is measured using IC as is well known to those skilled in the art. 50 It is calculated and expressed as:
[0230] In one preferred embodiment, the compound has an IC of less than about 25 μM in the 10-mer assay. 50More preferably, the compounds have an IC value in the 10-mer assay of less than about 10 μM, more preferably less than about 5 μM, even more preferably less than about 1 μM, even more preferably less than about 0.1 μM, and even more preferably less than about 0.01 μM. 50 Indicates the value.
[0231] Therapeutic Uses of Compounds of Formula I A further aspect of the present invention is a compound of formula (I) for use in the treatment or prevention of a disease selected from a proliferative disease, an autoimmune disease, a viral disease and an inflammatory disease.
[0232] [ka]
[0233] (In the formula, The XY group is -NHSO2- or -SO2NH-; R1 is H or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is selected from H, Cl and alkyl; R4 is selected from H, Cl and F; R5 is selected from H, alkyl, alkynyl, alkenyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R6 is H; R7 is H, CN, haloalkyl, Cl, F, SO2-alkyl, SO2NR 13 R 14 , heteroaryl and alkyl, wherein the heteroaryl group is optionally substituted with one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; R8 is selected from H, alkyl, haloalkyl, and halo; R9 is H, C1-C3-alkyl or halo; R 10 is H or alkyl; R 11 are NH2, OH, and NHC02R 12 (In the formula, R 12 is alkyl); or R 10 and R 11 together with the nitrogen to which they are attached form a 4-, 5-, 6-, or 7-membered monocyclic heterocycloalkyl group, in which one or two carbons are optionally replaced with groups selected from O, NH, S, and CO, said monocyclic heterocycloalkyl group being optionally substituted with one or more groups selected from alkyl, CN, OH, halo, and heteroaryl, which in turn are optionally further substituted with one or more groups selected from halo and alkyl; or R 10 and R 11 together with the nitrogen to which they are attached form an 8-, 9-, or 10-membered bicyclic heterocycloalkyl group, wherein one or two carbons in the bicyclic heterocycloalkyl ring are optionally replaced with groups selected from O, NH, S, and CO, and said bicyclic heterocycloalkyl group is optionally substituted with one or more groups selected from alkyl, CN, and halo; or R 10 and R 11 together with the nitrogen to which they are attached form a 6-12 membered bicyclic group containing spiro ring carbon atoms, in which one or two carbons in the bicyclic group are optionally replaced with a group selected from O, NH, S and CO, and in which the bicyclic group is optionally substituted with one or more groups selected from alkyl, CN, halo and heteroaryl, or in which the bicyclic group is optionally fused to a 5- or 6-membered aryl or heteroaryl group; R 13 and R 14 and R are each independently H or alkyl, or a pharmaceutically acceptable salt or hydrate thereof.
[0234] X, Y and R 1-11Preferred definitions for groups are as set out above for compounds of formula (Ia) and apply mutatis mutandis to compounds of formula (I). Details of suitable proliferative, autoimmune, viral and inflammatory diseases are the same as those set out above under the heading "Therapeutic Uses".
[0235] In one preferred embodiment, the compound of formula (I) for the above mentioned use is
[0236] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka]
[0237] and pharmaceutically acceptable salts and hydrates thereof.
[0238] A further aspect of the present invention relates to compounds of formula (I) as defined above other than compounds (54), (64), (69), (71), (72), (73), (74), (78) and (165).
[0239] Another aspect relates to compounds of formula (I) as defined above other than compounds (54), (64), (69), (71), (72), (73), (74), (78) and (165), for the uses as defined above.
[0240] Pharmaceutical Composition For use according to the present invention, the compounds described herein, or physiologically acceptable salts, esters, or other physiologically functional derivatives thereof, may be provided as pharmaceutical formulations comprising the compounds, or physiologically acceptable salts, esters, or other physiologically functional derivatives thereof, together with one or more pharmaceutically acceptable carriers, and optionally other therapeutic and / or prophylactic ingredients. Carriers must be acceptable in the sense of being compatible with the other ingredients of the formulation and not harmful to the recipient thereof. Pharmaceutical compositions may be for use in humans or animals in human and veterinary medicine.
[0241] Examples of such suitable excipients for the various different forms of pharmaceutical compositions described herein can be found in "Handbook of Pharmaceutical Excipients, 2000, Vol. 1, No. 1, pp. 111-115, 1997, pages 211-2 ... ndEdition, (1994), Edited by A Wade and PJ Weller. The carrier, or each of the carriers, if more than one is present, must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
[0242] Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (AR Gennaro edit. 1985).
[0243] Examples of suitable carriers include lactose, starch, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, etc. Examples of suitable diluents include ethanol, glycerol and water.
[0244] The choice of pharmaceutical carrier, excipient, or diluent can be selected having regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical composition may include, as or in addition to the carrier, excipient, or diluent, any suitable binders, lubricants, suspending agents, coating agents, solubilizing agents, buffers, flavoring agents, surface active agents, thickening agents, preservatives (including antioxidants), and the like, as well as substances included for the purpose of rendering the formulation isotonic with the blood of the intended recipient.
[0245] Examples of suitable binders include starch, gelatin, natural sugars such as glucose, anhydrous lactose, fluid lactose, beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose and polyethylene glycol.
[0246] Examples of suitable lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
[0247] Preservatives, stabilizers, dyes, and even flavoring agents may be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate, sorbic acid, and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents may also be used.
[0248] Pharmaceutical formulations include those suitable for oral, topical (including transdermal, buccal and sublingual), rectal or parenteral (including subcutaneous, intradermal, intramuscular and intravenous), nasal, and pulmonary administration, such as by inhalation. The formulations may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the active compound with liquid carriers or finely divided solid carriers, or both, and then, if necessary, shaping the product into the desired formulation.
[0249] Pharmaceutical formulations suitable for oral administration in which the carrier is solid are most preferably provided as unit-dose formulations such as boluses, capsules, or tablets, each containing a predetermined amount of active compound. Tablets can be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing the active compound in a free-flowing form, such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, glidant, surface active agent, or dispersing agent, in a suitable machine. Molded tablets can be made by molding the active compound with an inert liquid diluent. Tablets can be coated or, if uncoated, can be grooved. Capsules can be prepared by filling capsule shells with the active compound, either alone or in admixture with one or more accessory ingredients, and then sealing them in the usual manner. Cachets are similar to capsules, in that the active compound, along with any accessory ingredients, is sealed in a rice paper envelope. The active compound can also be formulated as dispersible granules, which can be suspended in water or sprinkled on food before administration, for example. The granules may be packaged, for example, in a sachet.Formulations suitable for oral administration wherein the carrier is a liquid may be presented as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water liquid emulsion.
[0250] Formulations for oral administration include controlled-release dosage forms, such as tablets, in which the active compound is formulated in a suitable release-controlling matrix or coated with a suitable release-controlling film. Such formulations can be particularly convenient for prophylactic use.
[0251] The pharmaceutical preparation suitable for rectal administration, in which the carrier is solid, is most preferably provided as a unit-dose suppository.Suitable carriers include cocoa butter and other materials commonly used in the art.Suppositories can be conveniently formed by mixing the active compound with a softened or melted carrier, followed by cooling in a mold and shaping.The pharmaceutical preparation suitable for parenteral administration includes a sterile solution or suspension of the active compound in an aqueous or oily medium.
[0252] Injectable preparations can be adapted for bolus injection or continuous infusion. Such preparations are conveniently provided in unit-dose or multi-dose containers that are sealed after the formulation is introduced until needed for use. Alternatively, the active compound can be in powder form, which is reconstituted with a suitable vehicle, such as sterile pyrogen-free water, before use.
[0253] The active compound may also be formulated as a long-acting depot preparation, which can be administered by intramuscular injection or implantation, for example, subcutaneously or intramuscularly. The depot preparation may, for example, comprise a suitable polymer or hydrophobic material, or an ion exchange resin. Such long-acting formulations are particularly convenient for prophylactic use.
[0254] Formulations suitable for pulmonary administration via the buccal cavity are provided such that particles containing the active compound and desirably having a diameter in the range of 0.5 to 7 microns are delivered to the recipient's bronchial tree.
[0255] One possibility is that such a formulation is in the form of a finely divided powder, which can be conveniently provided in a puncturable capsule, for example made of gelatin, for use in an inhalation device, or alternatively, as a self-propelling formulation containing the active compound, a suitable liquid or gaseous propellant, and optionally other ingredients such as surfactants and / or solid diluents. Suitable liquid propellants include propane and chlorofluorocarbons, and suitable gaseous propellants include carbon dioxide. Self-propelling formulations in which the active compound is dispensed in the form of droplets of a solution or suspension can also be used.
[0256] Such self-propelling formulations are similar to those known in the art and may be prepared by established procedures. Suitably, they are provided in a container equipped with a manually operable or automatically functioning valve having the desired spray characteristics, advantageously the valve being of the metered type that delivers a fixed volume, e.g., 25 to 100 microliters, upon each actuation of the valve.
[0257] As a further possibility, the active compound may be in the form of a solution or suspension for use in an atomizer or nebulizer, which uses accelerated airflow or ultrasonic agitation to generate a fine droplet mist for inhalation.
[0258] Formulations suitable for nasal administration include preparations generally similar to those described above for pulmonary administration. When dispensed, such formulations should desirably have a particle diameter in the range of 10-200 microns to enable retention in the nasal cavity; this can be achieved by the use of powders of appropriate particle size or by the selection of an appropriate valve, as appropriate. Other suitable formulations include coarse powders having particle diameters in the range of 20-500 microns for administration by rapid inhalation through the nasal passage from a container held close to the nose, and nasal drops containing 0.2-5% w / v of the active compound in an aqueous or oily solution or suspension.
[0259] Pharmaceutically acceptable carriers are well known to those skilled in the art and include, but are not limited to, 0.1 M, preferably 0.05 M, phosphate buffer or 0.8% saline. Furthermore, such pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic / aqueous solutions, emulsions, or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's solution, or fixed oils. Preservatives and other additives, such as antibacterial agents, antioxidants, chelating agents, inert gases, and the like, may also be present.
[0260] Suitable formulations for topical use may be provided, for example, as gels, creams, or ointments. Such preparations may be applied, for example, to a wound or ulcer, either by spreading it directly on the surface of the wound or ulcer, or on a suitable support such as a bandage, gauze, mesh, or the like, which may be applied to and over the area to be treated.
[0261] Liquid or powder formulations may also be provided that can be sprayed or sprinkled directly onto the area to be treated, such as a wound or ulcer. Alternatively, the formulation may be sprayed or sprinkled onto a carrier such as a bandage, gauze, mesh, etc., and then applied to the area to be treated.
[0262] According to a further aspect of the present invention there is provided a process for the preparation of a pharmaceutical or veterinary composition as described above, which process comprises bringing into association the active compound with the carrier, for example by mixing.
[0263] In general, the formulations are prepared by uniformly and intimately bringing into association the active agent(s) with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product. The present invention extends to a process for preparing a pharmaceutical composition, which process includes combining or bringing into association a compound described herein with a pharmaceutically or veterinarily acceptable carrier or vehicle.
[0264] Salts / Esters The compounds of the present invention may exist as salts or esters, particularly pharmaceutically and veterinarily acceptable salts or esters.
[0265] Pharmaceutically acceptable salts of the compounds of the present invention include suitable acid addition or base salts thereof. A review of suitable pharmaceutical salts can be found in Berge et al., J Pharm Sci, 66, 1-19 (1977). Salts are formed, for example, with strong inorganic acids, such as mineral acids, for example, hydrohalic acids, such as hydrochlorides, hydrobromides, and hydroiodides, sulfuric acid, phosphoric acid, sulfate, bisulfate, hemisulfate, thiocyanate, persulfate, and sulfonic acids; strong organic carboxylic acids, for example, unsubstituted or substituted (e.g., by halogen) alkanecarboxylic acids of 1 to 4 carbon atoms, such as acetic acid; saturated or unsaturated dicarboxylic acids, such as oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, phthalic acid, or tetraphthalic acid; hydroxycarboxylic acids, such as ascorbic acid, glycolic acid, lactic acid, malic acid, tartaric acid, or citric acid; amino acids, such as aspartic acid or glutamic acid; benzoic acid; or organic sulfonic acids, for example, unsubstituted or substituted (e.g., by halogen) (C1-C4)-alkyl- or aryl-sulfonic acids, such as methane- or p-toluenesulfonic acid. Salts that are not pharmaceutically or veterinarily acceptable may still be valuable as intermediates.
[0266] Preferred salts are, for example, acetate, trifluoroacetate, lactate, gluconate, citrate, tartrate, maleate, malate, pantothenate, adipate, alginate, aspartate, benzoate, butyrate, digluconate, cyclopentanoate, glucoheptanoate, glycerophosphate, oxalate, heptanoate, hexanoate, fumarate, nicotinate, palmoate, pectinate, 3-phenylpropionate, picrate, pivalate, propionate, salts, tartrates, lactobionates, pivolates, camphorates, undecanoates and succinates, organic sulfonic acids such as methanesulfonates, ethanesulfonates, 2-hydroxyethanesulfonates, camphorsulfonates, 2-naphthalenesulfonates, benzenesulfonates, p-chlorobenzenesulfonates and p-toluenesulfonates; and inorganic acids such as hydrochlorides, hydrobromides, hydroiodides, sulfates, bisulfates, hemisulfates, thiocyanates, persulfates, phosphoric and sulfonic acids.
[0267] Esters are formed using organic acids or alcohols / hydroxides, depending on the functional group being esterified. Organic acids include carboxylic acids, such as unsubstituted or substituted (e.g., by halogen) alkanecarboxylic acids of 1 to 12 carbon atoms, such as acetic acid; saturated or unsaturated dicarboxylic acids, such as oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, phthalic acid, or terephthalic acid; hydroxycarboxylic acids, such as ascorbic acid, glycolic acid, lactic acid, malic acid, tartaric acid, or citric acid; amino acids, such as aspartic acid or glutamic acid; benzoic acid; or organic sulfonic acids, such as unsubstituted or substituted (e.g., by halogen) (C1-C4)-alkyl- or aryl-sulfonic acids, such as methane- or p-toluenesulfonic acid. Suitable hydroxides include inorganic hydroxides, such as sodium hydroxide, potassium hydroxide, calcium hydroxide, and aluminum hydroxide. Alcohols include alkanealcohols of 1 to 12 carbon atoms, which may be unsubstituted or substituted (e.g., by halogen).
[0268] Enantiomers / Tautomers In all of the foregoing aspects of the invention, the invention includes, where appropriate, all enantiomers, diastereoisomers, and tautomers of the compounds of the invention. Those skilled in the art will recognize compounds that have optical properties (one or more chiral carbon atoms) or tautomeric properties. The corresponding enantiomers and / or tautomers may be isolated / prepared by methods known in the art.
[0269] Enantiomers are characterized by the absolute configuration of their chiral centers and described by the R- and S-sequencing rules of Cahn, Ingold and Prelog. Such conventions are well known in the art (see, for example, 'Advanced Organic Chemistry', 3 rd edition, ed. March, J., John Wiley and Sons, New York, 1985).
[0270] Compounds of the invention that contain chiral centers may be used as racemic mixtures, enantiomerically enriched mixtures or racemic mixtures may be separated using well-known techniques, or the individual enantiomers may be used alone.
[0271] Stereoisomers and geometric isomers Some of the compounds of the present invention may exist as stereoisomers and / or geometric isomers, e.g., they may have one or more asymmetric and / or geometric centers and therefore may exist in two or more stereoisomeric and / or geometric isomeric forms. The present invention contemplates the use of all individual stereoisomers and geometric isomers of these compounds, as well as mixtures thereof. The terms used in the claims encompass these forms, provided that said forms retain the appropriate functional activity (although not necessarily to the same degree).
[0272] The present invention also includes all suitable isotopic variations of the compounds or pharmaceutically acceptable salts thereof. An isotopic variation of a compound of the present invention or a pharmaceutically acceptable salt thereof is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature. Examples of isotopes that may be incorporated into the substances and their pharmaceutically acceptable salts include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, such as, for example, 2 H, 3 H, 13 C. 14 C. 15 N, 17 O. 18 O. 31 P, 32 P, 35 S, 18 F and 36 Certain isotopic variations of the substance and its pharmaceutically acceptable salts, such as 3 H or 14 Those incorporating radioactive isotopes such as C are useful for drug and / or substrate tissue distribution studies. 3 H and carbon-14, i.e. 14 C isotopes are particularly preferred for their ease of preparation and detectability. Additionally, deuterium, i.e. 2 Substitution with isotopes such as H can provide certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced required dosage, and therefore may be preferred in some circumstances. For example, the present invention includes compounds of general formula (I) in which any hydrogen atom has been replaced with a deuterium atom. Isotopic variations of the substances of the present invention and pharmaceutically acceptable salts thereof of the present invention can generally be prepared by conventional procedures using appropriate isotopic variations of suitable reagents.
[0273] Atropisomers Some of the compounds of the present invention may exist as atropisomers. Atropisomers are stereoisomers that arise from the inhibition of rotation around a single bond, where the energy difference due to steric strain or other contributing factors creates a sufficiently high degree of rotational restriction to allow the isolation of individual conformers. The present invention encompasses all such atropisomers.
[0274] Prodrug The present invention further includes compounds of the invention in prodrug form, i.e., covalently bonded compounds that release the active parent drug in vivo. Such prodrugs are generally compounds of the invention modified at one or more appropriate groups such that the modifications can be reversed after administration to a human or mammalian subject. Reversal is usually carried out by enzymes naturally present in such subjects, although it is possible to administer a second agent along with such a prodrug to effect reversal in vivo. Examples of such modifications include esters (e.g., any of those described above), and reversal can be carried out by esterases, etc. Other such systems are well known to those skilled in the art.
[0275] solvate The present invention also includes solvated forms of the compounds of the invention, and the terms used in the claims encompass these forms.
[0276] polymorph The present invention further relates to the compounds of the present invention in their various crystalline forms, polymorphic forms, and hydrate (anhydrous) forms. It is well established in the pharmaceutical industry that chemical compounds can be isolated in any of such forms by slight modifications to the methods of purification and / or isolation from solvents used in the synthetic preparation of such compounds.
[0277] Administration The pharmaceutical composition of the present invention may be adapted for rectal, nasal, intrabronchial, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intraarterial and intradermal), intraperitoneal or intrathecal administration. Preferably, the formulation is an oral administration formulation. The formulation may conveniently be provided in unit dosage form, i.e., in the form of a unit dose, or in the form of discrete portions containing multiples or sub-units of a unit dose. For example, the formulation may be in the form of tablets and sustained-release capsules, and may be prepared by any method well known in the art of pharmacy.
[0278] Formulations for oral administration herein may be provided as discrete units such as capsules, gellules, lozenges, cachets, pills, or tablets, each containing a predetermined amount of active agent; as powders or granules; as a solution, emulsion, or suspension of the active agent in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil liquid emulsion; or as a bolus. Preferably, these compositions contain 1 to 250 mg, more preferably 10 to 100 mg, of active ingredient per dose.
[0279] For compositions for oral administration (e.g., tablets and capsules), the term "acceptable carrier" includes common excipients, such as binders, e.g., syrup, acacia, gelatin, sorbitol, tragacanth, polyvinylpyrrolidone (povidone), methylcellulose, ethylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, sucrose, and starch; fillers and carriers, e.g., corn starch, gelatin, lactose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride, and alginic acid; and lubricants, e.g., magnesium stearate, sodium stearate, and other metal stearates, glycerol stearate, stearic acid, silicone fluid, talc wax, oils, and colloidal silica. Flavoring agents, e.g., peppermint, oil of wintergreen, cherry flavor, and the like, may also be used. It may be desirable to add a coloring agent to make the dosage form easily identifiable. Tablets may also be coated by methods well known in the art.
[0280] Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the active agent in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surfactant, or dispersing agent. Molded tablets may be made by molding, in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Tablets may be coated or grooved and may be formulated to provide slow or controlled release of the active agent.
[0281] Other formulations suitable for oral administration include lozenges containing the active agent in a flavored base, usually sucrose and acacia or tragacanth; pastilles containing the active agent in an inert base such as gelatin and glycerin, or sucrose and acacia; and mouthwashes containing the active agent in a suitable liquid carrier.
[0282] Other dosage forms include solutions or emulsions that can be injected intravenously, intraarterially, intrathecally, subcutaneously, intradermally, intraperitoneally, or intramuscularly, which are prepared from sterile or sterilizable solutions. Injectable forms typically contain between 10 and 1000 mg, preferably between 10 and 250 mg, of active ingredient per dose.
[0283] Pharmaceutical compositions of the present invention may also be in the form of a suppository, pessary, suspension, emulsion, lotion, ointment, cream, gel, spray, solution or dusting powder.
[0284] An alternative means of transdermal administration is by use of a skin patch. For example, the active ingredient may be incorporated into a cream consisting of an aqueous emulsion of polyethylene glycol or liquid paraffin. The active ingredient may also be incorporated, at a concentration of between 1 and 10% by weight, into an ointment consisting of a white wax or white soft paraffin base together with such stabilizers and preservatives as may be required.
[0285] Dosage Those skilled in the art can easily determine the appropriate dosage of one of the compositions of the present invention to be administered to a subject without undue experimentation.Typically, a doctor will determine the actual dosage that will be most suitable for each patient, and this will depend on various factors, including the activity of the specific compound used, the metabolic stability and duration of action of the compound, age, body weight, overall health, sex, dietary habits, administration mode and time, excretion rate, drug combination, the severity of specific condition, and individual treatment.The dosage disclosed herein is an example of average case.Of course, there may be individual situations where higher or lower dosage ranges are advantageous, and these are within the scope of the present invention.
[0286] The dosage will also vary depending on the mode of administration of the compound. For example, to achieve an "effective dose" for acute treatment, parenteral administration of the compound is typically preferred. Intravenous infusion of the compound in 5% dextrose in water or saline, or a similar formulation containing appropriate excipients, is most effective, but intramuscular bolus injection is also useful. Typically, the parenteral dose is about 0.01 to about 100 mg / kg; preferably 0.1 to 20 mg / kg, in a manner that maintains the plasma drug concentration at a concentration effective to modulate ERAP1. The compound may be administered 1 to 4 times daily at a level that achieves a total daily dose of about 0.4 to about 400 mg / kg / day. The exact amount of the compound of the present invention that is therapeutically effective and the route by which such a compound is best administered can be easily determined by one skilled in the art by comparing the blood level of the drug with the concentration required to have a therapeutic effect.
[0287] The compounds of the present invention may also be orally administered to a patient in a manner that provides a drug concentration sufficient to achieve one or more of the therapeutic indices disclosed herein. Typically, pharmaceutical compositions containing the compounds are administered at an oral dose of between about 0.1 and about 50 mg / kg in a manner consistent with the patient's condition. Preferably, the oral dose is between about 0.5 and about 20 mg / kg.
[0288] No unacceptable toxic effects are expected when the compounds of the present invention are administered in accordance with the present invention. Compounds of the present invention that may have good bioavailability can be tested in one of several biological assays to determine the concentration of the compound required to have a given pharmacological effect.
[0289] combination In a particularly preferred embodiment, one or more compounds of the present invention are administered in combination with one or more additional active agents, such as existing drugs available on the market. Thus, a further aspect of the present invention relates to a combination comprising a compound described herein and one or more additional active agents. In one preferred embodiment, the compound of the present invention can be administered sequentially, simultaneously, or sequentially with one or more other active agents.
[0290] Drugs are generally more effective when used in combination. In particular, combination therapy is desirable to avoid overlapping major toxicities, mechanisms of action, and resistance mechanisms. Furthermore, it is also desirable to administer most drugs at their maximum tolerated doses with minimal time intervals between such doses. The main advantage of combining chemotherapy drugs is that it can promote additive or possibly synergistic effects through biochemical interactions and can reduce the development of resistance.
[0291] Beneficial combinations may be suggested by studying the activity of a test compound with agents known or suspected to be valuable in treating a particular disease. This procedure may also be used to determine the order of administration of agents, i.e., before, concurrently with, or after delivery. Such scheduling may be characteristic of all active agents identified herein.
[0292] In one preferred embodiment, the additional active agent is an immunotherapeutic agent, more preferably a cancer immunotherapeutic agent. "Immunotherapeutic agent" refers to a treatment that uses a subject's own immune system to fight a disease, such as cancer.
[0293] In one preferred embodiment, the compound of the present invention inhibits the activity of ERAP1, and the compound is administered in combination with immunotherapy.
[0294] The compounds may increase the sensitivity of cancer cells to immunotherapy. The immunotherapy may be mediated by T cells. In one embodiment, the compounds may increase the number of CD8+ T cells in the tumor.
[0295] In one embodiment, the compounds may be used to treat cancers that respond poorly or do not respond to immunotherapy.
[0296] In one preferred embodiment, the additional active agent is a molecule capable of immune checkpoint intervention, a co-stimulatory antibody, a chemotherapeutic agent, a radiotherapy agent, a targeted therapy agent or an antibody, in particular a monoclonal antibody.
[0297] In one preferred embodiment, the additional active agent is a molecule capable of immune checkpoint intervention.
[0298] Immune checkpoint molecules include CTLA-4, PD-1, VISTA, B7-H2, B7-H3, PD-L1, B7-H4, B7-H6, ICOS, HVEM, PD-L2, CD160, gp49B, PIR-B, KIR family receptors, TIM-1, TIM-3, TIM-4, LAG-3, GITR, 4-IBB, OX-40, BTLA, SIRP, CD47, CD48, 2B4, B7.1, B7.2, ILT-2, ILT-4, TIGIT, HHLA2, IDO, CD39, CD73, A2aR, and butyrophilin.
[0299] Immune checkpoint molecules include both inhibitory and activating molecules, and intervention can be applied to either or both types of molecules.
[0300] Immune checkpoint inhibitors include, but are not limited to, PD-1 inhibitors, PD-L1 inhibitors, LAG-3 inhibitors, TIM-3 inhibitors, TIGIT inhibitors, BTLA inhibitors, and CTLA-4 inhibitors.Co-stimulatory antibodies deliver positive signals through immunoregulatory receptors, including, but not limited to, ICOS, CD137, CD27, OX-40, and GITR.
[0301] In one highly preferred embodiment, the additional active agent is an antibody checkpoint inhibitor. Suitable examples of antibody checkpoint inhibitors include, but are not limited to, anti-PD-1 antibodies, anti-PD-L1 antibodies, and anti-CTLA4 antibodies.
[0302] In one preferred embodiment, the antibody checkpoint inhibitor is an anti-PD-1 antibody, more preferably selected from pembrolizumab, cemiplimab, and nivolumab.
[0303] In one preferred embodiment, the antibody checkpoint inhibitor is an anti-PD-L1 antibody, more preferably selected from atezolizumab, avelumab, and durvalumab.
[0304] In one preferred embodiment, the antibody checkpoint inhibitor is an anti-CTLA4 antibody, more preferably selected from ipilimumab and tremelimumab.
[0305] In one preferred embodiment, the immunotherapy is an anti-cancer vaccine or a virus, such as an oncolytic virus.
[0306] In one preferred embodiment, the immunotherapy is a cell-based therapy. In one embodiment, the cell-based therapy may be a T cell therapy, such as adoptive T cell therapy, or therapy using CAR-T cells.
[0307] Adoptive cell-based immunotherapies may include irradiated autologous or allogeneic tumor cells, tumor lysates or apoptotic tumor cells, antigen-presenting cell-based immunotherapy, dendritic cell-based immunotherapy, adoptive T cell transfer, adoptive CAR T cell therapy, autoimmune enhancing therapy (AIET), cancer vaccines, and / or antigen-presenting cells. Such cell-based immunotherapies may be further modified to express one or more gene products to further modulate the immune response, for example, to express a cytokine such as GM-CSF, and / or to express a tumor-associated antigen (TAA) antigen such as Mage-1, gp-100, or a patient-specific neoantigen vaccine.
[0308] In further embodiments, immunotherapy may include non-cell-based immunotherapy. In one embodiment, antigen-containing compositions, with or without vaccine-enhancing adjuvants, may be used. Such compositions exist in many well-known forms, for example, as recombinant antigens, including peptide compositions, oncolytic viruses, and fusion proteins.
[0309] In alternative embodiments, immunomodulatory interleukins, such as IL-2, IL-6, IL-7, IL-12, IL-17, and IL-23, and modulators thereof (e.g., blocking antibodies or more potent or longer-lasting forms) may be used. Immunomodulatory cytokines, such as interferons, G-CSF, imiquimod, TF alpha, and the like, and modulators thereof (e.g., blocking antibodies or more potent or longer-lasting forms) may also be used. In another embodiment, immunomodulatory chemokines, such as CCL3, CCL26, and CXCL7, and the like, and modulators thereof (e.g., blocking antibodies or more potent or longer-lasting forms) may be used. In further embodiments, immunomodulatory molecules targeting immunosuppression, such as STAT3 signaling modulators, FkappaB signaling modulators, and immune checkpoint modulators, may be used.
[0310] In another embodiment, an immunomodulatory agent, such as an immunocytostatic agent, drug), glucocorticoids, cytostatics, immunophilins and their modulators (e.g., rapamycin, calcineurin inhibitors, tacrolimus, cyclosporine (cyclosporine), pimecrolimus, avetimus, gusperimus, ridaforolimus, everolimus, temsirolimus, zotarolimus, etc.), hydrocortisone (cortisol), cortisone acetate, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, beclomethasone, fludrocortisone acetate, deoxycorticosterone acetate (doca), aldosterone, non-glucocorticoid steroids, pyrimidine synthesis inhibitors, leflunomide, teriflunomide, folic acid analogs, methotrexate, antithymocyte globulin, antilymphocyte globulin, Thalidomide, lenalidomide, pentoxifylline, bupropion, curcumin, catechin, opioid, EVIPDH inhibitor, mycophenolic acid, myriocin, fingolimod, NF-xB inhibitor, raloxifene, drotrecogin alfa, denosumab, F-xB signaling cascade inhibitor, disulfiram, olmesartan, dithiocarbamate, proteasome inhibitor, bortezomib, MG132, Proline, PI-0052, curcumin, genistein, resveratrol, parthenolide, thalidomide, lenalidomide, flavopiridol, nonsteroidal anti-inflammatory drugs (NSAIDs), arsenic trioxide, dehydroxymethylepoxyquinomycin (DHMEQ), I3C (indole-3-carbinol) / DIM (di-indolemethane) (13C / DIM), Bayer 11-7082, luteolin, cell-penetrating peptide SN-50, IKBa-super-repressor overexpression, FKB decoy oligodeoxynucleotide (ODN), or any derivative or analog thereof may be used.
[0311] In yet another embodiment, immunomodulatory antibodies or proteins may be used, such as antibodies that bind to CD40, Toll-like receptors (TLRs), OX40, GITR, CD27, or 4-IBB, T-cell bispecific antibodies, anti-IL-2 receptor antibodies, anti-CD3 antibodies, OKT3 (muromonab), otelixizumab, teplizumab, visilizumab, anti-CD4 antibodies, clenoliximab, keliximab, zanolimumab, anti-CD11a antibodies, efalizumab, anti-CD18 antibodies, erulizumab, rovelizumab, anti-CD20 antibodies, afutuzumab, Ocrelizumab, ofatumumab, pascolizumab, rituximab, anti-CD23 antibody, lumiliximab, anti-CD40 antibody, teneliximab, toralizumab, anti-CD40L antibody, ruplizumab, anti-CD62L antibody, aselizumab, anti-CD80 antibody, galiximab, anti-CD147 antibody, gavilimomab, B-lymphocyte stimulator (BLyS) inhibitor antibody, belimumab, CTLA4-Ig fusion protein, abatacept, belatacept, anti-CTLA4 antibody, ipilimumab Mabs, tremelimumab, anti-eotaxin 1 antibody, bertilimumab, anti-a4-integrin antibody, natalizumab, anti-IL-6R antibody, tocilizumab, anti-LFA-1 antibody, ozlimomab, anti-CD25 antibody, basiliximab, daclizumab, inolimomab, anti-CD5 antibody, zolimomab, anti-CD2 antibody, siplizumab, nerelimomab, faralimomab, atlizumab, atolimumab, cedelizumab, dorlimomab alitoxin, dorlixizumab, fonti These include izumab, gentenerumab, gomiliximab, levrilizumab, maslimomab, morolimumab, pexelizumab, reslizumab, rovelizumab, talizumab, terimomab-alitonox, bapaliximab, beparimomab, aflibercept, alefacept, rilonacept, IL-1 receptor antagonists, anakinra, anti-IL-5 antibodies, mepolizumab, IgE inhibitors, omalizumab, talizumab, IL12 inhibitors, IL23 inhibitors, and ustekinumab.
[0312] In one embodiment, the subject may be undergoing or may have previously been treated with a chemotherapy agent. Examples of chemotherapy agents include, but are not limited to, alkylating agents such as thiotepa and CYTOXAN cyclophosphamide; alkylsulfonates such as busulfan, improsulfan, and piposulfan; aziridines such as benzodopa, carboquone, metuledopa, and uredopa; ethylenimines and methylmelamines, including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, and trimethylolmelamine; acetogenins (e.g., bullatacin and bullatacinone); camptothecins (including the synthetic analog topotecan); bryostatin; kallistatin; CC-1065 (including its synthetic analogs adozelesin, carzelesin, and bizelesin); cryptophycins (e.g., cryptophycin 1 and cryptophycin 2). 8); dolastatins; duocarmycins (including synthetic analogs, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; sarcodictine; spongistatins; nitrogen mustards, such as chlorambucil, chloranafazine, colofosfamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, nobembine, phenesterine, prednimustine, trophosfamide, uracil mustard; nitrosoureas, such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustin; antibiotics, such as enediyne antibiotics (e.g., calicheamicins, particularly calicheamicin gamma II and calicheamicin omega II (e.g., Agnew, Chem. Intl. Ed. Engl., 33: 183-186 (1994); dynemicins, including dynemicin A; bisphosphonates, such as clodronate; esperamicin;and neocarzinostatin chromophores and related chromoprotein enediyne antibiotic chromophores), aclacinomycin, actinomycin, ausramycin, azaserine, bleomycin, cactinomycin, carabicin, caminomycin, carzinophilin, chromomycin, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, adremiamycin, doxorubicin (including morpholinodoxorubicin, cyanomorpholinodoxorubicin, 2-pyrrolinodoxorubicin, and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycin, peplomycin, potfilomycin, puromycin, queramycin, rodorubicin, streptonigrin benzodiazepine, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogues such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogues such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calsterone, dromostanolone propionate, epithiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid supplements such as florinic acid acid); aceglatone; aldophosphamide glycosides; aminolevulinic acid; eniluracil; amsacrine; bestravcil; bisantrene; edatraxate; demecolcine; diaziconazole; elformitine; elliptinium acetate; epothilone; etoglucide; gallium nitrate; hydroxyurea; lentinan; lonidynin; maytansinoids, such as maytansine and ansamitocin; mitoguazone; mitoxantrone; mopidammol; nitraelin; pentostatin; fenamet; pirarubicin; losoxantrone; podophyllic acid;2-Ethylhydrazide; procarbazine; PSK polysaccharide complex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin; schizofuran; spirogermanium; tenuazonic acid; triazicon; 2,2',2"-trichlorotriethylamine; trichothecenes (e.g., T-2 toxin, veraculin A, roridin A, and anguidine); urethane; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxoids, such as TAXOL paclitaxel (Bristol-Myers Squibb Oncology, Princeton, NJ), ABRAXANE cremophor free, an albumin-modified nanoparticle formulation of paclitaxel (American Pharmaceutical Partners, Schaumberg, 111.), and TAXOTERE doxetaxel (Rhone-Poulenc Rorer, Antony, France); chlorambucil; GEMZAR gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin, oxaliplatin, and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; NAVELBINE vinorelbine; novantrone; teniposide; edatrexate; daunomycin; aminoptera phosphate; Xeloda; ibandronate; irinotecan (Camptosar, CPT-11) (including treatment regimens of irinotecan with 5-FU and leucovorin); topoisomerase inhibitor RFS2000; difluoromethylornithine (DMFO); retinoids, such as retinoic acid; capecitabine; combretastatin; leucovorin (LV); oxaliplatin, including oxaliplatin treatment regimens (FOLFOX); lapatinib (Tykerb);Inhibitors of PKC-α, Raf, H-Ras, EGFR (e.g., erlotinib (Tarceva)), and VEGF-A that reduce cell proliferation, as well as pharmaceutically acceptable salts, acids, or derivatives of any of the above, may also be included. In addition, the treatment method may further include the use of radiation. In addition, the treatment method may further include the use of photodynamic therapy.
[0313] The invention will now be further described by way of the following non-limiting examples and with reference to the following figures: [Brief explanation of the drawings]
[0314] [Figure 1] Figure 1 shows the cellular effects of representative compounds 1 and 242 according to the present invention on antigen presentation, as measured by assessing the effect on the presentation of an ovalbumin-specific peptide (SIINFEKL). More specifically, Figure 1 shows representative IC curves for exemplary compounds according to the present invention. Data were normalized to the signal obtained in the absence of compound (high) and in the absence of antigen (low) and presented as mean ± STD (n=2). [Figure 2] Figure 1 shows a summary of IC50 data generated for exemplary compounds 1 and 242 according to the present invention as determined by the OVA antigen presentation assay described above. Data are presented as mean ± SEM (n=6). [Figure 3] 3 shows the effect of compound 1 according to the present invention on global antigen processing, as determined using an unbiased proteomics pipeline. More specifically, FIG. 3 shows the effect of ERAP1 siRNA and compound inhibition (1 and 10 μM) compared to the control on the immunopeptidome of SiHa cells, as measured by the effect on the total proportion of 8, 9, 10, 11, 12, and 13 amino acid peptides.
[0315] [Example] Where the preparation of starting materials is not described, they are commercially available, known in the literature, or readily obtainable by those skilled in the art using standard procedures. Where compounds are shown to have been prepared similarly to previous examples or intermediates, it will be understood by those skilled in the art that reaction times, number of equivalents of reagents, solvents, concentrations, and temperatures may be modified for each particular reaction, and that it may be necessary or desirable to use different work-up or purification techniques.
[0316] General Scheme Abbreviation A list of some common abbreviations is provided below: If other abbreviations not listed are used, they will be understood by those skilled in the art.
[0317] aq: aqueous; br: broad; ca.: approximately; d: doublet; DCM: dichloromethane; dioxane: 1,4-dioxane; DMAP: 4-dimethylaminopyridine; DMF: dimethylformamide; EDC: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride; Et3N: triethylamine; EtOAc: ethyl acetate; EtOH: ethanol; h: hour; HPLC: high-performance liquid chromatography; IPA: isopropanol; LC: liquid chromatography; m: multiplet; M: mole, molecular ion; MeCN: acetonitrile; MeOH: methanol; min: minute; MS: mass spectrometry; NMR: nuclear magnetic resonance; PDA: photodiode array; q: quartet; RT: room temperature (ca. 20°C); R T: Retention time; s: Singlet, solid; t: Triplet; TBME: tert-butyl methyl ether; TFA: trifluoroacetic acid; THF: tetrahydrofuran; UPLC: ultra-high performance liquid chromatography; UV: ultraviolet; quant.: quantitative; SEM: [2-(trimethylsilyl)ethoxy]methyl acetal; dppf: 1,1'-ferrocenediyl-bis(diphenylphosphine); NBS: n-bromosuccinimide; XantPhos-Pd-G3: [(4,5-bis(diphenylphosphino)-9,9-dimethylxanthene)-2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate (CAS: 1445085-97-1); XPhos Pd G3: (2-Dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate (CAS: 1445085-55-1); Pd-174: allyl(2-di-tert-butylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)palladium(II) triflate (CAS: 1798782-25-8); TBAF: tetra-n-butylammonium fluoride.
[0318] Other abbreviations are intended to convey their generally accepted meaning.
[0319] [ka]
[0320] Reagents: (a) ClSO3H, 100°C; (b) amine, pyridine, DCM, RT
[0321] Chlorosulfonylation of I-1 using chlorosulfonic acid gave the sulfonyl chloride I-2, which upon reaction with an appropriate amine in the presence of pyridine gave the sulfonamide I-3.
[0322] [ka]
[0323] Reagents: (A) amine, DCM; (b) H2, 10% Pd / C, EtOH; (c) Fe, NH4Cl, IPA, water; (d) NH4OH(aq), Na2S2O4, THF, HO, RT; (e) sulfonyl chloride, pyridine, DCM, RT; (f) LiOH(aq), THF, MeOH; (g) LiOH(aq), dioxane.
[0324] Fluoro-2-nitro-4-(trifluoromethyl)benzene (I-4) was reacted with an appropriate amine in a nucleophilic substitution reaction, followed by reduction of the resulting nitro compound I-5 to the aniline I-6, which was then reacted with an appropriate sulfonyl chloride to afford the sulfonamide I-7. Ester hydrolysis afforded the corresponding carboxylic acid I-8.
[0325] [ka]
[0326] Reagents: (a) aniline, pyridine, DCM, RT; (b) amine, THF, 60°C; (c) LiOH(aq), THF, 50°C.
[0327] Reaction of sulfonyl chloride I-9 with an appropriate aniline afforded sulfonamide I-10. Nucleophilic displacement with an appropriate amine afforded I-11, which upon hydrolysis afforded the corresponding carboxylic acid I-12.
[0328] [ka]
[0329] Reagents: (a) sulfonyl chloride, pyridine, DCM, RT; (b) LiOH(aq), dioxane or THF, RT.
[0330] Sulfonamides I-14 were prepared by reaction of anilines I-13 with the appropriate sulfonyl chloride. Ester hydrolysis afforded the corresponding carboxylic acids I-15.
[0331] [ka]
[0332] Reagents: (a) aniline, pyridine, DCM, RT; (b) NaOH(aq), MeOH, HO, RT; (c) LiOH(aq), THF, RT.
[0333] Sulfonamides I-17 were prepared by reaction of sulfonyl chlorides I-16 with the appropriate aniline. Ester hydrolysis afforded the corresponding carboxylic acids I-18.
[0334] [ka]
[0335] Reagents: (a) amines, MeCN; (b) bis(pinacolato)diboron, PdCl2(dppf)·DCM, KOAc, dioxane; (c) H2, Pd / C, MeOH; (d) sulfonyl chlorides, pyridine, DCM, RT; (e) aryl halides, Xphos Pd G3, K3PO4, dioxane, water; (f) LiOH(aq), THF, MeOH; (g) HCl, dioxane.
[0336] 4-Bromo-1-fluoro-2-nitrobenzene (I-19) was reacted with an appropriate amine in a nucleophilic substitution reaction, followed by conversion of the resulting aryl bromide to the boronate ester I-20. Reduction of the nitro group then afforded the corresponding aniline I-21, which was reacted with the appropriate sulfonyl chloride to afford the sulfonamide I-22. Installation of the remaining substituents via Suzuki coupling followed by ester hydrolysis afforded the corresponding carboxylic acid I-24. Alternatively, the steps can be performed in an alternate sequence as shown.
[0337] General experimental conditions All starting materials and solvents were obtained from commercial sources or prepared according to the cited literature. Reaction mixtures were magnetically stirred, and reactions were carried out at room temperature (ca. 20 °C) unless otherwise specified. Column chromatography was performed on an automated flash chromatography system, e.g., CombiFlash Rf system, using pre-packed silica (40 μm) cartridges unless otherwise specified. 1 H NMR spectra were recorded using a 500 MHz Bruker Avance III HD spectrometer equipped with a Bruker 5 mm SmartProbe™. Chemical shifts are expressed in parts per million using the central peak of the residual protic solvent or an internal standard of tetramethylsilane as the reference material. Spectra were recorded at 298 K unless otherwise specified. Analytical UPLC-MS experiments to determine retention times and associated mass ions were performed using a Waters ACQUITY UPLC® H-Class system equipped with an ACQUITY PDA Detector and an ACQUITY QDa Mass Detector, implementing one of the analytical methods described below. Analytical LC-MS experiments to determine retention times and associated mass ions were performed using an Agilent 1200 Series HPLC system coupled to an Agilent 1956, 6100, or 6120 Series single quadrupole mass spectrometer, implementing one of the analytical methods described below. Preparative HPLC purification was performed using a Waters X-Select CSH C18, 5 μm, 19 × 50 mm column with a gradient of MeCN and water, both adjusted with 0.1% v / v formic acid, or a Waters X-Bridge BEH C18, 5 μm, 19 × 50 mm column with a gradient of MeCN and 10 mM ammonium bicarbonate (aq). Fractions were collected following UV detection at a single wavelength measured with a variable wavelength detector. Structural nomenclature was generated using a "structure-to-name" conversion from ChemDraw® Professional 17 (PerkinElmer).
[0338] Analysis method Method 1 - Acidic 3min method Column: Waters ACQUITY UPLC® CSH C18, 1.7 μm, 2.1 × 30 mm, 40°C Detection: UV at 254 nm unless otherwise specified, MS with electrospray ionization Solvents: A: 0.1% v / v formic acid in water, B: 0.1% v / v formic acid in MeCN gradient:
[0339] [Table 1]
[0340] Method 2 - Basic 3min method Column: Waters ACQUITY UPLC® BEH C18, 1.7 μm, 2.1 × 30 mm, 40°C Solvent: A: 10 mM ammonium bicarbonate (aq), B: MeCN (Other parameters are the same as Method 1)
[0341] Method 3 - Acidic 4min method Column: Waters X-Select CSH C18, 2.5 μm, 4.6 × 30 mm, 40 °C Detection: UV at 254 nm unless otherwise specified, MS with electrospray ionization Solvents: A: 0.1% v / v formic acid in water, B: 0.1% v / v formic acid in MeCN gradient:
[0342] [Table 2]
[0343] Method 4 - Basic 4-minute method Column: Waters X-Bridge BEH C18, 2.5 μm, 4.6 × 30 mm, 40 °C Solvent: A: 10 mM ammonium bicarbonate (aq), B: MeCN (Other parameters are the same as Method 3) [Example 1]
[0344] 4-Ethyl-3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid [ka]
[0345] Step 1: 3-(Chlorosulfonyl)-4-ethylbenzoic acid: 4-Ethylbenzoic acid (1 g, 6.66 mmol) in chlorosulfonic acid (10 ml, 149 mmol) was heated at 100° C. overnight. The mixture was cooled and carefully added to stirring ice. The resulting precipitate was collected by filtration to give the title compound (1.58 g, 6.04 mmol, 91% yield, 95% purity) as a white solid. 1 H NMR (500 MHz, DMSO-d6) δ 8.34 (d, J = 1.9 Hz, 1H), 7.82 (dd, J = 7.9, 2.0 Hz, 1H), 7.32 (d, J = 7.9 Hz, 1H), 3.08 (q, J = 7.5 Hz, 2H), 1.19 (t, J = 7.5 Hz, 3H). No exchangeable protons were observed.
[0346] Step 2: 4-Ethyl-3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid: A solution of 2-(piperidin-1-yl)-5-(trifluoromethyl)aniline (0.200 g, 0.819 mmol) in pyridine (3 mL, 37.1 mmol) was treated with the product from Step 1 above (0.244 g, 0.983 mmol), and the solution was stirred at room temperature for 24 hours. The solvent was removed in vacuo, and the crude product was purified by silica gel chromatography (24 g cartridge, 0-100% EtOAc / isohexane, followed by 0-50% EtOAc / DCM) to give the title compound (36.3 mg, 0.076 mmol, 9.23% yield, 97% purity) as a tan solid. UPLC-MS (Method 1) m / z 457.4 (M+H) at 1.87 min + , 455.2(MH) - . 1H NMR(500MHz,DMSO-d6)δ13.28(bs,1H), 9.44(bs,1H), 8.36(d,J=1.8Hz,1H), 8 .09(dd,J=8.0,1.8Hz,1H), 7.60(d,J=8.0Hz,1H), 7.42(dd,J=8.4,2.2Hz,1H) , 7.29(d,J=2.1Hz,1H), 7.25(d,J=8.4Hz,1H), 3.04(q,J=7.4Hz,2H), 2.72(t, J=4.9Hz,4H), 1.57(p,J=5.0Hz,4H), 1.50~1.45(m,2H), 1.21(t,J=7.4Hz,3H). [Example 3]
[0347] 4-Isopropyl-3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid [ka]
[0348] Step 1: 3-(Chlorosulfonyl)-4-isopropylbenzoic acid: 4-Isopropylbenzoic acid (1 g, 6.09 mmol) in chlorosulfonic acid (5 mL, 74.7 mmol) was heated at 100° C. overnight. The mixture was cooled and carefully added to stirring ice. The resulting precipitate was collected by filtration and evaporated to dryness in vacuo to afford the title compound (1.28 g, 4.63 mmol, 76% yield, 95% purity) as a tan solid. 1 H NMR(500MHz,DMSO-d6)δ12.50(bs,1H), 8.36(d,J=1.9Hz,1H), 7.83(dd,J=8.1,1 .9Hz,1H), 7.44(d,J=8.1Hz,1H), 4.20(septet, J=6.8Hz,1H), 1.16(d,J=6.9Hz,6H).
[0349] Step 2: 4-Isopropyl-3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid: A solution of 2-(piperidin-1-yl)-5-(trifluoromethyl)aniline (0.070 g, 0.287 mmol) in DCM (1 mL) and pyridine (0.139 mL, 1.720 mmol) was added to a solution of the product from Step 1 above (0.090 g, 0.344 mmol) in DCM (1 mL), and the solution was stirred at room temperature for 16 hours. The solvent was removed in vacuo, and the residue was purified by silica gel chromatography (24 g cartridge, 0-50% EtOAc / DCM) to give the title compound (14.3 mg, 0.029 mmol, 10% yield, 95% purity) as a light tan solid. UPLC-MS (Method 1) m / z 471.4 (M+H) at 1.93 min + , 469.3(MH) - . 1 H NMR(500MHz,DMSO-d6)δ13.29(bs,1H), 9.40(bs,1H), 8.45(d,J=1.9Hz,1H), 8 .13(dd,J=8.3,1.9Hz,1H), 7.76(d,J=8.2Hz,1H), 7.42(dd,J=8.2,1.9Hz,1H) , 7.27(d,J=8.3Hz,1H), 7.19(d,J=1.9Hz,1H), 3.86(septet, J=6.8Hz,1H), 2.78( t,J=5.2Hz,4H), 1.58(p,J=5.5Hz,4H), 1.51~1.45(m,2H), 1.24~1.10(m,6H). [Example 4]
[0350] 3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-(trifluoromethoxy)benzoic acid [ka]
[0351] Step 1: 3-(Chlorosulfonyl)-4-(trifluoromethoxy)benzoic acid: 4-(trifluoromethoxy)benzoic acid (1 g, 4.85 mmol) in chlorosulfonic acid (5 mL, 74.7 mmol) was heated at 100° C. overnight. The mixture was cooled and carefully added to stirring ice. The resulting precipitate was collected by filtration and evaporated to dryness in vacuo to afford the title compound (0.770 g, 2.28 mmol, 46.9% yield, 90% purity) as a cream-colored solid. 1 H NMR (500MHz, DMSO-d6) δ12.50(bs,1H), 8.40(d,J=2.2Hz,1H), 8.00(dd,J=8.5,2.2Hz,1H), 7.41(dq,J=8.5,1.8Hz,1H).
[0352] Step 2: 3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-(trifluoromethoxy)benzoic acid: A solution of 2-(piperidin-1-yl)-5-(trifluoromethyl)aniline (0.070 g, 0.287 mmol) in DCM (1 mL) and pyridine (0.139 mL, 1.72 mmol) was added to a solution of the product from Step 1 above (0.105 g, 0.344 mmol) in DCM (1 mL), and the solution was stirred at room temperature for 16 hours. The solvent was removed in vacuo, and the residue was purified by silica gel chromatography (24 g cartridge, 0-50% EtOAc / DCM) to give the title compound (5.6 mg, 10.4 μmol, 3.6% yield, 95% purity) as a cream-colored solid. UPLC-MS (Method 1) m / z 513.3 (M+H) at 1.94 min + , 511.1(MH) - . 1 H NMR(500MHz,DMSO-d6)δ13.68(bs,1H), 9.50(bs,1H), 8.45(d,J=1.7Hz,1H), 8.27(dd,J=8.2,1.5Hz,1H), 7.68(d,J=8.7Hz,1H), 7.46~7.44(m,2H), 7.27(d,J=8.2Hz,1H), 2.71(t,J=5.0Hz,4H), 1.62~1.34(m,6H). [Example 6]
[0353] 3-(N-(2-(cis-3,5-dimethylpiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid [ka]
[0354] Step 1: cis-3,5-Dimethyl-1-(2-nitro-4-(trifluoromethyl)phenyl)piperidine: EtN (0.5 mL, 3.59 mmol) was added to a solution of 1-fluoro-2-nitro-4-(trifluoromethyl)benzene (201 μL, 1.44 mmol) and cis-3,5-dimethylpiperidine (211 mg, 1.87 mmol) in DCM (6 mL), and the resulting solution was stirred at room temperature for 20 h. The crude product was purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc in isohexane followed by 0-10% MeOH / DCM) to give the title compound (356 mg, 1.12 mmol, 78% yield, 95% purity) as a pale orange solid. UPLC-MS (Method 1) m / z 303.4 (M+H) at 2.01 min. + .
[0355] Step 2: 2-(cis-3,5-dimethylpiperidin-1-yl)-5-(trifluoromethyl)aniline: The product from Step 1 above (150 mg, 0.496 mmol) was dissolved in EtOH (9.9 ml), and the reaction mixture was hydrogenated in a Thales Nano H-cube® flow reactor (10% Pd / C, 30 × 4 mm cartridge, full hydrogen mode, 40 °C, flow rate 1 ml / min, 2-flow). The reaction mixture was concentrated in vacuo and azeotroped with MeOH (6 ml) to give the title compound (133 mg, 0.479 mmol, 96% yield, 98% purity) as a pale brown oil. UPLC-MS (Method 2) m / z 273.3 (M+H) at 2.00 min. + , 271.1(MH) - .
[0356] Step 3: Methyl 3-(N-(2-(cis-3,5-dimethylpiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoate: The product from Step 2 above (51.4 mg, 0.189 mmol) was dissolved in a mixture of DCM (1 mL) and pyridine (50 μL, 0.618 mmol) and treated with a solution of methyl 3-(chlorosulfonyl)-4-methoxybenzoate (60 mg, 0.227 mmol) in DCM (1 mL). The resulting solution was stirred at room temperature for 3 days. The reaction mixture was directly loaded and purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to afford the title compound (63 mg, 0.120 mmol, 63.3% yield, 95% purity) as a cream-colored solid. UPLC-MS (Method 1) m / z 501.4 (M+H) at 2.05 min + , 498.9(MH) - .
[0357] Step 4: 3-(N-(2-(cis-3,5-dimethylpiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid: The product from Step 3 above (61 mg, 0.122 mmol) was dissolved in THF (2 ml) and treated with 1.1 M LiOH(aq) (443 μl, 0.487 mmol). MeOH was added dropwise until a clear solution formed. The reaction mixture was heated at 40° C. for 24 hours and then cooled to room temperature overnight. The reaction mixture was diluted with water (3 ml), concentrated in vacuo and the resulting aqueous solution was diluted with water (5 ml). 1 M HCl(aq) was added dropwise until the pH was approximately 6. The resulting white precipitate was collected by filtration and washed with water. The solid was suspended in MeCN (4 ml), concentrated in vacuo, and dried at 45° C. to give the title compound (55 mg, 0.113 mmol, 88% yield, 95% purity) as a pale yellow solid. UPLC-MS (Method 1) m / z 487.4 (M+H) at 1.89 min + , 485.2(MH) - . 1H NMR(500MHz,DMSO-d6)δ13.16(s,1H), 8.82(s,1H), 8.34(d,J=2.3Hz,1H), 8.15 (dd,J=8.7,2.3Hz,1H), 7.47(d,J=2.1Hz,1H), 7.36(dd,J=8.5,2.1Hz,1H), 7.3 0(d,J=8.7Hz,1H), 7.29(d,J=8.5Hz,1H), 3.84(s,3H), 2.89~2.80(m,2H), 2.14 (t,J=11.0Hz,2H), 1.82~1.65(m,3H), 0.81(d,J=6.4Hz,6H), 0.67~0.59(m,1H). [Example 7]
[0358] 3-(N-(2-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid [ka]
[0359] Step 1: 3-(2-nitro-4-(trifluoromethyl)phenyl)-8-oxa-3-azabicyclo[3.2.1]octane: EtN (0.583 ml, 4.18 mmol) was added to a solution of 1-fluoro-2-nitro-4-(trifluoromethyl)benzene (0.167 ml, 1.20 mmol) and 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (221 mg, 1.44 mmol) in DCM (5 ml), and the resulting solution was stirred at room temperature for 2 hours. 1 M HCl (aq) (2 ml) was added, and the organic phase was separated by passing through a phase separator and concentrated in vacuo to give the title compound (384 mg, 1.08 mmol) as a yellow solid. UPLC-MS (Method 2) m / z 303.2 (M+H) at 1.54 min. + . 1H NMR(500MHz,DMSO-d6)δ8.13~8.08(m,1H), 7.84(dd,J=8.9,2.3Hz,1H), 7.46(d,J=8. 9Hz,1H), 4.39~4.32(m,2H), 3.16~3.11(m,2H), 3.02~2.97(m,2H), 1.89~1.77(m,4H).
[0360] Step 2: 2-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-5-(trifluoromethyl)aniline: The product from Step 1 above (323 mg, 1.07 mmol) was dissolved in EtOH (21.2 ml), and the reaction mixture was hydrogenated in a Thales Nano H-cube® flow reactor (10% Pd / C, 30 × 4 mm cartridge, full hydrogen mode, 40 °C, flow rate 1 ml / min, 4 flow paths). The reaction mixture was concentrated in vacuo and azeotroped with MeOH (8 ml) to give the title compound (310 mg, 1.059 mmol, 100% yield, 93% purity) as an off-white solid. UPLC-MS (Method 2) m / z 273.3 (M+H) at 1.43 min. + . 1 H NMR(500MHz,DMSO-d6)δ7.05(d,J=8.2Hz,1H), 7.02(d,J=2.2Hz,1H), 6.86(dd,J=8.2,2.2Hz,1H), 5.01(br s,2H), 4.36~4.31(m,2H), 2.88~2.82(m,2H), 2.79(dd,J=11.5,2.0Hz,2H), 2.09~2.03(m,2H), 1.88~1.80(m,2H).
[0361] Step 3: Methyl 3-(N-(2-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoate: Pyridine (58 μL, 0.72 mmol) was added to a solution of the product from Step 2 above (66.5 mg, 0.239 mmol) and methyl 3-(chlorosulfonyl)-4-methoxybenzoate (80 mg, 0.287 mmol) in DCM (2 mL) at room temperature. The resulting solution was stirred at 40° C. for 4 hours, after which additional methyl 3-(chlorosulfonyl)-4-methoxybenzoate (80 mg, 0.287 mmol) and pyridine (58 μL, 0.718 mmol) were added, and the mixture was stirred at 40° C. for an additional 19 hours. The reaction mixture was concentrated in vacuo. The crude product was purified by silica gel chromatography (25 g cartridge, 0-80% EtOAc / isohexane) to give the title compound (88.3 mg, 0.173 mmol, 72.3% yield, 98% purity) as an off-white solid. UPLC-MS (Method 2) m / z 501.3 (M+H) at 1.59 min + , 499.2(MH) - .
[0362] Step 4: 3-(N-(2-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid: 1M LiOH(aq) (0.699 ml, 0.699 mmol) was added to a solution of the product from Step 3 above (87.4 mg, 0.175 mmol) in THF (1.4 ml) at room temperature, and the resulting solution was stirred at room temperature for 24 hours. The reaction mixture was concentrated in vacuo, and the residue was redissolved in water (3 ml) and acidified to pH 4-5 using 1M HCl(aq). The precipitate was isolated by filtration and then dried to give the title compound (74 mg, 0.152 mmol, 87% yield, 100% purity) as a white solid. UPLC-MS (Method 1) m / z 487.3 (M+H) at 1.45 min + , 485.1(MH) - . 1H NMR (500MHz, DMSO-d6) δ13.13 (br s, 1H), 8.88 (br s,1H), 8.24(d,J=2.2Hz,1H), 8.18(dd,J=8.7,2.2Hz,1H), 7.46~7.34(m,2H), 7.27(d,J=8.5Hz,1H), 6.98(d,J=2.1Hz,1H), 4.40~4.33(m,2H), 3.95(s,3H), 3.01(d,J=11.2Hz,2H), 2.95(dd,J=11.6,2.0Hz,2H), 2.13~2.05(m,2H), 1.92~1.84(m,2H). [Example 8]
[0363] 4-Methoxy-3-(N-(2-(cis-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid [ka]
[0364] Step 1: cis-2-Methyl-5-(2-nitro-4-(trifluoromethyl)phenyl)octahydropyrrolo[3,4-c]pyrrole: EtN (0.417 ml, 2.99 mmol) was added to a solution of 1-fluoro-2-nitro-4-(trifluoromethyl)benzene (0.167 ml, 1.20 mmol) and cis-2-methyloctahydropyrrolo[3,4-c]pyrrole (187 mg, 1.44 mmol) in DCM (5 ml) at room temperature, and the resulting solution was stirred at room temperature for 2 hours. 1 M HCl (aq) (2 ml) was added, and the organic phase was dried by passing through a phase separator and concentrated in vacuo to give the title compound (402 mg, 1.20 mmol, quantitative yield, 93% purity) as an orange solid. UPLC-MS (Method 2) m / z 316.3 (M+H) at 1.40 min. + . 1H NMR(500MHz,DMSO-d6)δ8.04~8.01(m,1H), 7.72(dd,J=9.1,2.4Hz,1H), 7.22(d,J=9.0Hz,1H), 3. 49~3.42(m,2H), 3.13(dd,J=10.8,3.4Hz,2H), 2.94~2.85(m,2H), 2.53~2.44(m,4H), 2.24(s,3H). The signal at 2.49 ppm is obscured by the DMSO signal.
[0365] Step 2: 2-(cis-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-5-(trifluoromethyl)aniline: The product from Step 1 above (376 mg, 1.19 mmol) was dissolved in EtOH (23.9 ml), and the reaction mixture was hydrogenated in a Thales Nano H-cube® flow reactor (10% Pd / C, 30 × 4 mm cartridge, full hydrogen mode, 40 °C, flow rate 1 ml / min, 2 flows). The reaction mixture was concentrated in vacuo and azeotroped with MeOH (12 ml) to give the title compound (355 mg, 1.17 mmol, 98% yield, 94% purity) as an off-white solid. UPLC-MS (Method 2) 286.3 (M+H) at 1.24 min. + .
[0366] Step 3: Methyl 4-methoxy-3-(N-(2-(cis-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoate: Pyridine (58 μL, 0.72 mmol) was added to a slurry of the product from Step 2 above (72.6 mg, 0.239 mmol) and methyl 3-(chlorosulfonyl)-4-methoxybenzoate (80 mg, 0.287 mmol) in DCM (2 mL) at room temperature. The resulting solution was stirred at 40° C. for 4 hours, after which additional methyl 3-(chlorosulfonyl)-4-methoxybenzoate (80 mg, 0.287 mmol) and pyridine (0.058 mL, 0.718 mmol) were added, and the mixture was stirred at 40° C. for an additional 19 hours. The reaction mixture was concentrated in vacuo and the crude product was purified by silica gel chromatography (25 g cartridge, 0-10% MeOH / DCM) to give the title compound (158 mg, 0.193 mmol, 81% yield, 63% purity) as an off-white solid. UPLC-MS (Method 2) m / z 514.4 (M+H) at 1.26 min + , 512.2(MH) - .
[0367] Step 4: 4-Methoxy-3-(N-(2-(cis-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid: 1M LiOH(aq) (1.23 ml, 1.23 mmol) was added to a solution of the product from Step 3 above (158 mg, 0.308 mmol) in THF (2.5 ml) at room temperature, and the solution was stirred at room temperature for 26 hours. The reaction mixture was concentrated in vacuo, and the residue was redissolved in water (3 ml) and acidified to pH 4-5 using 1M HCl(aq). The precipitate was isolated by filtration and then dried in vacuo to give the title compound (63.5 mg, 0.127 mmol, 41.3% yield, 98% purity) as an off-white solid. UPLC-MS (Method 2) m / z 500.3 (M+H) at 0.83 min + , 498.3(MH) - . 1H NMR(500MHz,DMSO-d6)δ8.22(d,J=2.2Hz,1H), 8.13(dd,J=8.7,2.2Hz,1H), 7.31(d,J=8.7Hz,1H), 7.28~7.24(m,1H), 6.97~6.91(m,2H), 3. 90(s,3H), 3.36(dd,J=9.8,6.5Hz,2H), 3.22(dd,J=10.0,2.7Hz,2H), 2.86~2.80(m,2H), 2.75~2.69(m,2H), 2.64~2.59(m,2H), 2.38(s,3H). Two exchangeable protons were not observed. [Example 9]
[0368] 3-(N-(2-(3,3-difluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid [ka]
[0369] Step 1: 3,3-Difluoro-1-(2-nitro-4-(trifluoromethyl)phenyl)piperidine: EtN (0.500 mL, 3.59 mmol) was added to a solution of 1-fluoro-2-nitro-4-(trifluoromethyl)benzene (0.201 mL, 1.44 mmol) and 3,3-difluoropiperidine hydrochloride (271 mg, 1.72 mmol) in DCM (6 mL), and the resulting solution was stirred at room temperature for 20 h. Water (3 mL) was added, and the phases were separated using a phase separator. The aqueous phase was extracted with DCM (2 × 3 mL), and the organic phases were combined, dried by passing through a phase separator, and concentrated in vacuo. The crude product was purified by silica gel chromatography (12 g cartridge, 0–100% EtOAc / isohexane) to afford the title compound (399 mg, 1.26 mmol, 87.8% yield, >98% purity) as a bright yellow solid. UPLC-MS (Method 2) m / z 1.64 min, 309.0 (MH) - .
[0370] Step 2: 2-(3,3-Difluoropiperidin-1-yl)-5-(trifluoromethyl)aniline: The product from Step 1 above (156 mg, 0.503 mmol) was dissolved in EtOH (10.1 ml), and the reaction mixture was hydrogenated in a Thales Nano H-cube® flow reactor (10% Pd / C, 30 × 4 mm, full hydrogen mode, 40 °C, flow rate 1 ml / min, 2-flow). The reaction mixture was concentrated in vacuo and azeotroped with MeOH (6 ml) to give the title compound (119 mg, 0.408 mmol, 81% yield, 96% purity) as a colorless oil. UPLC-MS (Method 2) m / z 280.8 (M+H) at 1.64 min. + .
[0371] Step 3: Methyl 3-(N-(2-(3,3-difluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoate: The product from Step 2 above (53.0 mg, 0.189 mmol) was dissolved in a mixture of DCM (1 mL) and pyridine (0.05 mL, 0.618 mmol) and treated with a solution of methyl 3-(chlorosulfonyl)-4-methoxybenzoate (60.0 mg, 0.227 mmol) in DCM (1 mL). The resulting solution was stirred at room temperature for 4 days. The crude product was purified by silica gel chromatography (12 g cartridge, 0-10% MeOH / DCM) to afford the title compound (39.9 mg, 0.075 mmol, 39.4% yield, 95% purity) as a white solid. UPLC-MS (Method 1) m / z 509.4 (M+H) at 1.75 min. + , 507.2(MH) - .
[0372] Step 4: 3-(N-(2-(3,3-Difluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid: The product from Step 3 above (38 mg, 0.075 mmol) was dissolved in THF (2 ml) and treated with 1.1 M LiOH (aq) (272 μl, 0.299 mmol), and MeOH was added dropwise until the mixture went into solution. The reaction mixture was stirred at 30° C. for 4 days. The reaction mixture was diluted with water (3 ml) and concentrated in vacuo, and the resulting aqueous solution was diluted with water (to approximately 5 ml) and neutralized to pH approximately 6 with 1 M HCl. The resulting chunky suspension was sonicated to give a cloudy solution. The white precipitate was collected by filtration, washed with water, and the solid was suspended in MeCN (4 ml), concentrated in vacuo, and dried at 45° C. to give the title compound (34 mg, 0.065 mmol, 87% yield, 95% purity) as a white solid. UPLC-MS (Method 1) m / z 495.1 (M+H) at 1.59 min + , 493.1(MH) - , purity 98% (254nm). 1 H NMR (500MHz, DMSO-d6) δ13.18 (br s, 1H), 8.60 (br s,1H), 8.37(d,J=2.2Hz,1H), 8.16(dd,J=8.7,2.2Hz,1H), 7.41~7.36(m,3H), 7.32(d,J=8.8Hz,1H) , 3.91(s,3H), 3.17(t,J=11.1Hz,2H), 2.95(t,J=5.3Hz,2H), 2.13~2.00(m,2H), 1.88~1.84(m,2H). [Example 10]
[0373] 3-(N-(2-(8-azabicyclo[3.2.1]octan-8-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid [ka]
[0374] Step 1: 8-(2-Nitro-4-(trifluoromethyl)phenyl)-8-azabicyclo[3.2.1]octane: EtN (0.236 ml, 1.69 mmol) was added to a solution of 1-fluoro-2-nitro-4-(trifluoromethyl)benzene (0.095 ml, 0.677 mmol) and 8-azabicyclo[3.2.1]octane hydrochloride (100 mg, 0.677 mmol) in DCM (2 ml), and the resulting solution was stirred at room temperature for 20 hours. Water (3 ml) was added, and the phases were separated using a phase separator. The aqueous phase was extracted with DCM (2 × 3 ml), and the organic phases were combined, dried by passing through a phase separator, and concentrated in vacuo. The crude product was purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to give the title compound (183 mg, 0.597 mmol, 88.2% yield, 98% purity). UPLC-MS (Method 2) m / z 301.3 (M+H) at 1.85 min + .
[0375] Step 2: 2-(8-Azabicyclo[3.2.1]octan-8-yl)-5-(trifluoromethyl)aniline: The product from Step 1 above (134 mg, 0.446 mmol) was dissolved in EtOH (8.9 ml), and the reaction mixture was hydrogenated in a Thales Nano H-cube® flow reactor (10% Pd / C, 30 × 4 mm, full hydrogen mode, 40 °C, flow rate 1 ml / min, 2-flow). The reaction mixture was concentrated in vacuo and azeotroped with MeOH (6 ml) to give the title compound (104 mg, 0.366 mmol, 82% yield, 95% purity) as a colorless oil. UPLC-MS (Method 2) m / z 271.3 (M+H) at 1.83 min. + .
[0376] Step 3: Methyl 3-(N-(2-(-8-azabicyclo[3.2.1]octan-8-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoate: The product from Step 2 above (51.1 mg, 0.189 mmol) was dissolved in a mixture of DCM (1 mL) and pyridine (0.05 mL, 0.618 mmol) and treated with a solution of methyl 3-(chlorosulfonyl)-4-methoxybenzoate (60.0 mg, 0.227 mmol) in DCM (1 mL). The resulting solution was stirred at room temperature for 4 days. The crude product was purified by silica gel chromatography (12 g cartridge, 0–10% MeOH / DCM) to afford the title compound (32.1 mg, 0.061 mmol, 32.4% yield, 95% purity) as a white solid. UPLC-MS (method 1) m / z 1.90 min 499.3 (M+H) + , 497.2(MH) - .
[0377] Step 4: 3-(N-(2-(-8-Azabicyclo[3.2.1]octan-8-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid: The product from Step 3 above (30 mg, 0.060 mmol) was dissolved in THF (2 ml) and treated with 1.1 M LiOH(aq) (219 μl, 0.241 mmol). MeOH was added dropwise until the mixture went into solution, and the reaction was stirred at 30° C. for 4 days. The reaction mixture was diluted with water (3 ml), concentrated in vacuo, and the resulting aqueous solution was diluted with water (to approximately 5 ml) and neutralized to pH approximately 6 with 1 M HCl. The resulting chunky suspension was sonicated to give a cloudy solution, and the precipitate was collected by filtration and washed with water. The solid was suspended in MeCN (4 ml), concentrated in vacuo, and dried at 45° C. The crude product was purified by preparative HPLC (Waters, Acidic (0.1% formic acid), Acidic, Waters X-Select Prep-C18, 5 μm, 19 × 50 mm column, 50-80% MeCN in water) to give the title compound (9.0 mg, 0.018 mmol, 29.3% yield, 95% purity) as a white solid. UPLC-MS (Method 1) m / z 485.2 (M+H) at 1.74 min. + , 483.3(MH)- . 1 H NMR (500MHz, DMSO-d6) δ13.12 (br s, 1H), 8.96 (br s,1H), 8.21(d,J=2.2Hz,1H), 8.16(dd,J=8.8,2.2Hz,1H), 7.34(d,J=8.7Hz,1H), 7.27(dd,J=8.7,2.3Hz,1H), 7.01(d,J=8.7Hz ,1H), 6.95~6.92(m,1H), 4.29(s,2H), 3.93(s,3H), 1.91~1.86(m,2H), 1.79~1.68(m,6H), 1.55~1.46(m,1H), 1.45~1.37(m,1H). [Example 11]
[0378] 3-(N-(2-(5-oxa-2-azaspiro[3.4]octan-2-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid [ka]
[0379] Step 1: 2-(2-nitro-4-(trifluoromethyl)phenyl)-5-oxa-2-azaspiro[3.4]octane: EtN (500 μL, 3.59 mmol) was added to a solution of 1-fluoro-2-nitro-4-(trifluoromethyl)benzene (201 μL, 1.44 mmol) and 5-oxa-2-azaspiro[3.4]octane hemioxalate (349 mg, 2.21 mmol) in DCM (6 mL), and the resulting solution was stirred at room temperature for 20 hours. 1 M HCl (aq) (2 mL) was added, and the organic phase was dried by passing through a phase separator. The organic phase was concentrated in vacuo to give the title compound (438 mg, 1.44 mmol, 100% yield, 99% purity) as a pale yellow sticky oil. UPLC-MS (Method 2) m / z 303.3 (M+H) at 1.59 min + .
[0380] Step 2: 2-(5-oxa-2-azaspiro[3.4]octan-2-yl)-5-(trifluoromethyl)aniline: The product from Step 1 above (217 mg, 0.718 mmol) was dissolved in EtOH (14.4 ml), and the reaction mixture was hydrogenated in a Thales Nano H-cube® flow reactor (10% Pd / C, 30 × 4 mm, full hydrogen mode, 40 °C, flow rate 1 ml / min, 2-flow). The reaction mixture was concentrated in vacuo and azeotroped with MeOH (6 ml) to give the title compound (198 mg, 0.691 mmol, 96% yield, 95% purity) as a white solid. UPLC-MS (Method 2) m / z 273.3 (M+H) at 1.37 min. + .
[0381] Step 3: Methyl 3-(N-(2-(5-oxa-2-azaspiro[3.4]octan-2-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoate: The product from Step 2 above (0.073 g, 0.268 mmol) was dissolved in a mixture of DCM (1 mL) and pyridine (0.087 mL, 1.07 mmol) and treated with a solution of methyl 3-(chlorosulfonyl)-4-methoxybenzoate (0.085 g, 0.321 mmol) in DCM (1 mL). The resulting solution was stirred at room temperature for 20 hours. The crude product was directly purified by silica gel chromatography (12 g cartridge, 0–100% EtOAc / isohexane) to afford the title compound (93.7 mg, 0.178 mmol, 70.0% yield, 95% purity) as an off-white solid. UPLC-MS (method 1) m / z 1.54 min at 501.4 (M+H) + , 498.8(MH) - .
[0382] Step 4: 3-(N-(2-(5-oxa-2-azaspiro[3.4]octan-2-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid: The product from Step 3 above (92 mg, 0.184 mmol) was dissolved in THF (2 ml) and treated with 1.1 M LiOH (aq) (668 μl, 0.735 mmol). MeOH was added dropwise until the mixture went into solution, and the reaction was stirred at 30° C. for 3 days. The reaction mixture was diluted with water (3 ml), concentrated in vacuo, and the resulting aqueous solution was diluted with water (to approximately 5 ml) and neutralized to pH approximately 6 with 1 M HCl. The resulting chunky suspension was sonicated to give a cloudy solution. The white precipitate was collected by filtration, washed with water, and the solid was suspended in MeCN (4 ml), concentrated in vacuo, and dried at 45° C. The crude product was purified by preparative HPLC (Waters, Acidic (0.1% formic acid), Acidic, Waters X-Select Prep-C18, 5 μm, 19 × 50 mm column, 35-65% MeCN in water) to give the title compound (3 mg, 5.98 μmol, 3.25% yield, 97% purity) as a fluffy white solid. UPLC-MS (Method 1) m / z 487.0 (M+H) at 1.37 min + , 485.2(MH) - . 1 H NMR (500MHz, methanol-d4) δ8.33(d,J=2.2Hz,1H), 8.29(dd,J=8.7,2.2Hz,1H), 7.35(d,J=8.7Hz,1H), 7.30(dd,J=8.6,2.2Hz,1H), 6.70(d,J=2.1Hz,1H) , 6.55(d,J=8.6Hz,1H), 4.21(d,J=9.0Hz,2H), 4.08(d,J=9.0Hz,2H), 4.02( s,3H), 3.88(t,J=7.0Hz,2H), 2.20(t,J=7.0Hz,2H), 2.00(p,J=7.0Hz,2H). Two exchangeable protons were not observed. [Example 12]
[0383] 3-(N-(2-(4,4-difluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid [ka]
[0384] Step 1: 4,4-Difluoro-1-(2-nitro-4-(trifluoromethyl)phenyl)piperidine: EtN (0.47 mL, 3.37 mmol) was added to a solution of 1-fluoro-2-nitro-4-(trifluoromethyl)benzene (0.188 mL, 1.34 mmol) and 4,4-difluoropiperidine (196 mg, 1.62 mmol) in DCM (5 mL), and the resulting solution was stirred at room temperature for 19 hours. Water (2.5 mL) was added, and the organic phase was isolated using a phase separator and concentrated in vacuo to give the title compound (434 mg, 1.04 mmol, 77% yield, 74% purity) as an orange oil. UPLC (Method 2) 1.67 min. 1 H NMR (500MHz, DMSO-d6) δ8.20(d,J=2.3Hz,1H), 7.89(dd,J=8.9,2.4Hz,1H), 7.53(d,J=8.8Hz,1H), 3.28~3.23(m,4H), 2.16~2.06(m,4H).
[0385] Step 2: 2-(4,4-Difluoropiperidin-1-yl)-5-(trifluoromethyl)aniline: The product from Step 1 above (180 mg, 0.580 mmol) was dissolved in EtOH (23.2 ml), and the reaction mixture was hydrogenated in a Thales Nano H-cube® flow reactor (10% Pd / C, 30 × 4 mm, full hydrogen mode, 21 °C, flow rate 1 ml / min, 1 flow path). The reaction mixture was concentrated in vacuo and azeotroped with MeOH (8 ml) to give the title compound (159 mg, 0.545 mmol, 94% yield, 96% purity) as an off-white solid. UPLC-MS (Method 2) m / z 281.3 (M+H) at 1.63 min. + . 1H NMR(500MHz,DMSO-d6)δ7.04(d,J=8.1Hz,1H), 6.97(d,J=2.2Hz,1H), 6.82(dd,J=8.2,2.1Hz,1H), 5.27(s,2H), 2.93(br t,J=5.5Hz,4H), 2.24~2.09(m,4H).
[0386] Step 3: Methyl 3-(N-(2-(4,4-difluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoate: Pyridine (0.058 ml, 0.718 mmol) was added to a solution of the product from Step 2 above (69.8 mg, 0.239 mmol) and methyl 3-(chlorosulfonyl)-4-methoxybenzoate (80 mg, 0.287 mmol) in DCM (2.0 ml) at room temperature. The reaction mixture was stirred and heated at 40° C. for 18 hours. Additional methyl 3-(chlorosulfonyl)-4-methoxybenzoate (33 mg, 0.120 mmol) was added and the resulting solution was stirred at 40° C. for an additional 3 hours. The reaction mixture was concentrated in vacuo and the crude product was purified by silica gel chromatography (10 g cartridge, 0-30% EtOAc / isohexane) to give the title compound (107 mg, 0.196 mmol, 82% yield, 93% purity) as an off-white solid. UPLC-MS (Method 2) m / z 509.3 (M+H) at 1.72 min + , 507.2(MH) - .
[0387] Step 4: 3-(N-(2-(4,4-Difluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid: 1M LiOH(aq) (0.632 ml, 0.632 mmol) was added to a solution of the product from Step 3 above (107 mg, 0.210 mmol) in THF (1.26 ml) at room temperature. The resulting clear solution was stirred at room temperature for 20 hours. Additional 1M LiOH(aq) (0.211 ml, 0.211 mmol) was added and the solution was stirred for a further hour. The reaction mixture was concentrated in vacuo and the residue redissolved in water (3 ml) and acidified to pH 4-5 using 1M HCl(aq). The precipitate was dissolved in DCM (10 ml) and the phases separated. The aqueous phase was extracted with DCM (2 x 3 ml). The combined organic phase was dried by passing through a phase separator and concentrated in vacuo. The crude product was purified by silica gel chromatography (10 g cartridge, 0-3.5% MeOH / DCM) to give an off-white solid (40.1 mg). The product was purified by preparative HPLC (Waters, Acidic (0.1% formic acid), Acidic, Waters X-Select Prep-C18, 5 μm, 19 × 50 mm column, 50-80% MeCN in water) to give the title compound (19 mg, 0.038 mmol, 18.3% yield, 100% purity) as a white solid. UPLC-MS (Method 1) m / z 495.3 (M+H) at 1.61 min. + , 493.2(MH) - . 1 H NMR (500MHz, DMSO-d6) δ13.15 (br s, 1H), 9.30 (br s,1H), 8.36(d,J=2.2Hz,1H), 8.16(dd,J=8.7,2.3Hz,1H), 7.48~7.44(m,1H), 7.41~7.35(m,1H), 7.35(d,J=8.5Hz,1H), 7.32(d,J=8.8Hz,1H), 3.87(s,3H), 2.96~2.86(m,4H), 2.18~2.08(m,4H). [Example 13]
[0388] 3-(N-(2-(8-hydroxy-3-azabicyclo[3.2.1]octan-3-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid [ka]
[0389] Step 1: 3-(2-nitro-4-(trifluoromethyl)phenyl)-3-azabicyclo[3.2.1]octan-8-ol: EtN (500 μL, 3.59 mmol) was added to a solution of 1-fluoro-2-nitro-4-(trifluoromethyl)benzene (201 μL, 1.44 mmol) and 3-azabicyclo[3.2.1]octan-8-ol hydrochloride (250 mg, 1.53 mmol) in DCM (6 mL), and the resulting solution was stirred at room temperature for 20 h. 1 M HCl (aq) (2 mL) was added, and the organic phase was dried by passing through a phase separator and concentrated in vacuo to give the title compound (468 mg, 1.44 mmol, 100% yield, 97% purity) as a pale orange solid. UPLC-MS (Method 2) m / z 315.1 (M−H) at 1.53 min. - .
[0390] Step 2: 3-(2-amino-4-(trifluoromethyl)phenyl)-3-azabicyclo[3.2.1]octan-8-ol: The product from Step 1 above (227 mg, 0.718 mmol) was dissolved in EtOH (14.4 ml), and the reaction mixture was hydrogenated in a Thales Nano H-cube® flow reactor (10% Pd / C, 30 × 4 mm, full hydrogen, 40 °C, flow rate 1 ml / min, 2 flows). The reaction mixture was concentrated in vacuo and azeotroped with MeOH (6 ml) to give the title compound (186 mg, 0.585 mmol, 81% yield, 90% purity) as a pale pink solid. UPLC-MS (Method 2) m / z 287.3 (M+H) at 1.38 min. + , 285.2(MH) - .
[0391] Step 3: Methyl 3-(N-(2-(8-hydroxy-3-azabicyclo[3.2.1]octan-3-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoate: The product from Step 2 above (63.1 mg, 0.220 mmol) was dissolved in a mixture of DCM (1 mL) and pyridine (71.3 μL, 0.882 mmol) and treated with a solution of methyl 3-(chlorosulfonyl)-4-methoxybenzoate (70 mg, 0.264 mmol) in DCM (1 mL). The resulting solution was stirred at room temperature for 20 hours. The crude product was purified by silica gel chromatography (12 g cartridge, 0–100% EtOAc / isohexane) to afford the title compound (51 mg, 0.087 mmol, 39.6% yield, 88% purity) as a white solid. UPLC-MS (method 1) m / z 1.60 min 515.4 (M+H) + 、 513.2(MH) - .
[0392] Step 4: 3-(N-(2-(8-hydroxy-3-azabicyclo[3.2.1]octan-3-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid: The product from Step 3 above (49 mg, 0.095 mmol) was dissolved in THF (2 ml) and treated with 1.1 M LiOH(aq) (346 μl, 0.381 mmol). MeOH was added dropwise until the mixture went into solution, and the reaction was stirred at 30° C. for 20 hours. The reaction mixture was diluted with water (3 ml), concentrated in vacuo, and the resulting aqueous solution was diluted with water (to approximately 5 ml). The aqueous phase was washed with EtOAc (2×5 ml) and neutralized to pH approximately 6 with 1 M HCl. The resulting chunky suspension was sonicated to give a cloudy solution, which was concentrated in vacuo to approximately 2 ml. The precipitate was collected by filtration and washed with water (2×2 ml). The solid was suspended in MeCN (4 ml), concentrated in vacuo, and dried at 45° C. to give the title compound (21.9 mg, 0.042 mmol, 44.6% yield, 97% purity) as a white solid. UPLC-MS (Method 1) m / z 501.3 (M+H) at 1.42 min + , 499.2(MH) - . 1H NMR(500MHz,DMSO-d6)δ13.17(s,1H), 8.69(s,1H), 8.34(d,J=2.2Hz,1H), 8.17(dd,J=8.7,2.2Hz,1H), 7.40~7.32(m,3H), 7.17(d,J=1.6Hz) ,1H), 5.07(s,1H), 3.93(s,3H), 3.90~3.82(m,1H), 3.33~3.31(m,2H), 2.61(dd,J=10.7,3.6Hz,2H), 2.01~1.97(m,2H), 1.86~1.73(m,4H).
[0393] The following examples were prepared in a similar manner to Example 13, substituting the appropriate starting materials and intermediates where necessary.
[0394] [Table 3] TIFF0007595355000078.tif174132TIFF0007595355000079.tif176133TIFF0007595355000080.tif185135TIFF0007595355 000081.tif186133TIFF0007595355000082.tif187133TIFF0007595355000083.tif160134TIFF0007595355000084.tif99132
[0395] [Example 29]
[0396] 3-(N-(2-(3-hydroxy-3-methylpiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid [ka]
[0397] Step 1: 3-Methyl-1-(2-nitro-4-(trifluoromethyl)phenyl)piperidin-3-ol: EtN (0.500 ml, 3.59 mmol) was added to a solution of 1-fluoro-2-nitro-4-(trifluoromethyl)benzene (0.201 ml, 1.44 mmol) and 3-methylpiperidin-3-ol (198 mg, 1.72 mmol) in DCM (6 ml) at room temperature. The clear solution was stirred at room temperature for 17 hours. The organic phase was washed with 1 M HCl (aq) (3 ml), dried by passing the organic phase through a phase separator, and concentrated in vacuo to give the title compound (452 mg, 1.35 mmol, 94% yield, 91% purity) as a red / orange oil. UPLC-MS (Method 1) m / z 305.2 (M+H) at 1.49 min + . 1 H NMR(500MHz,DMSO-d6)δ8.07(d,J=2.3Hz,1H), 7.76(dd,J=9.0,2.4Hz,1H), 7.44(d,J=8.9Hz,1H), 4.51(s,1H), 3.16(ddd,J=13.2,6.1,3.7Hz,1H), 3.0 8(ddd,J=12.8,8.3,3.2Hz,1H), 3.00(d,J=12.6Hz,1H), 2.90(d,J=12.7Hz, 1H), 1.87~1.76(m,1H), 1.60~1.55(m,2H), 1.55~1.48(m,1H), 1.10(s,3H).
[0398] Step 2: 1-(2-Amino-4-(trifluoromethyl)phenyl)-3-methylpiperidin-3-ol: 5% Pd / C (50% w / w water) Type 87L (50 mg, 0.012 mmol) in EtOH (0.5 ml) was added to a solution of the product from Step 1 above (224 mg, 0.670 mmol) in EtOH (3.0 ml) at room temperature. The reaction mixture was hydrogenated at 4 bar for 19 hours at room temperature. The catalyst was removed by filtration through Celite® and washed with MeOH (20 ml). The organic phase was concentrated in vacuo, and the residue was redissolved in EtOAc (10 ml). The organic phase was washed with water (5 ml), dried over MgSO4, filtered, and concentrated in vacuo to give the title compound (112 mg, 0.404 mmol, 60.3% yield, 99% purity) as a pale orange solid. UPLC-MS (Method 1) m / z 275.3 (M+H) at 1.42 min + . 1 H NMR(500MHz,DMSO-d6)δ6.94(d,J=8.1Hz,1H), 6.92(d,J=1.8Hz,1H), 6.81(dd,J=8.1,1.8Hz,1H), 5.27(br s,2H), 4.58(s,1H), 2.91~2.81(m,1H), 2.73~2.67(m,1H), 2.60~2.51(m,2 H), 1.95~1.84(m,1H), 1.60~1.50(m,2H), 1.47~1.38(m,1H), 1.15(s,3H).
[0399] Step 3: Methyl 3-(N-(2-(3-hydroxy-3-methylpiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoate: Pyridine (0.075 ml, 0.933 mmol) was added to a cloudy solution of the product from Step 2 above (64.6 mg, 0.233 mmol) and methyl 3-(chlorosulfonyl)-4-methoxybenzoate (78 mg, 0.280 mmol) in DCM (2.0 ml) at room temperature. The resulting clear solution was stirred at room temperature for 20 hours. The reaction mixture was concentrated in vacuo, and the crude product was purified by silica gel chromatography (12 g cartridge, 30–100% EtOAc / isohexane) to afford the title compound (98.5 mg, 0.196 mmol, 84% yield, 100% purity) as an off-white foam. UPLC-MS (method 1) m / z 1.66 min 503.4 (M+H) + , 501.2(MH) - .
[0400] Step 4: 3-(N-(2-(3-Hydroxy-3-methylpiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid: 1M LiOH(aq) (0.784 ml, 0.784 mmol) was added to a solution of the product from Step 3 above (98.5 mg, 0.196 mmol) in THF (1.57 ml) at room temperature. The solution was stirred at room temperature for 18 hours and then concentrated in vacuo. The residue was redissolved in water (3 ml) and acidified to a pH of 4-5 using 1M HCl(aq). The precipitate was isolated by filtration and then redissolved in EtOAc (5 ml). The organic phase was washed with water (3 ml), dried over MgSO4, filtered, and concentrated in vacuo to give the title compound (64 mg, 0.130 mmol, 73.4% yield, 99% purity) as an off-white solid. UPLC-MS (Method 1) m / z 489.4 (M+H) at 1.49 min + , 487.3(MH) - . 1H NMR (500MHz, DMSO-d6) δ13.14 (br s, 1H), 9.44 (br s,1H), 8.41(d,J=2.2Hz,1H), 8.14(dd,J=8.7,2.2Hz,1H), 7.54(d,J=2.1Hz,1H), 7.30(dd,J=8.4,1.7Hz,1H), 7.27(d,J=8.8Hz,1H), 7.20(d,J=8.3Hz,1H), 5.02(br s,1H), 3.78(s,3H), 2.93~2.85(m,1H), 2.63(td,J=11.1,2.4Hz,1H), 2.56~2.52(m,1H), 2.52~2.48(m,1 H), 2.03~1.90(m,1H), 1.62~1.55(m,1H), 1.54~1.46(m,1H), 1.37(td,J=12.6,4.5Hz,1H), 1.02(s,3H). [Example 30]
[0401] 3-(N-(2-(cis-3,5-dimethylpiperidin-1-yl)-5-(trifluoromethyl)phenylsulfamoyl)-4-ethylbenzoic acid [ka]
[0402] A solution of the product from Example 6, Step 2 (72 mg, 0.264 mmol) in DCM (1 mL) and pyridine (0.128 mL, 1.59 mmol) was added to a suspension of the product from Example 1, Step 1 (79 mg, 0.317 mmol) in DCM (1 mL), and the solution was stirred at room temperature for 4 days. The crude product was purified directly by silica gel chromatography (12 g cartridge, 0-10% MeOH / DCM). The product from chromatography was partitioned between isohexane (3 mL) and MeCN (3 mL). The phases were separated, and the MeCN phase was washed with isohexane (2 × 3 mL) and concentrated in vacuo. The product was loaded onto a silica plug in a minimum amount of DCM and the column was eluted with DCM (5 ml), isohexane (5 ml), 5% MeOH in EtOAc (5 ml) and then 5% MeOH in EtOAc (5 ml) to give the title compound (26.7 mg, 0.052 mmol, 19.80% yield, 95% purity) as a white solid. UPLC-MS (Method 1) m / z 485.4 (M+H) at 2.06 min + , 483.3(MH) - . 1 H NMR (500MHz, methanol-d4) δ8.54(d,J=1.8Hz,1H), 8.15(dd,J=8.0,1.8Hz,1H), 7.59(d,J=2.0Hz,1H), 7.55(d,J=8.0Hz,1H), 7.36~7.27(m,2H), 3.0 7(q,J=7.5Hz,2H), 2.79~2.72(m,2H), 2.18(t,J=11.1Hz,2H), 1.89~1.76 (m,3H), 1.28(t,J=7.5Hz,3H), 0.90(d,J=6.5Hz,6H), 0.75~0.64(m,1H). Two exchangeable protons were not observed. [Example 31]
[0403] 3-(N-(2-(2,2-dimethylpiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid [ka]
[0404] Step 1: 2,2-Dimethyl-1-(2-nitro-4-(trifluoromethyl)phenyl)piperidine: EtN (0.500 ml, 3.59 mmol) was added to a solution of 2,2-dimethylpiperidine (195 mg, 1.72 mmol) and 1-fluoro-2-nitro-4-(trifluoromethyl)benzene (0.201 ml, 1.44 mmol) in DCM (6 ml), and the resulting solution was stirred at room temperature for 96 hours. Additional 2,2-dimethylpiperidine (75 mg, 0.663 mmol) was added, and the reaction was stirred at room temperature for 1 day. Water (3 ml) was added, and the phases were separated. The aqueous phase was then extracted with DCM (2 x 3 ml). The organic phases were combined, dried by passing through a phase separator, and concentrated in vacuo. The crude product was purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to give the title compound (163 mg, 0.512 mmol, 35.7% yield, 95% purity) as a dark orange viscous oil. UPLC-MS (Method 2) m / z 303.3 (M+H) at 1.96 min. + .
[0405] Step 2: 2-(2,2-Dimethylpiperidin-1-yl)-5-(trifluoromethyl)aniline: Iron powder (297 mg, 5.33 mmol) was added to a solution of the product from Step 1 above (161 mg, 0.533 mmol) and ammonium chloride (34.2 mg, 0.639 mmol) in IPA (5 mL) and water (2.5 mL) at room temperature. The resulting suspension was heated and stirred at 90° C. for 1 hour, then cooled to room temperature overnight. Additional iron powder (297 mg, 5.33 mmol) was added, and the reaction was heated at 90° C. for an additional 2 hours, then cooled to room temperature. The reaction mixture was filtered through Celite®, washed with excess MeOH (100 mL), and concentrated in vacuo. The residue was redissolved in DCM (25 mL) and washed with water (5 mL). The aqueous phase was extracted with DCM (2 x 5 ml) and the combined organic phases were washed with brine (10 ml), dried over MgSO, filtered and concentrated in vacuo to give the title compound (78 mg, 0.215 mmol, 40.3% yield, 75% purity) as a pale yellow oil. UPLC-MS (Method 2) m / z 273.3 (M+H) at 1.95 min + .
[0406] Step 3: Methyl 3-(N-(2-(2,2-dimethylpiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoate: The product from Step 2 above (51.4 mg, 0.189 mmol) was dissolved in a mixture of DCM (1 mL) and pyridine (0.05 mL, 0.618 mmol) and treated with a solution of methyl 3-(chlorosulfonyl)-4-methoxybenzoate (60 mg, 0.227 mmol) in DCM (1 mL). The resulting solution was stirred at room temperature for 18 hours. The reaction mixture was loaded directly onto silica gel and purified by column chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to afford the title compound (64 mg, 0.121 mmol, 64.3% yield, 100% purity) as a white sticky solid. UPLC-MS (Method 1) m / z 501.4 (M+H) at 1.95 min + , 499.1(MH) - .
[0407] Step 4: 3-(N-(2-(2,2-Dimethylpiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid: The product from Step 3 above (62 mg, 0.124 mmol) was dissolved in THF (2 ml) and treated with 1.1 M LiOH(aq) (450 μl, 0.495 mmol). The reaction was stirred at room temperature for 1 day. MeOH was added dropwise until the mixture went into solution and the reaction mixture was heated at 40° C. for 4 hours, then cooled to room temperature overnight. The reaction mixture was diluted with water (3 ml), concentrated in vacuo and the resulting aqueous solution was diluted with water (5 ml). 1 M HCl(aq) was added dropwise to bring the pH to approximately 6. The resulting white precipitate was collected by filtration and washed with water. The solid was suspended in MeCN (4 ml), concentrated in vacuo, and dried at 45° C. to give the title compound (57 mg, 0.111 mmol, 90% yield, 99% purity) as a white solid. UPLC-MS (Method 1) m / z 487.3 (M+H) at 1.80 min + , 485.2(MH) - . 1H NMR(500MHz,DMSO-d6)δ13.20(br s,1H), 8.96(s,1H), 8.41(d,J=2.2Hz,1H), 8.14(dd,J=8.7,2.2Hz,1H), 7.59(s,1H), 7.4 7(d,J=8.3Hz,1H), 7.33~7.27(m,2H), 3.93(s,3H), 1.73~1.55(m,6H), 1.32~0.62(m,8H). [Example 32]
[0408] 3-(N-(2-(1,4-oxazepan-4-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid [ka]
[0409] Step 1: 4-(2-nitro-4-(trifluoromethyl)phenyl)-1,4-oxazepane: EtN (0.500 ml, 3.59 mmol) was added to a solution of 1-fluoro-2-nitro-4-(trifluoromethyl)benzene (0.201 ml, 1.44 mmol) and 1,4-oxazepane hydrochloride (237 mg, 1.72 mmol) in DCM (6 ml), and the resulting solution was stirred at room temperature for 7 days. Water (3 ml) was added, and the phases were separated using a phase separator. The aqueous phase was extracted with DCM (2 × 3 ml), and the organic phases were combined, dried by passing through a phase separator, and concentrated in vacuo to give the title compound as an orange viscous oil (429 mg, 1.14 mmol, 98% yield, 95% purity). UPLC-MS (Method 2) m / z 290.8 (M+H) at 1.48 min. + .
[0410] Step 2: 2-(1,4-Oxazepan-4-yl)-5-(trifluoromethyl)aniline: Iron powder (822 mg, 14.71 mmol) was added to a solution of the product from Step 1 above (427 mg, 1.471 mmol) and ammonium chloride (94 mg, 1.765 mmol) in IPA (5 mL) and water (2.5 mL) at room temperature. The resulting suspension was heated and stirred at 90° C. for 1 hour, then cooled to room temperature. The reaction mixture was filtered through Celite®, washed with excess MeOH (100 mL), and concentrated in vacuo. The residue was redissolved in DCM (25 mL) and washed with water (5 mL). The aqueous phase was extracted with DCM (2×5 mL), and the combined organic phases were washed with brine (10 mL), dried over MgSO4, filtered, and concentrated in vacuo. The crude product was purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to give the title compound (186 mg, 0.700 mmol, 47.6% yield, 98% purity) as a dark orange solid. UPLC-MS (Method 2) m / z 261.3 (M+H) at 1.39 min + .
[0411] Step 3: Methyl 3-(N-(2-(1,4-oxazepan-4-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoate: The product from Step 2 above (54.8 mg, 0.189 mmol) was dissolved in a mixture of DCM (1 mL) and pyridine (0.05 mL, 0.618 mmol) and treated with a solution of methyl 3-(chlorosulfonyl)-4-methoxybenzoate (60 mg, 0.227 mmol) in DCM (1 mL). The resulting solution was stirred at room temperature for 18 hours. The reaction mixture was loaded onto silica gel and purified by column chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to give the title compound (66 mg, 0.132 mmol, 70.1% yield, 98% purity) as a cream-colored solid. UPLC-MS (Method 1) m / z 489.3 (M+H) at 1.59 min. + , 487.2(MH) - .
[0412] Step 4: 3-(N-(2-(1,4-Oxazepan-4-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid: The product from Step 3 above (64 mg, 0.131 mmol) was dissolved in THF (2 ml) and treated with 1.1 M LiOH (aq) (476 μl, 0.524 mmol) and stirred at room temperature for 1 day. MeOH was added dropwise until the mixture went into solution and the reaction mixture was heated at 40° C. for 4 hours, then cooled to room temperature overnight. The reaction mixture was diluted with water (3 ml) and concentrated in vacuo, and the resulting aqueous solution was diluted with water (to approximately 5 ml) and neutralized to pH approximately 6 with 1 M HCl. The resulting chunky suspension was sonicated to give a cloudy solution and the white precipitate was collected by filtration and washed with water. The solid was suspended in MeCN (4 ml), concentrated in vacuo, and dried at 45° C. to give the title compound (60 mg, 0.120 mmol, 92% yield, 95% purity) as a pale grey solid. UPLC-MS (Method 1) m / z 475.4 (M+H) at 1.43 min + , 473.3(MH) - . 1 H NMR(500MHz,DMSO-d6)δ13.12(s,1H), 9.11(s,1H), 8.23(s,1H), 8.16(dd,J=8.7,2.2Hz,1H), 7.38~7.32(m,2H) , 7.23(d,J=8.5Hz,1H), 7.10(s,1H), 3.93(s,3H), 3.76~3.70(m,4H), 3.29~3.20(m,4H), 1.91(t,J=5.8Hz,2H). [Example 33]
[0413] 3-(N-(2-(spiro[isobenzofuran-1,4'-piperidin]-1'-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid [ka]
[0414] Step 1: 1'-(2-Nitro-4-(trifluoromethyl)phenyl)spiro[isobenzofuran-1,4'-piperidine]: EtN (0.417 ml, 2.99 mmol) was added to a solution of 1-fluoro-2-nitro-4-(trifluoromethyl)benzene (0.167 ml, 1.20 mmol) and spiro[isobenzofuran-1,4'-piperidine] hydrochloride (324 mg, 1.44 mmol) in DCM (6 ml) at room temperature, and the reaction mixture was stirred at room temperature for 68 hours. Water (2 ml) was added, and the phases were separated. The aqueous phase was extracted with DCM (2 × 3 ml), and the combined organic phases were dried by passing through a phase separator and concentrated in vacuo to give the title compound (536 mg, 0.907 mmol, 76% yield, 64% purity) as an orange oil. UPLC-MS (method 1) m / z 379.2 (M+H) at 1.91 min + . 1 H NMR(500MHz,DMSO-d6)δ8.17(d,J=1.6Hz,1H), 7.86(dd,J=8.9,2.3Hz,1H), 7.53(d,J=8.8Hz,1H), 7.34~ 7.27(m,4H), 5.04(s,2H), 3.39~3.29(m,4H), 2.06(dt,J=17.4,5.8Hz,2H), 1.74(dd,J=13.9,2.5Hz,2H).
[0415] Step 2: 2-(spiro[isobenzofuran-1,4'-piperidin]-1'-yl)-5-(trifluoromethyl)aniline: Iron powder (335 mg, 6.00 mmol) was added to a solution of the product from Step 1 above (227 mg, 0.600 mmol) and ammonium chloride (38.5 mg, 0.720 mmol) in IPA (3.5 mL) and water (1.25 mL) and heated to 90°C for 2 hours. The reaction mixture was cooled to room temperature, filtered, and washed with excess MeOH (100 mL). The filtrate was concentrated in vacuo, redissolved in DCM (25 mL), and washed with water (5 mL). The aqueous phase was extracted with DCM (2 x 5 mL), and the combined organic phases were washed with brine (10 mL), dried by passing through a phase separator, and concentrated in vacuo. The crude product was purified by silica gel chromatography (12 g cartridge, 0-35% EtOAc / isohexane) to give the title compound (144 mg, 0.401 mmol, 66.8% yield, 97% purity) as an orange powder. UPLC-MS (Method 1) m / z 349.2 (M+H) at 1.83 min + . 1 H NMR(500MHz,DMSO-d6)δ7.36~7.24(m,4H), 7.07(d,J=8.1Hz,1H), 6.98(d,J=2.1Hz,1H), 6.85(dd,J=8.2,2.1Hz,1H), 5.2 2(s,2H), 5.03(s,2H), 3.12~3.01(m,2H), 2.91(td,J=12.0,2.3Hz,2H), 2.18(td,J=12.9,4.5Hz,2H), 1.79~1.67(m,2H).
[0416] Step 3: Methyl 3-(N-(2-(spiro[isobenzofuran-1,4'-piperidin]-1'-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoate: Pyridine (0.058 ml, 0.718 mmol) was added to a solution of the product from Step 2 above (86 mg, 0.239 mmol) and methyl 3-(chlorosulfonyl)-4-methoxybenzoate (80 mg, 0.287 mmol) in DCM (2 ml) at room temperature. The reaction mixture was stirred and heated at 40°C for 18 hours. Additional methyl 3-(chlorosulfonyl)-4-methoxybenzoate (33 mg, 0.120 mmol) was added and the reaction mixture was stirred at 40°C for an additional 3 hours. The reaction mixture was concentrated in vacuo and the crude product was purified by silica gel chromatography (25 g cartridge, 0-45% EtOAc / isohexane) to give the title compound (117 mg, 0.187 mmol, 78% yield, 92% purity) as an off-white solid. UPLC-MS (Method 2) m / z 577.4 (M+H) at 1.89 min + , 575.2(MH) - .
[0417] Step 4: 3-(N-(2-(spiro[isobenzofuran-1,4'-piperidin]-1'-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid: 1M LiOH(aq) (0.812 ml, 0.812 mmol) was added to a solution of the product from Step 3 above (117 mg, 0.203 mmol) in THF (1.6 ml) at room temperature. The solution was stirred at room temperature for 25 hours and then concentrated in vacuo. The residue was redissolved in water (3 ml) and acidified to pH 4-5 using 1M HCl(aq). The precipitate was isolated by filtration and taken to dryness in vacuo to give the title compound (92 mg, 0.164 mmol, 81% yield, 94% purity) as an off-white solid. UPLC-MS (Method 1) m / z 563.3 (M+H) at 1.80 min + , 561.1(MH) - . 1H NMR(500MHz,DMSO-d6)δ9.02(br s,1H), 8.39(d,J=2.3Hz,1H), 8.15(dd,J=8.7,2.2Hz,1H), 7.51(d,J=1.7Hz,1H), 7.39~7.27(m,7H), 5.0 2(s,2H), 3.88(s,3H), 3.01(t,J=11.9Hz,2H), 2.96~2.90(m,2H), 2.19~2.08(m,2H), 1.73~1.65(m,2H). No exchangeable protons were observed.
[0418] The following examples were prepared in a similar manner to Example 33, substituting the appropriate starting materials and intermediates where necessary.
[0419] [Table 4] TIFF0007595355000091.tif112132TIFF0007595355000092.tif170132TIFF0007595355000093.tif94135
[0420] [Example 41]
[0421] 4-Methoxy-3-(N-(2-(2-oxopiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid [ka]
[0422] Step 1: 1-(2-Nitro-4-(trifluoromethyl)phenyl)piperidin-2-one: NaH (63.1 mg, 1.58 mmol, 60% w / w in mineral oil) was added to a solution of piperidin-2-one (142 mg, 1.44 mmol) in anhydrous DMF (3 mL) at 0° C. under N. The reaction was stirred at this temperature for 10 minutes, and then a solution of 1-fluoro-2-nitro-4-(trifluoromethyl)benzene (0.201 mL, 1.44 mmol) in anhydrous DMF (3 mL) was added dropwise at 0° C. The reaction was stirred overnight at room temperature. The reaction mixture was diluted with EtOAc (100 mL) and washed successively with water (50 mL) and brine (2×50 mL). The organic phase was separated, dried over MgSO, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to give the title compound (245 mg, 0.808 mmol, 56.3% yield, 100% purity) as a pale yellow solid. UPLC-MS (Method 2) m / z 289.5 (M+H) at 1.23 min + .
[0423] Step 2: 1-(2-Amino-4-(trifluoromethyl)phenyl)piperidin-2-one: Iron powder (508 mg, 9.09 mmol) was added to a suspension of the product from Step 1 above (131 mg, 0.455 mmol) and ammonium chloride (29.2 mg, 0.545 mmol) in propan-2-ol (5 mL) and water (2.5 mL) at room temperature. The resulting suspension was heated and stirred at 90° C. for 2 hours. The reaction was filtered through Celite®, washed with excess MeOH (100 mL), and concentrated in vacuo. The residue was redissolved in DCM (25 mL), washed successively with water (10 mL) and brine (10 mL), dried over MgSO4, filtered, and concentrated in vacuo. The crude product was purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to give the title compound (22 mg, 0.076 mmol, 16.7% yield, 89% purity) as a cream-colored solid. UPLC-MS (Method 2) m / z 259.3 (M+H) at 1.07 min + .
[0424] Step 3: Methyl 4-methoxy-3-(N-(2-(2-oxopiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoate: The product from Step 2 above (22 mg, 0.085 mmol) was dissolved in a mixture of DCM (0.5 ml) and pyridine (22.5 μl, 0.279 mmol) and treated with a solution of methyl 3-(chlorosulfonyl)-4-methoxybenzoate (27.1 mg, 0.102 mmol) in DCM (0.5 ml). The resulting solution was stirred at room temperature for 18 hours. Additional methyl 3-(chlorosulfonyl)-4-methoxybenzoate (11.3 mg, 0.043 mmol) and pyridine (6.89 μl, 0.085 mmol) were added and the reaction mixture was stirred at room temperature for 1 hour. The crude product was directly purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to give the title compound (18.6 mg, 0.037 mmol, 43.5% yield, 97% purity) as a white solid. UPLC-MS (Method 1) m / z 487.6 (M+H) at 1:40 min + , 484.8(MH) - .
[0425] Step 4: 4-Methoxy-3-(N-(2-(2-oxopiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid: The product from Step 3 above (18.6 mg, 0.038 mmol) was dissolved in THF (1 ml) and treated with 1.1 M LiOH (aq) (139 μl, 0.153 mmol). The reaction was stirred at room temperature for 1 day, then MeOH was added dropwise until the mixture went into solution and the reaction mixture was heated at 40° C. for 20 hours before being cooled to room temperature. The reaction mixture was diluted with water (3 ml) and concentrated in vacuo and the resulting aqueous solution was diluted with water (~5 ml) and neutralized to ~pH 6 with 1 M HCl. The white precipitate was collected by filtration and washed with water. The solid was suspended in MeCN (4 ml), concentrated in vacuo, and dried at 45° C. to give the title compound (17.1 mg, 0.034 mmol, 90% yield, 95% purity) as a pale yellow solid. UPLC-MS (Method 1) m / z 473.0 (M+H) at 1.23 min + , 471.1(MH) - .1 H NMR(500MHz,DMSO-d6)δ13.12(s,1H), 9.70(s,1H), 8.33(d,J=2.2Hz,1H), 8.15(dd,J=8.7,2.2Hz,1H), 7.65(s,1H) ), 7.54~7.39(m,2H), 7.31(d,J=8.8Hz,1H), 3.80(s,3H), 3.09~3.23(m,2H), 2.44~2.22(m,2H), 1.90~1.70(m,4H). [Example 42]
[0426] 3-(N-(2-(1,4-oxazepan-4-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methylbenzoic acid [ka]
[0427] A solution of the product from Example 32, Step 2 (62 mg, 0.238 mmol) in DCM (1 mL) and pyridine (0.116 mL, 1.43 mmol) was added to a solution of 3-(chlorosulfonyl)-4-methylbenzoic acid (67.1 mg, 0.286 mmol) in DCM (1 mL), and the solution was stirred at room temperature for 4 days. The crude product was directly purified by silica gel chromatography (12 g cartridge, 0-10% MeOH / DCM) to give a cream-colored solid (23 mg). 8 mg of this crude product was loaded onto a silica plug in a minimal amount of DCM, and the column was eluted with DCM (5 mL), isohexane (5 mL), 5% MeOH in EtOAc (5 mL), and then 20% MeOH in EtOAc (5 mL) to give the title compound (7.0 mg, 0.015 mmol, 6.09% yield, 95% purity) as a white solid. UPLC-MS (method 1) m / z 459.4 (M+H) at 1.64 min + , 457.3(MH) - . 1H NMR (500 MHz, methanol-d4) δ 8.58 (d, J = 2.1 Hz, 1H), 8.48 (s, 1H), 8.00 (dd, J = 7.9, 2.1 Hz, 1H), 7.52–7.42 (m, 3H), 3.97 (t, J = 6.2 Hz, 2H), 3.94–3.89 (m, 2H), 3.28–3.22 (m, 4H), 2.79 (s, 3H), 2.15–2.07 (m, 2H). Two exchangeable protons were not observed. [Example 43]
[0428] 3-(N-(2-(1,4-oxazepan-4-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-ethylbenzoic acid [ka]
[0429] A solution of the product from Example 32, Step 2 (62 mg, 0.238 mmol) in DCM (1 mL) and pyridine (0.116 mL, 1.429 mmol) was added to a solution of the product from Example 1, Step 1 (71.1 mg, 0.286 mmol) in DCM (1 mL), and the solution was stirred at room temperature for 4 days. The crude product was purified directly by silica gel chromatography (12 g cartridge, 0-10% MeOH / DCM) to give a cream-colored solid. This was loaded onto a silica plug in minimal DCM, and the column was eluted sequentially with DCM (5 mL), isohexane (5 mL), 5% MeOH in EtOAc (5 mL), and then 5% MeOH in EtOAc (5 mL) to give the title compound (11.7 mg, 0.024 mmol, 9.87% yield, 95% purity) as a white solid. UPLC-MS (Method 1) m / z 473.4 (M+H) at 1.61 min. + , 471.2(MH) - . 1H NMR (500 MHz, methanol-d4) δ 8.53 (d, J = 1.8 Hz, 1H), 8.17 (dd, J = 8.0, 1.8 Hz, 1H), 7.57 (d, J = 8.0 Hz, 1H), 7.34–7.28 (m, 3H), 3.90 (t, J = 5.9 Hz, 2H), 3.86–3.81 (m, 2H), 3.23–3.16 (m, 4H), 3.08 (q, J = 7.5 Hz, 2H), 2.02 (p, J = 5.8 Hz, 2H), 1.29 (t, J = 7.5 Hz, 3H). Two exchangeable protons were not observed. [Example 46]
[0430] 4-Methoxy-3-(N-(2-(2-(3-methylisoxazol-5-yl)pyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid [ka]
[0431] Step 1: 3-Methyl-5-(1-(2-nitro-4-(trifluoromethyl)phenyl)pyrrolidin-2-yl)isoxazole: EtN (302 mg, 2.99 mmol) was added to a solution of 1-fluoro-2-nitro-4-(trifluoromethyl)benzene (0.167 ml, 1.20 mmol) and 3-methyl-5-(pyrrolidin-2-yl)isoxazole (218 mg, 1.44 mmol) in DCM (5 ml), and the resulting solution was stirred at room temperature for 19 hours. Water (2.5 ml) was added, and the organic phase was dried by passing through a phase separator and concentrated in vacuo to give the title compound (489 mg, 1.19 mmol, 99% yield, 83% purity) as a yellow oil. UPLC-MS (Method 2) m / z 342.4 (M+H) at 1.61 min + . 1H NMR(500MHz,DMSO-d6)δ8.07(m,1H), 7.71(dd,J=9.1,2.0Hz,1H), 7.17(d,J=9.1Hz,1H), 6.18(s,1H), 5.34(t,J=7.3 Hz,1H), 3.55~3.50(m,1H), 3.02~2.98(m,1H), 2.54~2.51(m,1H), 2.16(s,3H), 2.08~2.02(m,1H), 2.02~1.89(m,2H).
[0432] Step 2: 2-(2-(3-Methylisoxazol-5-yl)pyrrolidin-1-yl)-5-(trifluoromethyl)aniline: Ammonium hydroxide (28% aqueous solution) (0.319 ml, 2.30 mmol) and sodium dithionite (1.18 g, 5.74 mmol) were added to a solution of the product from Step 1 above (236 mg, 0.574 mmol) in THF (2.5 ml) and water (2.5 ml) at room temperature, followed by stirring at room temperature for 2 hours. The reaction mixture was concentrated in vacuo and the residue was redissolved in DCM (10 ml) and washed with water (5 ml). The aqueous phase was extracted with DCM (2 x 5 ml) and the organic phases were combined, washed with brine (5 ml), dried by passing through a phase separator and concentrated in vacuo. The crude product was purified by silica gel chromatography (10 g cartridge, 0-50% EtOAc / isohexane) to give the title compound (95 mg, 0.302 mmol, 52.6% yield, 99% purity) as a reddish-brown oil. UPLC-MS (Method 1) m / z 312.1 (M+H) at 1.52 min + . 1 H NMR(500MHz,DMSO-d6)δ7.03(d,J=8.2Hz,1H), 6.92(d,J=2.2Hz,1H), 6.74(dd,J=8.3,2.1Hz,1H), 6.05(s,1H), 5.17(s,2H), 4.98( dd,J=7.9,5.9Hz,1H), 3.72~3.65(m,1H), 2.76~2.68(m,1H), 2.45~2.37(m,1H), 2.10(s,3H), 2.08~1.99(m,1H), 1.98~1.87(m,2H).
[0433] Step 3: Methyl 4-methoxy-3-(N-(2-(2-(3-methylisoxazol-5-yl)pyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoate: Pyridine (0.069 ml, 0.852 mmol) was added to a solution of the product from Step 2 above (88 mg, 0.284 mmol) and methyl 3-(chlorosulfonyl)-4-methoxybenzoate (95 mg, 0.341 mmol) in DCM (2.5 ml) at room temperature. The reaction mixture was stirred at room temperature for 65 hours and then at 40° C. for 5 hours. The crude reaction mixture was filtered and the filtered product was redissolved in MeCN (10 ml) and concentrated in vacuo to give the title compound (69 mg, 0.123 mmol, 43.2% yield, 96% purity) as an off-white solid. UPLC-MS (method 2) m / z 540.3 (M+H) at 1.58 min + , 538.2(MH) - .
[0434] Step 4: 4-Methoxy-3-(N-(2-(2-(3-methylisoxazol-5-yl)pyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid: 1M LiOH(aq) (0.384 ml, 0.384 mmol) was added to a suspension of the product from Step 3 above (69 mg, 0.128 mmol) in THF (0.768 ml) at room temperature. The resulting clear solution was stirred at room temperature for 20 hours. Additional 1M LiOH(aq) (0.128 ml, 0.128 mmol) was added and the solution was stirred for a further hour. The reaction mixture was concentrated in vacuo and the residue redissolved in water (2 ml) and acidified to pH 4-5 using 1M HCl(aq). The precipitate was dissolved in DCM (10 ml) and the phases separated. The aqueous phase was extracted with DCM (2 x 3 ml) and the combined organic phases were dried by passing through a phase separator and concentrated in vacuo to give the title compound (47.9 mg, 0.091 mmol, 71.3% yield, 97% purity) as a pale yellow solid. UPLC-MS (Method 1) m / z 526.3 (M+H) at 1.46 min + , 524.2(MH) - . 1H NMR (500MHz, DMSO-d6) δ13.08 (br s, 1H), 9.39 (br s,1H), 8.17(dd,J=8.7,2.3Hz,1H), 8.10(d,J=2.2Hz,1H), 7.38(d,J=8.8Hz,1H) , 7.27(dd,J=8.8,2.3Hz,1H), 6.78(d,J=8.8Hz,1H), 6.67(d,J=2.3Hz,1H), 6.02( s, 1H), 5.35 (t, J = 6.4 Hz, 1H), 4.01 (apparent dt, J = 9.7, 7.0 Hz, 1H), 3.95 (s, 3H), 3.45 (ddd, J = 9.9, 7.3, 5.2 Hz, 1H), 2.40–2.35 (m, 1H), 2.13 (s, 3H), 2.01–1.85 (m, 3H). [Example 49]
[0435] Methyl ester: Methyl 4-methoxy-3-((2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfonamido)benzoate [ka]
[0436] Step 1: Methyl 3-(2-bromo-5-(trifluoromethyl)phenylsulfonamido)-4-methoxybenzoate: A mixture of 2-bromo-5-(trifluoromethyl)benzene-1-sulfonyl chloride (230 μL, 1.32 mmol), methyl 3-amino-4-methoxybenzoate (200 mg, 1.10 mmol), and pyridine (268 μL, 3.31 mmol) in DCM (4 mL) was stirred at room temperature over the weekend. The mixture was concentrated onto silica and purified by silica gel chromatography (24 g cartridge, 0-100% EtOAc / isohexane) to give the title compound (510 mg, 1.07 mmol, 97% yield, 98% purity) as a pale beige solid. UPLC-MS (Method 2) m / z 468.0 / 470.0 (M / M+2) at 1.43 min. + . 1H NMR(500MHz,DMSO-d6)δ10.26(s,1H), 8.12(d,J=8.3Hz,1H), 8.10(d,J=2.2Hz,1H), 7.92( dd,J=8.3,2.2Hz,1H), 7.83~7.77(m,2H), 7.08(d,J=8.6Hz,1H), 3.80(s,3H), 3.56(s,3H).
[0437] Step 2: Methyl 4-methoxy-3-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenylsulfonamido)benzoate: A mixture of the product from Step 1 above (100 mg, 0.214 mmol) and piperidine (25 μl, 0.253 mmol) in THF (1 ml) was heated to 60° C. and stirred overnight. Additional piperidine (25 μl, 0.253 mmol) was added and stirring continued at 60° C. for 7 hours. Additional piperidine (25 μl, 0.253 mmol) was added and stirring continued at 60° C. overnight. Upon cooling to room temperature, the mixture was concentrated in vacuo and the residue was loaded onto silica and purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to afford the title compound (82 mg, 0.165 mmol, 78% yield, 95% purity) as a white solid. UPLC-MS (method 2) m / z 473.3 (M+H) at 1.84 min + . 1 H NMR(500MHz,DMSO-d6)δ9.04(s,1H), 8.05(s,1H), 7.93(d,J=8.4Hz,1H), 7.87(s,1H), 7.67(d,J=8.7Hz,1H), 7.59(d,J=8 .4Hz,1H), 7.05(d,J=8.7Hz,1H), 3.78(s,3H), 3.73(s,3H), 2.92(t,J=5.3Hz,4H), 1.77~1.65(m,4H), 1.57~1.51(m,2H). [Example 49]
[0438] 4-Methoxy-3-((2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfonamido)benzoic acid [ka]
[0439] A mixture of the product from Example 49 methyl ester, Step 2 above (70 mg, 0.148 mmol) in THF (1.25 mL) and 2M LiOH(aq) (0.25 mL, 0.500 mmol) was stirred at 50 °C overnight. Additional 2M LiOH(aq) (0.25 mL, 0.500 mmol) was added, and stirring was continued at 50 °C for 5 h. The mixture was diluted with HO (5 mL), acidified to pH 4 with 1M HCl(aq), and extracted with EtOAc (3 × 10 mL). The combined organic extracts were washed with brine (10 mL), passed through a phase separator, and the solvent was removed in vacuo. The residue was loaded onto silica and purified by silica gel chromatography (4 g cartridge, 0–10% MeOH / DCM) and triturated with TBME to give the title compound (44.3 mg, 0.093 mmol, 62.6% yield, 96% purity) as a white solid. UPLC-MS (method 2) m / z 459.3 (M+H) at 1.19 min + , 457.2(MH) - . 1 H NMR(500MHz,DMSO-d6)δ12.71(s,1H), 8.99(s,1H), 8.05(d,J=2.3Hz,1H), 7.93(dd,J=8.5,2.3Hz,1H), 7.89(d,J=2.1Hz,1H), 7.64(dd,J =8.7,2.1Hz,1H), 7.60(d,J=8.5Hz,1H), 7.02(d,J=8.7Hz,1H), 3.71(s,3H), 2.92(t,J=5.1Hz,4H), 1.76~1.65(m,4H), 1.59~1.48(m,2H). Generic Compound A: 4-Methoxy-2-((2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfonamido)benzoic acid
[0440] [ka]
[0441] Step 1: Methyl 2-(2-fluoro-5-(trifluoromethyl)phenylsulfonamido)-4-methoxybenzoate: A mixture of 2-fluoro-5-(trifluoromethyl)benzene-1-sulfonyl chloride (87 mg, 0.331 mmol), methyl 2-amino-4-methoxybenzoate (50 mg, 0.276 mmol), and pyridine (0.067 mL, 0.828 mmol) in DCM (2 mL) was stirred at room temperature overnight. The mixture was concentrated onto silica and purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to give the title compound (98 mg, 0.180 mmol, 65.4% yield, 75% purity) as a white solid. UPLC-MS (Method 2) yielded 405.5 (MH) at 1.67 min. - . 1 H NMR(500MHz,DMSO-d6)δ11.13(s,1H), 8.24~8.12(m,2H), 7.87(d,J=8.9Hz,1H), 7.73 (t,J=9.5Hz,1H), 6.94(d,J=2.5Hz,1H), 6.83~6.76(m,1H), 3.79(s,3H), 3.77(s,3H).
[0442] Step 2: Methyl 4-methoxy-2-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenylsulfonamido)benzoate: A mixture of the product from Step 1 above (98 mg, 0.180 mmol) and piperidine (0.06 mL, 0.606 mmol) in THF (2 mL) was stirred at 60° C. for 6 days. The mixture was concentrated onto silica and purified by silica gel chromatography (12 g cartridge, 0-50% EtOAc / isohexane) to give the title compound (52 mg, 0.109 mmol, 60.4% yield, 99% purity) as a white solid. UPLC-MS (Method 2) m / z 473.3 (M+H) at 2.01 min + . 1H NMR(500MHz,DMSO-d6)δ11.11(s,1H), 8.28(d,J=2.3Hz,1H), 8.06~7.95(m,1H), 7.85(d,J=8.9Hz,1H), 7.59(d,J=8.5Hz,1H), 6.73( d,J=2.5Hz,1H), 6.63(dd,J=8.9,2.5Hz,1H), 3.84(s,3H), 3.66(s,3H), 2.84(t,J=5.3Hz,4H), 1.74~1.64(m,4H), 1.58~1.49(m,2H).
[0443] Step 3: 4-Methoxy-2-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenylsulfonamido)benzoic acid: A mixture of the product from Step 2 above (52 mg, 0.109 mmol) and 2M LiOH(aq) (250 μl, 0.500 mmol) in THF (1.25 ml) was stirred at 50° C. overnight. The mixture was diluted with HO (2 ml) and acidified to pH ∼4 with 1M HCl. The mixture was extracted with EtOAc (3 × 15 ml), and the combined organic extracts were washed with brine, passed through a phase separator, and the solvent removed in vacuo. The residue was loaded onto silica and purified by silica gel chromatography (4 g cartridge, 0–5% MeOH / DCM) to afford the title compound (14.1 mg, 0.030 mmol, 27.1% yield, 96% purity) as a white solid. UPLC-MS (method 2) m / z 459.3 (M+H) at 1.22 minutes + , 457.2(MH) - . 1 H NMR(500MHz,DMSO-d6)δ13.63(s,1H), 11.65(s,1H), 8.29(d,J=2.3Hz,1H), 7.99(dd,J=8.5,2.3Hz,1H), 7.83(d,J=8.9Hz,1H), 7.58(d,J= 8.5Hz,1H), 6.65(d,J=2.4Hz,1H), 6.57(dd,J=8.9,2.4Hz,1H), 3.64(s,3H), 2.86(t,J=5.1Hz,4H), 1.77~1.66(m,4H), 1.60~1.46(m,2H).
[0444] The following examples were prepared in a similar manner to general compound A, substituting the appropriate starting materials and intermediates where necessary.
[0445] [Table 5]
[0446] Example 54 Methyl ester: methyl 4-methoxy-3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoate
[0447] [ka]
[0448] A solution of 2-(piperidin-1-yl)-5-(trifluoromethyl)aniline (0.100 g, 0.409 mmol) in DCM (1 mL) and pyridine (0.1 mL, 1.236 mmol) was added to a solution of methyl 3-(chlorosulfonyl)-4-methoxybenzoate (0.130 g, 0.491 mmol) in DCM (1 mL), and the solution was stirred at room temperature for 23 h. The solvent was removed in vacuo, and the crude product was purified by silica gel chromatography (12 g cartridge, 0-50% EtOAc / isohexane) to give an orange oil. This was further purified by silica gel chromatography (24 g cartridge, 0-50% EtOAc / isohexane) to give the title compound (0.143 g, 0.294 mmol, 71.7% yield, 97% purity) as a pale yellow oil that slowly crystallized. UPLC-MS (method 2) m / z 473.2 (M+H) at 1.83 min + , 471.1(MH) - . 1H NMR(500MHz,DMSO-d6)δ8.81(br s,1H), 8.37(d,J=2.3Hz,1H), 8.19(dd,J=8.7,2.3Hz,1H), 7.45(d,J=2.0Hz,1H), 7.40~7.30 (m,3H), 3.94(s,3H), 3.86(s,3H), 2.78~2.75(m,4H), 1.68~1.64(m,4H), 1.56~1.52(m,2H). [Example 54]
[0449] 4-Methoxy-3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid [ka]
[0450] 1M LiOH(aq) (3 ml, 3.00 mmol) was added to a solution of the product from Example 54 methyl ester (0.068 g, 0.144 mmol) in dioxane (3 ml), and the solution was stirred at room temperature overnight. The solvent was removed in vacuo, and the residue was redissolved in water (5 ml) and extracted with EtOAc (3 x 5 ml). The aqueous phase was acidified with 1M HCl(aq), and the product was extracted into EtOAc (3 x 10 ml). The combined organic phases were dried over MgSO4, filtered, and the solvent removed in vacuo to give the title compound (0.047 g, 0.100 mmol, 69.8% yield, 98% purity) as an off-white solid. UPLC-MS (Method 2) m / z 459.2 (M+H) at 1.15 min + , 457.0(MH) - . 1 H NMR(500MHz,DMSO-d6)δ13.16(s,1H), 8.76(s,1H), 8.37(d,J=2.2Hz,1H), 8.16(dd,J=8.7,2.2Hz,1H), 7.45(d,J =1.9Hz,1H), 7.38~7.30(m,3H), 3.93(s,3H), 2.76(t,J=5.3Hz,4H), 1.67(p,J=5.3Hz,4H), 1.55(p,J=5.3Hz,2H). [Example 55]
[0451] 3-(N-(2-(azepan-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-isopropylbenzoic acid [ka]
[0452] A solution of 2-(azepan-1-yl)-5-(trifluoromethyl)aniline (50 mg, 0.194 mmol) in DCM (1 mL) and pyridine (0.094 mL, 1.16 mmol) was added to a solution of 3-(chlorosulfonyl)-4-isopropylbenzoic acid (61.0 mg, 0.232 mmol) in DCM (1 mL), and the solution was stirred at room temperature for 4 days. The crude product was directly purified by silica gel chromatography (12 g cartridge, 0-10% MeOH / DCM) to give a pale yellow solid (11.1 mg). 9 mg of this was loaded onto a silica plug in minimal DCM, and the column was eluted with DCM (5 mL), isohexane (5 mL), 5% MeOH in EtOAc (5 mL), and then 5% MeOH in EtOAc (5 mL) to give the title compound (5.4 mg, 10.6 μmol, 5.47% yield, 95% purity) as a pale yellow solid. UPLC-MS (Method 2) m / z 485.4 (M+H) at 1.99 min + , 483.1(MH) - . 1 H NMR (500 MHz, methanol-d4) δ 8.58 (d, J = 1.8 Hz, 1H), 8.20 (dd, J = 8.2, 1.8 Hz, 1H), 7.70 (d, J = 8.2 Hz, 1H), 7.33–7.21 (m, 3H), 3.90 (septet, J = 6.8 Hz, 1H), 3.20–3.13 (m, 4H), 1.86–1.77 (m, 4H), 1.76–1.71 (m, 4H), 1.24 (d, J = 6.7 Hz, 6H). Two exchangeable protons were not observed.
[0453] The following examples were prepared in a similar manner to Example 55, substituting the appropriate starting materials and intermediates where necessary.
[0454] [Table 6] TIFF0007595355000106.tif149128
[0455] [Example 64]
[0456] 4-Methoxy-3-(N-(2-(piperidin-1-yl)phenyl)sulfamoyl)benzoic acid [ka]
[0457] Step 1: Methyl 4-methoxy-3-(N-(2-(piperidin-1-yl)phenyl)sulfamoyl)benzoate: A solution of 2-(piperidin-1-yl)aniline hydrochloride (0.050 g, 0.235 mmol) in DCM (1 mL) and pyridine (0.114 mL, 1.410 mmol) was added to a solution of methyl 3-(chlorosulfonyl)-4-methoxybenzoate (0.075 g, 0.282 mmol) in DCM (1 mL), and the solution was stirred at room temperature for 96 h. The solvent was removed in vacuo, and the crude product was purified by silica gel chromatography (24 g cartridge, 0–50% EtOAc / isohexane) to afford the title compound (0.095 g, 0.169 mmol, 71.9% yield, 72% purity) as a pale yellow oil that slowly crystallized. UPLC-MS (method 2) m / z 405.2 (M+H) at 1.69 min + , 403.4(MH) - .
[0458] Step 2: 4-Methoxy-3-(N-(2-(piperidin-1-yl)phenyl)sulfamoyl)benzoic acid: 1M LiOH(aq) (0.470 ml, 0.470 mmol) was added to a solution of the product from Step 1 above (0.095 g, 0.235 mmol) in dioxane (3 ml), and the solution was stirred at room temperature overnight. The solvent was removed in vacuo, and the residue was redissolved in water (5 ml) and extracted with EtOAc (3 x 5 ml). The aqueous phase was acidified with 1M HCl(aq), and the product was extracted into EtOAc (3 x 10 ml). The combined organic phases were dried over MgSO, filtered, and the solvent removed in vacuo. The crude product was purified by silica gel chromatography (12 g cartridge, 0-70% EtOAc / isohexane) to give the title compound (40 mg, 0.097 mmol, 41.4% yield, 95% purity) as a white solid. UPLC-MS (method 1) m / z 391.3 (M+H) at 1.41 min + , 389.3(MH) - . 1 H NMR(500MHz,DMSO-d6)δ13.23(bs,1H), 8.60(s,1H), 8.39(d,J=2.3Hz,1H), 8.14(dd,J=8.7,2.3Hz,1H), 7.31(d,J=8.8Hz,1H), 7.25(dd,J= 7.4,2.1Hz,1H), 7.22(dd,J=7.5,2.2Hz,1H), 7.12~6.85(m,2H), 3.96(s,3H), 2.75~2.63(m,4H), 1.69(p,J=5.5Hz,4H), 1.58~1.52(m,2H). [Example 65]
[0459] 3-(N-(4-chloro-2-(piperidin-1-yl)phenyl)sulfamoyl)-4-methoxybenzoic acid [ka]
[0460] Step 1: Methyl 3-(N-(4-chloro-2-(piperidin-1-yl)phenyl)sulfamoyl)-4-methoxybenzoate: A solution of 4-chloro-2-(piperidin-1-yl)aniline (0.050 g, 0.237 mmol) in DCM (1 mL) and pyridine (0.115 mL, 1.42 mmol) was added to a solution of methyl 3-(chlorosulfonyl)-4-methoxybenzoate (0.075 g, 0.285 mmol) in DCM (1 mL), and the solution was stirred at room temperature for 96 hours. The solvent was removed in vacuo, and the crude product was purified by silica gel chromatography (24 g cartridge, 0–50% EtOAc / isohexane) to afford the title compound (0.093 g, 0.165 mmol, 69.6% yield) as a pale yellow oil that slowly crystallized. UPLC-MS (method 2) m / z 439.3 (M+H) at 1.81 min + , 437.2(MH) - .
[0461] Step 2: 3-(N-(4-chloro-2-(piperidin-1-yl)phenyl)sulfamoyl)-4-methoxybenzoic acid: 1M LiOH(aq) (0.424 ml, 0.424 mmol) was added to a solution of the product from Step 1 above (0.093 g, 0.212 mmol) in dioxane (3 ml) and the solution was stirred at room temperature overnight. The solvent was removed in vacuo and the residue redissolved in water (5 ml) and extracted with EtOAc (3 x 5 ml). The aqueous phase was acidified with 1M HCl(aq) and the product extracted into EtOAc (3 x 10 ml). The combined organic phases were dried over MgSO4, filtered and the solvent removed in vacuo. The crude product was purified by silica gel chromatography (12 g cartridge, 0-80% EtOAc / isohexane) to give the title compound (34 mg, 0.076 mmol, 35.9% yield, 95% purity) as a white solid. UPLC-MS (Method 1) m / z 425.3 (M+H) at 1.69 min + , 423.2(MH) - . 1H NMR(500MHz,DMSO-d6)δ13.24(bs,1H), 8.58(s,1H), 8.36(d,J=2.3Hz,1H), 8.16(dd,J=8.7,2.2Hz,1H), 7.32(d,J=8.8Hz,1H) ), 7.28~7.14(m,2H), 7.07(dd,J=8.8,2.4Hz,1H), 3.96(s,3H), 2.72~2.68(m,4H), 1.66(p,J=5.5Hz,4H), 1.56~1.50(m,2H). [Example 66]
[0462] 3-(N-(5-chloro-2-(piperidin-1-yl)phenyl)sulfamoyl)-4-methoxybenzoic acid [ka]
[0463] Step 1: Methyl 3-(N-(5-chloro-2-(piperidin-1-yl)phenyl)sulfamoyl)-4-methoxybenzoate: A solution of 5-chloro-2-(piperidin-1-yl)aniline hydrochloride (0.050 g, 0.202 mmol) in DCM (1 mL) and pyridine (0.098 mL, 1.21 mmol) was added to a solution of methyl 3-(chlorosulfonyl)-4-methoxybenzoate (0.064 g, 0.243 mmol) in DCM (1 mL), and the solution was stirred at room temperature for 96 hours. The solvent was removed in vacuo, and the crude product was purified by silica gel chromatography (24 g cartridge, 0–50% EtOAc / isohexane) to afford the title compound (0.066 g, 0.143 mmol, 70.6% yield, 95% purity) as a pale yellow oil that slowly crystallized. UPLC-MS (method 2) m / z 439.3 (M+H) at 1.81 min + , 437.3(MH) - .
[0464] Step 2: 3-(N-(5-chloro-2-(piperidin-1-yl)phenyl)sulfamoyl)-4-methoxybenzoic acid: 1M LiOH(aq) (0.301 ml, 0.301 mmol) was added to a solution of the product from Step 1 above (0.066 g, 0.150 mmol) in dioxane (3 ml) and the solution was stirred at room temperature overnight. The solvent was removed in vacuo and the residue redissolved in water (5 ml) and extracted with EtOAc (3 x 5 ml). The aqueous phase was acidified with 1M HCl(aq) and the product extracted into EtOAc (3 x 10 ml). The combined organic phases were dried over MgSO4, filtered and the solvent removed in vacuo. The crude product was purified by silica gel chromatography (12 g cartridge, 0-70% EtOAc / isohexane) to give the title compound (22 mg, 0.049 mmol, 32.7% yield, 95% purity) as a white solid. UPLC-MS (Method 1) m / z 425.1 (M+H) at 1.67 min + , 423.2(MH) - . 1 H NMR (500MHz, DMSO-d6) δ13.25 (br s, 1H), 8.69 (br s,1H), 8.38(d,J=2.2Hz,1H), 8.17(dd,J=8.7,2.2Hz,1H), 7.34(d,J=8.8Hz,1H), 7.25(d,J=2.5Hz,1H), 7.24(d,J= 8.5Hz,1H), 7.05(dd,J=8.5,2.5Hz,1H), 3.96(s,3H), 2.75~2.61(m,4H), 1.67(p,J=5.5Hz,4H), 1.56~1.50(m,2H). [Example 67]
[0465] 4-Methyl-3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid [ka]
[0466] Step 1: Methyl 4-methyl-3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoate: 2-(piperidin-1-yl)-5-(trifluoromethyl)aniline (50 mg, 0.205 mmol) was dissolved in a mixture of DCM (1 ml) and pyridine (0.05 ml, 0.618 mmol) and treated with a solution of methyl 3-(chlorosulfonyl)-4-methylbenzoate (52 mg, 0.209 mmol) in DCM (1 ml). The resulting solution was stirred at room temperature for 18 hours. Additional methyl 3-(chlorosulfonyl)-4-methylbenzoate (15 mg, 0.060 mmol) was added and the reaction was stirred at room temperature for a further 24 hours. The reaction mixture was loaded directly onto silica gel (12 g cartridge, 0-50% EtOAc / isohexane) and purified to give the title compound (73 mg, 0.155 mmol, 76% yield, 97% purity) as a colorless oil that crystallized on standing. UPLC-MS (Method 1) m / z 457.1 (M+H) at 1.95 min + , 455.3(MH) - .
[0467] Step 2: 4-Methyl-3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid: The product from Step 1 above (71 mg, 0.151 mmol) was dissolved in THF (2 ml) and treated with 1.1 M LiOH(aq) (499 μl, 0.549 mmol). MeOH was added to give a clear solution which was allowed to stand at room temperature. After 2 days, the solution was diluted with water (2 ml) and allowed to stand at room temperature for a further 24 hours. The solution was further diluted with water (2 ml) and concentrated in vacuo. The resulting aqueous suspension was diluted with water (2 ml), filtered, and washed with water (1 ml). The resulting solution was neutralized with 1 M HCl(aq) (0.4 ml), sonicated, and then adjusted to pH ∼6 with 1 M HCl(aq) (2 drops). The resulting off-white precipitate was collected by filtration and washed with water. The solid was suspended in MeCN (4 ml), concentrated in vacuo, and dried at 45° C. to give the title compound (55 mg, 0.122 mmol, 81% yield, 98% purity) as a tan powder. UPLC-MS (Method 1) m / z 443.3 (M+H) at 1.81 min +, 441.3(MH) - . [Example 68]
[0468] 3-(N-(2-(azepan-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid [ka]
[0469] Step 1: Methyl 3-(N-(2-(azepan-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoate: 2-(azepan-1-yl)-5-(trifluoromethyl)aniline (48.8 mg, 0.189 mmol) was dissolved in a mixture of DCM (1 mL) and pyridine (0.05 mL, 0.618 mmol) and treated with a solution of methyl 3-(chlorosulfonyl)-4-methoxybenzoate (60 mg, 0.227 mmol) in DCM (1 mL). The resulting solution was stirred at room temperature for 18 hours. The reaction mixture was loaded directly onto silica gel and purified by silica gel chromatography (12 g cartridge, 0–70% EtOAc / isohexane) to afford the title compound (44 mg, 0.084 mmol, 44.5% yield, 93% purity) as a pale yellow sticky solid. UPLC-MS (method 1) m / z 1.91 min 487.4 (M+H) + , 485.2(MH) - .
[0470] Step 2: 3-(N-(2-(azepan-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid: The product from Step 1 above (42 mg, 0.086 mmol) was dissolved in THF (2 ml) and treated with 1.1 M LiOH(aq) (235 μl, 0.259 mmol). The reaction mixture was stirred at room temperature for 2 days. Additional 1.1 M LiOH(aq) (78 μl, 0.086 mmol) was added and the reaction warmed to 30° C. for 18 hours. The reaction mixture was diluted with water (3 ml), concentrated in vacuo, and the resulting aqueous solution was diluted with water (to approximately 5 ml) and neutralized with 1 M HCl(aq) (0.4 ml). The resulting chunky suspension was sonicated to give a cloudy solution and neutralized to pH approximately 6 with 1 M HCl. The aqueous phase was acidified with 1M HCl (aq) and the product extracted into EtOAc (3 x 10 ml). The combined organic phases were dried over MgSO, filtered and the solvent removed in vacuo. The crude product was purified by silica gel chromatography (12 g cartridge, 0-70% EtOAc / isohexane) to give the title compound (2.2 mg, 4.42 μmol, 5.12% yield, 95% purity) as a white solid. UPLC-MS (Method 1) m / z 473.4 (M+H) at 1.79 min + , 471.1(MH) - . 1 H NMR (500MHz, DMSO-d6) δ13.13 (br s, 1H), 8.76 (br s,1H), 8.36(d,J=2.2Hz,1H), 8.14(dd,J=8.7,2.2Hz,1H), 7.44(d,J=1.9Hz,1H), 7.38~7.26(m,3H), 3.91(s,3H), 2.92 (d,J=11.4Hz,2H), 2.67~2.57(m,2H), 1.72~1.65(m,1H), 1.55~1.43(m,1H), 1.34~1.20(m,3H), 0.97(d,J=6.5Hz,3H). [Example 69]
[0471] 4-chloro-3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid [ka]
[0472] Step 1: Methyl 4-chloro-3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoate: 2-(piperidin-1-yl)-5-(trifluoromethyl)aniline (45.4 mg, 0.186 mmol) was dissolved in a mixture of DCM (1 mL) and pyridine (0.05 mL, 0.618 mmol) and treated with a solution of methyl 4-chloro-3-(chlorosulfonyl)benzoate (60 mg, 0.223 mmol) in DCM (1 mL). The resulting solution was stirred at room temperature for 18 hours. The reaction mixture was loaded directly onto silica and purified by silica gel chromatography (12 g cartridge, 0–70% EtOAc / isohexane) to afford the title compound (45.5 mg, 0.094 mmol, 50.3% yield, 98% purity) as a tan solid. UPLC-MS (method 1) m / z 477.3 (M+H) at 2.00 min + , 475.1(MH) - .
[0473] Step 2: 4-Chloro-3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid: The product from Step 1 above (43 mg, 0.090 mmol) was dissolved in THF (2 ml) and treated with 1.1 M LiOH(aq) (328 μl, 0.361 mmol). The reaction was stirred at room temperature for 2 days. The reaction mixture was diluted with water (3 ml) and concentrated in vacuo, and the resulting aqueous solution was diluted with water (to approximately 5 ml) and neutralized with 1 M HCl(aq) (0.4 ml). The resulting chunky suspension was sonicated to give a cloudy solution and neutralized to pH approximately 6 with 1 M HCl(aq). The aqueous phase was acidified with 1 M HCl(aq) and the product was extracted into EtOAc (3×10 ml). The combined organic phases were dried over MgSO4, filtered, and the solvent removed in vacuo. The crude product was purified by silica gel chromatography (12 g cartridge, 0-10% MeOH / DCM) to give the title compound (20.5 mg, 0.042 mmol, 46.7% yield, 95% purity) as a white solid. UPLC-MS (Method 1) m / z 463.3 (M+H) at 1.88 min + , 461.2(MH) - . 1 H NMR (500MHz, DMSO-d6) δ13.48 (br s, 1H), 9.54 (br s,1H), 8.44(d,J=2.0Hz,1H), 8.12(dd,J=8.3,2.1Hz,1H), 7.80(d,J=8.3Hz,1H), 7.42(d,J=8.3Hz,1 H), 7.34(s,1H), 7.29(d,J=8.4Hz,1H), 2.77(t,J=5.1Hz,4H), 1.58~1.51(m,4H), 1.50~1.43(m,2H).
[0474] The following examples were prepared in a similar manner to Example 69, substituting the appropriate starting materials and intermediates where necessary.
[0475] [Table 7] TIFF0007595355000114.tif177130TIFF0007595355000115.tif134126TIFF0007595355 000116.tif149131TIFF0007595355000117.tif171125TIFF0007595355000118.tif83126
[0476] [Example 161]
[0477] 4-Hydroxy-3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid [ka]
[0478] Step 1: Methyl 4-methoxy-3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoate: A solution of 2-(piperidin-1-yl)-5-(trifluoromethyl)aniline (0.130 g, 0.532 mmol) in DCM (1 mL) and pyridine (0.258 mL, 3.19 mmol) was added to a solution of methyl 3-(chlorosulfonyl)-4-methoxybenzoate (0.169 g, 0.639 mmol) in DCM (1 mL), and the solution was stirred at room temperature for 16 h. The solvent was removed in vacuo. The crude product was purified by silica gel chromatography (24 g cartridge, 0–50% EtOAc / DCM) to afford the title compound (0.230 g, 0.433 mmol, 81% yield, 89% purity) as a white solid. UPLC-MS (Method 1) m / z 473.4 (M+H) at 1.86 min + , 471.3(MH) - . 1H NMR(500MHz,DMSO-d6)δ8.81(s,1H), 8.37(d,J=2.3Hz,1H), 8.19(dd,J=8.7,2.3Hz,1H), 7.45(d,J=2.0Hz,1H ), 7.41~7.28(m,3H), 3.94(s,3H), 3.86(s,3H), 2.84~2.69(m,4H), 1.66(p,J=5.6Hz,4H), 1.57~1.51(m,2H).
[0479] Step 2: Methyl 4-hydroxy-3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoate: A solution of the product from Step 1 above (0.230 g, 0.438 mmol) in DCM (10 ml) was treated with 1.0 M BBr3 in DCM (0.166 ml, 1.75 mmol) and the solution was stirred at room temperature for 16 hours. The solvent was removed in vacuo to give the title compound as a yellow oil (0.200 g, 0.393 mmol, 90% yield, 90% purity). UPLC-MS (Method 1) m / z 459 (M+H) at 1.7 min + .
[0480] Step 3: 4-Hydroxy-3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid: 1M LiOH(aq) (1.31 ml, 1.31 mmol) was added to a solution of the product from Step 2 above (0.2 g, 0.436 mmol) in MeOH (10 ml) and the solution was stirred at room temperature overnight. The solvent was removed in vacuo and the residue redissolved in water (5 ml) and extracted with EtOAc (3 x 5 ml). The aqueous phase was acidified with 1M HCl(aq) and the product extracted into EtOAc (3 x 10 ml). The combined organic phases were dried over MgSO4, filtered and the solvent removed in vacuo. The crude product was purified by silica gel chromatography (24 g cartridge, 0-50% EtOAc / DCM) to give the title compound (60 mg, 0.128 mmol, 29.4% yield, 95% purity) as a white solid. UPLC-MS (Method 1) m / z 445.3 (M+H) at 1.56 min + , 443.2(MH) - . 1H NMR (500 MHz, DMSO-d6) δ 12.96 (br s, 1H), 8.29 (d, J = 2.3 Hz, 1H), 7.98 (dd, J = 8.6, 2.3 Hz, 1H), 7.52 (d, J = 1.8 Hz, 1H), 7.37–7.33 (m, 2H), 7.04 (d, J = 8.6 Hz, 1H), 2.75 (t, J = 5.2 Hz, 4H), 1.68 (p, J = 5.5 Hz, 4H), 1.58–1.51 (m, 2H). Two exchangeable protons were not observed. [Example 165]
[0481] 4-Methoxy-3-(N-methyl-N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid [ka]
[0482] Step 1: Methyl 4-methoxy-3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoate: A mixture of 2-(piperidin-1-yl)-5-(trifluoromethyl)aniline (100 mg, 0.409 mmol), methyl 3-(chlorosulfonyl)-4-methoxybenzoate (130 mg, 0.491 mmol), and pyridine (100 μL, 1.24 mmol) in DCM (1.5 mL) was stirred overnight at room temperature. The mixture was concentrated onto silica and purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to give the title compound (189 mg, 0.384 mmol, 94% yield, 96% purity) as a white solid. UPLC-MS (Method 2) m / z 473.3 (M+H) at 1.80 min + . 1H NMR(500MHz,DMSO-d6)δ8.80(s,1H), 8.36(d,J=2.2Hz,1H), 8.18(dd,J=8.8,2.2Hz,1H), 7.44(d,J=2.0Hz,1H ), 7.40~7.29(m,3H), 3.93(s,3H), 3.85(s,3H), 2.76(t,J=5.2Hz,4H), 1.70~1.61(m,4H), 1.59~1.49(m,2H).
[0483] Step 2: Methyl 4-methoxy-3-(N-methyl-N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoate: To a suspension of sodium hydride (12 mg, 0.500 mmol) in THF (1 ml) at 0 °C was added the product from Step 1 above (189 mg, 0.384 mmol) in THF (1 ml). The mixture was allowed to warm to room temperature and stirred for 30 minutes, after which iodomethane (30 μl, 0.480 mmol) was added and the mixture was stirred at room temperature overnight. The mixture was quenched with HO (10 ml) and extracted with EtOAc (3 × 20 ml). The combined organic extracts were washed with brine (15 ml), passed through a phase separator and the solvent removed in vacuo. The residue was loaded onto silica and purified by silica gel chromatography (12 g cartridge, 0-50% EtOAc / isohexane) to give the title compound (172 mg, 0.283 mmol, 73.7% yield, 80% purity) as a clear, colorless oil. UPLC-MS (Method 2) m / z 487.3 (M+H) at 1.83 min + . 1 H NMR(500MHz,DMSO-d6)δ8.25(dd,J=8.7,2.2Hz,1H), 8.22(d,J=2.2Hz,1H), 7.54(dd,J=8.6,2.2Hz,1H), 7.48(d,J=8.7Hz,1H), 7.21(d,J =8.6Hz,1H), 7.02(d,J=2.2Hz,1H), 4.00(s,3H), 3.83(s,3H), 3.27(s,3H), 3.06(t,J=5.1Hz,4H), 1.64~1.57(m,4H), 1.57~1.50(m,2H).
[0484] Step 3: 4-Methoxy-3-(N-methyl-N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid: A mixture of the product from Step 2 above (170 mg, 0.349 mmol) and 2M LiOH(aq) (0.35 ml, 0.700 mmol) in THF (1.5 ml) was stirred at 50 °C overnight. The mixture was diluted with HO (5 ml), acidified to pH ∼4 with 1M HCl(aq), and extracted with EtOAc (3 × 10 ml). The combined organic extracts were washed with brine (10 ml), passed through a phase separator, and the solvent removed in vacuo. The residue was loaded onto silica and purified by silica gel chromatography (4 g cartridge, 0–10% MeOH / DCM) to afford the title compound (66.1 mg, 0.134 mmol, 38.3% yield, 96% purity) as a white solid. UPLC-MS (method 2) m / z 473.3 (M+H) at 1.17 min + , 471.2(MH) - . 1 H NMR(500MHz,DMSO-d6)δ13.10(s,1H), 8.22(m,2H), 7.53(dd,J=8.5,2.3Hz,1H), 7.48~7.41(m,1H), 7.20(d,J=8.5 Hz,1H), 7.01(d,J=2.2Hz,1H), 3.99(s,3H), 3.28(s,3H), 3.09~3.02(m,4H), 1.65~1.57(m,4H), 1.57~1.48(m,2H). [Example 171]
[0485] 2-Methoxy-N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)-5-(tetrazol-5-yl)benzenesulfonamide [ka]
[0486] Step 1: 5-cyano-2-methoxy-N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)benzenesulfonamide: 2-(piperidin-1-yl)-5-(trifluoromethyl)aniline (200 mg, 0.819 mmol) was dissolved in a mixture of DCM (2 mL) and pyridine (0.15 mL, 1.86 mmol) and treated with a solution of 5-cyano-2-methoxybenzenesulfonyl chloride (237 mg, 1.02 mmol) in DCM (1 mL). The resulting solution was allowed to stand at room temperature for 18 hours, then diluted with water (ca. 0.1 mL) and concentrated in vacuo. The crude product was purified by silica gel chromatography (12 g cartridge, 0–50% EtOAc / isohexane) to afford the title compound (325 mg, 0.717 mmol, 88% yield, 99% purity) as a pale yellow solid. UPLC-MS (method 1) m / z 440.4 (M+H) at 1.82 min + , 438.1(MH) - .
[0487] Step 2: 2-Methoxy-N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)-5-(tetrazol-5-yl)benzenesulfonamide: The product from Step 1 above (100 mg, 0.228 mmol) was combined with sodium azide (74.0 mg, 1.14 mmol) and zinc bromide (102 mg, 0.455 mmol) in IPA (1 mL) and water (0.3 mL). The resulting mixture was heated at 80 °C overnight and then concentrated in vacuo. The crude product was purified by silica gel chromatography (24 g cartridge, 0-100% EtOAc / isohexane followed by 0-10% MeOH / DCM) to afford the title compound (7.9 mg, 0.016 mmol, 6.84% yield, 95% purity) as a white solid. UPLC-MS (Method 1) m / z 483.4 (M+H) at 1.67 min + , 481.2(MH) - . 1H NMR (500 MHz, DMSO-d6) δ 8.79 (s, 1H), 8.55 (d, J = 2.2 Hz, 1H), 8.27 (dd, J = 8.7, 2.2 Hz, 1H), 7.51 (s, 1H), 7.44 (d, J = 8.8 Hz, 1H), 7.37–7.33 (m, 2H), 3.94 (s, 3H), 2.78 (t, J = 5.3 Hz, 4H), 1.70–1.65 (m, 4H), 1.57–1.50 (m, 2H). Not a single exchangeable proton was observed. [Example 177]
[0488] 3-(N-(2-(3-hydroxypiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid [ka]
[0489] Step 1: 1-(2-nitro-4-(trifluoromethyl)phenyl)piperidin-3-ol: EtN (0.500 ml, 3.59 mmol) was added to a solution of 1-fluoro-2-nitro-4-(trifluoromethyl)benzene (0.201 ml, 1.44 mmol) and piperidin-3-ol (174 mg, 1.72 mmol) in DCM (6 ml) at room temperature. The clear solution was stirred at room temperature for 17 hours. The organic phase was washed with 1 M HCl (3 ml), dried by passing through a phase separator, and concentrated in vacuo to give the title compound (468 mg, 1.40 mmol, 98% yield, 87% purity) as a red / orange oil. UPLC-MS (Method 1) m / z 291.5 (M+H) at 1.39 min + . 1H NMR(500MHz,DMSO-d6)δ8.12~8.07(m,1H), 7.80(dd,J=9.0,2.4Hz,1H), 7.41(d, J=8.9Hz,1H), 4.91(d,J=4.3Hz,1H), 3.65~3.57(m,1H), 3.26(dd,J=12.4,3.9Hz ,1H), 3.21(dt,J=13.0,4.5Hz,1H), 2.98~2.91(m,1H), 2.75(dd,J=12.3,8.5Hz, 1H), 1.93~1.85(m,1H), 1.81~1.73(m,1H), 1.56~1.46(m,1H), 1.40~1.30(m,1H).
[0490] Step 2: 1-(2-Amino-4-(trifluoromethyl)phenyl)piperidin-3-ol: 5% Pd / C (50% w / w water) Type 87L (50 mg, 0.012 mmol) in EtOH (0.5 ml) was added to a solution of the product from Step 1 above (234 mg, 0.701 mmol) in EtOH (3.0 ml) at room temperature. The reaction mixture was hydrogenated (4 bar) at room temperature for 19 hours. The catalyst was removed by filtration through Celite® and washed with MeOH (15 ml). The filtrate was concentrated in vacuo, and the residue was dissolved in MeOH (10 ml), dried over MgSO4, filtered, and concentrated in vacuo to give a white solid. MeCN (10 ml) was added and the resulting slurry was redried over a large excess of MgSO, filtered and concentrated in vacuo to give the title compound (153 mg, 0.576 mmol, 82% yield, 98% purity) as a yellow solid. UPLC-MS (Method 1) m / z 261.4 (M+H) at 1.29 min + . 1 H NMR(500MHz,DMSO-d6)δ6.96(d,J=8.1Hz,1H), 6.94(d,J=2.2Hz,1H), 6.84~6.80(m,1H), 5.14(s,2H), 4.79(d,J=5.4Hz,1H), 3.74~3.66(m, 1H), 3.04~2.96(m,1H), 2.92~2.85(m,1H), 2.58~2.50(m,1H), 2.49~2 .41(m,1H), 1.86~1.75(m,2H), 1.65~1.55(m,1H), 1.37~1.28(m,1H).
[0491] Step 3: Methyl 3-(N-(2-(3-hydroxypiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoate: Pyridine (0.075 ml, 0.933 mmol) was added to a cloudy solution of the product from Step 2 above (62.0 mg, 0.233 mmol) and methyl 3-(chlorosulfonyl)-4-methoxybenzoate (78 mg, 0.280 mmol) in DCM (2.0 ml) at room temperature. The resulting clear solution was stirred at room temperature for 20 hours, and the reaction mixture was concentrated in vacuo. The crude product was purified by silica gel chromatography (10 g cartridge, 0-100% EtOAc / isohexane) to give the title compound (88.1 mg, 0.177 mmol, 76% yield, 98% purity) as a yellow oil. UPLC-MS (Method 1) m / z 489.3 (M+H) at 1.59 min + , 487.2(MH) - .
[0492] Step 4: 3-(N-(2-(3-hydroxypiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid: 1M LiOH(aq) (0.707 ml, 0.707 mmol) was added to a solution of the product from Step 3 above (88.1 mg, 0.177 mmol) in THF (1.4 ml) at room temperature. The reaction mixture was stirred at room temperature for 18 hours and then concentrated in vacuo. The residue was dissolved in water (3 ml) and acidified to a pH of 4-5 using 1M HCl. The precipitate was isolated by filtration and then dissolved in EtOAc (5 ml). The organic phase was washed with water (3 ml), dried over MgSO4, filtered, and concentrated in vacuo to give the title compound (50 mg, 0.104 mmol, 59% yield, 99% purity) as a pale pink solid. UPLC-MS (method 1) m / z 475.4 (M+H) at 1.38 min + , 473.1(MH) - . 1H NMR (500MHz, DMSO-d6) δ13.16 (br s, 1H), 9.14 (br s,1H), 8.39(d,J=2.2Hz,1H), 8.14(dd,J=8.7,2.2Hz,1H), 7.46(d,J=1.8Hz,1H), 7.33~7.27(m,2H), 7.25(d,J=8.3Hz,1H), 5.09(br s,1H), 3.89(s,3H), 3.79~3.73(m,1H), 2.87~2.79(m,2H), 2.74~2.68(m,1H), 2.67~2. 62(m,1H), 1.93~1.85(m,1H), 1.77~1.69(m,1H), 1.60~1.51(m,1H), 1.51~1.43(m,1H). [Example 178]
[0493] (S)-3-(N-(2-(3-hydroxypyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid [ka]
[0494] Step 1: (S)-1-(2-nitro-4-(trifluoromethyl)phenyl)pyrrolidin-3-ol: EtN (0.500 ml, 3.59 mmol) was added to a solution of 1-fluoro-2-nitro-4-(trifluoromethyl)benzene (0.201 ml, 1.44 mmol) and (S)-pyrrolidin-3-ol (0.139 ml, 1.72 mmol) in DCM (6 ml) at room temperature. The clear solution was stirred at room temperature for 17 hours. The organic phase was washed with 1 M HCl (3 ml), dried by passing through a phase separator, and concentrated in vacuo to give the title compound (445 mg, 1.37 mmol, 95% yield, 85% purity) as an orange oil. UPLC-MS (Method 1) m / z 277.2 (M+H) at 1.33 min + . 1H NMR(500MHz,DMSO-d6)δ8.06~8.03(m,1H), 7.72(dd,J=9.1,2.3Hz,1H), 7.19(d,J=9.1Hz,1H), 5.05(d,J=3.4Hz,1H), 4.41~4.36(m,1H), 3 .50(apparent td,J=9.8,6.8Hz,1H), 3.41(dd,J=11.1,4.3Hz,1H), 3.25~3.19(m,1H), 2.85~2.80(m,1H), 2.04~1.96(m,1H), 1.94~1.88(m,1H).
[0495] Step 2: (S)-1-(2-Amino-4-(trifluoromethyl)phenyl)pyrrolidin-3-ol: 5% Pd / C (50% w / w water) Type 87L (50 mg, 0.012 mmol) in EtOH (0.5 ml) was added to a solution of the product from Step 1 above (220 mg, 0.677 mmol) in EtOH (3.0 ml) at room temperature. The reaction mixture was hydrogenated (4 bar) at room temperature for 19 hours. The catalyst was removed by filtration through Celite® and washed with MeOH (20 ml). The organic phase was concentrated in vacuo, and the residue was dissolved in DCM (10 ml). The organic phase was washed with water (5 ml), dried over MgSO4, filtered, and concentrated in vacuo to give the title compound (134 mg, 0.522 mmol, 77% yield, 96% purity) as a dark brown oil. UPLC-MS (method 1) m / z 247.3 (M+H) at 1.08 min + . 1 H NMR(500MHz,DMSO-d6)δ6.92(d,J=1.8Hz,1H), 6.88(d,J=8.2Hz,1H), 6.80(dd,J=8.2,1.5Hz,1H), 4.97(br s,2H), 4.86(d,J=4.9Hz,1H), 4.35~4.28(m,1H), 3.31~3.22(m,2H), 2.99(ddd,J=9.1 ,7.9,5.0Hz,1H), 2.90(dd,J=10.0,3.0Hz,1H), 2.12~2.04(m,1H), 1.79~1.71(m,1H).
[0496] Step 3: (S)-Methyl 3-(N-(2-(3-hydroxypyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoate: Pyridine (0.075 ml, 0.933 mmol) was added to a cloudy solution of the product from Step 2 above (60.5 mg, 0.233 mmol) and methyl 3-(chlorosulfonyl)-4-methoxybenzoate (78 mg, 0.280 mmol) in DCM (2.0 ml) at room temperature. The resulting clear solution was stirred at room temperature for 20 hours and then concentrated in vacuo. The crude product was purified by silica gel chromatography (10 g cartridge, 0-100% EtOAc / isohexane) to give the title compound (96.7 mg, 0.196 mmol, 84% yield, 96% purity) as an orange oil. UPLC-MS (Method 1) m / z 475.4 (M+H) at 1.35 min + , 473.2(MH) - .
[0497] Step 4: (S)-3-(N-(2-(3-hydroxypyrrolidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid: 1M LiOH(aq) (0.783 ml, 0.783 mmol) was added to a solution of the product from Step 3 above (96.7 mg, 0.196 mmol) in THF (1.6 ml) at room temperature. The reaction mixture was stirred at room temperature for 20 hours and then concentrated in vacuo. The residue was dissolved in water (3 ml) and acidified to a pH of 4-5 using 1M HCl. The precipitate was isolated by filtration and then dissolved in EtOAc (5 ml). The organic phase was washed with water (3 ml), dried over MgSO4, and concentrated in vacuo. The crude product was purified by silica gel chromatography (10 g cartridge, 0-5% MeOH / DCM) to give the title compound (22.3 mg, 0.046 mmol, 26.3% yield, 96% purity) as an off-white solid. UPLC-MS (Method 1) m / z 461.3 (M+H) at 1.17 min + , 459.2(MH) - . 1H NMR(500MHz,DMSO-d6)δ13.06(brs,1H), 9.30(br s,1H), 8.17(dd,J=8.7,2.2Hz,1H), 8.06(d,J=2.2Hz,1H), 7.39(d,J=8.8Hz,1H), 7.29(dd,J=8.8,2.4Hz,1H), 6.74(d,J=8.9Hz,1H), 6.50(d,J=2.3Hz,1H), 4.96(br s,1H), 4.37~4.31(m,1H), 3.99(s,3H), 3.79(dd,J=11.0,4.8Hz,1H), 3.59~3.52(m ,1H), 3.49~3.43(m,1H), 3.38~3.34(m,1H), 1.96~1.88(m,1H), 1.87~1.81(m,1H). [Example 179]
[0498] 4-Methoxy-3-(N-(2-(3-methoxypiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid [ka]
[0499] Step 1: 3-Methoxy-1-(2-nitro-4-(trifluoromethyl)phenyl)piperidine: EtN (0.500 ml, 3.59 mmol) was added to a solution of 1-fluoro-2-nitro-4-(trifluoromethyl)benzene (0.201 ml, 1.44 mmol) and 3-methoxypiperidine (198 mg, 1.72 mmol) in DCM (6 ml) at room temperature. The clear solution was stirred at room temperature for 16 hours. The organic phase was washed with 1 M HCl (3 ml), dried by passing through a phase separator, and concentrated in vacuo to give the title compound (438 mg, 1.41 mmol, 98% yield, 98% purity) as an orange oil. 1H NMR (500MHz, DMSO-d6) δ8.13~8.10(m,1H), 7.81(dd,J=8.9,2.4Hz,1H), 7.43(d,J=8.9Hz,1H), 3.42~3.33(m,2H), 3.24(s,3H), 3.19(apparently dt,J= 12.9,4.7Hz,1H), 3.03~2.96(m,1H), 2.86(dd,J=12.2,7.5Hz,1H), 2.00 ~1.93(m,1H), 1.82~1.73(m,1H), 1.57~1.47(m,1H), 1.47~1.38(m,1H).
[0500] Step 2: 2-(3-Methoxypiperidin-1-yl)-5-(trifluoromethyl)aniline: 5% Pd / C (50% w / w water) Type 87L (50 mg, 0.012 mmol) in EtOH (0.5 ml) was added to a solution of the product from Step 1 (214 mg, 0.689 mmol) in EtOH (3.0 ml) at room temperature. The reaction mixture was hydrogenated (4 bar) at room temperature for 18 hours. The catalyst was removed by filtration through a pad of Celite® and washed with EtOH (15 ml). The filtrate was concentrated in vacuo and azeotroped with MeOH (6 ml) to give the title compound (151 mg, 0.484 mmol, 70% yield, 88% purity) as an off-white solid. UPLC-MS (Method 1) m / z 275.3 (M+H)+ (ES+) at 1.58 min. 1 H NMR(500MHz,DMSO-d6)δ6.99(d,J=8.1Hz,1H), 6.95(d,J=2.2Hz,1H), 6.83(dd,J=8.1,1.5Hz,1H), 5.12(br s,2H), 3.46~3.40(m,1H), 3.29(s,3H), 3.17~3.09(m,1H), 2.99~2.93(m,1H), 2.57~2. 46(m,2H), 1.98~1.90(m,1H), 1.80~1.73(m,1H), 1.67~1.58(m,1H), 1.40~1.29(m,1H).
[0501] Step 3: Methyl 4-methoxy-3-(N-(2-(3-methoxypiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoate: Pyridine (0.081 ml, 1.01 mmol) was added to a cloudy solution of the product from Step 2 above (79 mg, 0.252 mmol) and methyl 3-(chlorosulfonyl)-4-methoxybenzoate (80 mg, 0.302 mmol) in DCM (2.0 ml) at room temperature. The resulting clear solution was stirred at room temperature for 18 hours and then concentrated in vacuo. The crude product was purified by silica gel chromatography (10 g cartridge, 0-60% EtOAc / isohexane) to give the title compound (84 mg, 0.167 mmol, 66% yield, 100% purity) as a cream-colored solid. UPLC-MS (Method 1) m / z 503.4 (M+H) at 1.77 min + , 501.2(MH) - .
[0502] Step 4: 4-Methoxy-3-(N-(2-(3-methoxypiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid: 1M LiOH(aq) (0.669 ml, 0.669 mmol) was added to a solution of the product from Step 3 above (84 mg, 0.167 mmol) in THF (1.3 ml) at room temperature. The reaction mixture was stirred at room temperature for 18 hours and then concentrated in vacuo. The residue was dissolved in water (3 ml) and washed with EtOAc (5 ml). The aqueous phase was acidified to pH 4-5 using 1M HCl and the product was extracted into EtOAc (5 ml × 3). The combined organic phases were dried over MgSO and concentrated in vacuo to give the title compound (63 mg, 0.128 mmol, 77% yield, 100% purity) as a white solid. UPLC-MS (method 1) m / z 1.60 min 489.3 (M+H) + , 487.1(MH) - . 1H NMR(500MHz,DMSO-d6)δ13.19(brs,1H), 9.06(br s,1H), 8.39(d,J=2.2Hz,1H), 8.15(dd,J=8.7,2.2Hz,1H), 7.47(d,J=1.6Hz,1H), 7.35~7.23(m,3H), 3.89(s,3H) ), 3.47~3.41(m,1H), 3.35(s,3H), 2.98~2.88(m,2H), 2.78~2.71(m,2H), 1.85~1.70(m,2H), 1.69~1.55(m,2H). [Example 180]
[0503] 3-(N-(2-(4-ethoxypiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid [ka]
[0504] Step 1: 4-Ethoxy-1-(2-nitro-4-(trifluoromethyl)phenyl)piperidine: EtN (0.500 ml, 3.59 mmol) was added to a solution of 1-fluoro-2-nitro-4-(trifluoromethyl)benzene (0.201 ml, 1.44 mmol) and 4-ethoxypiperidine (222 mg, 1.72 mmol) in DCM (6 ml) at room temperature. The clear solution was stirred at room temperature for 16 hours. The organic phase was washed with 1 M HCl (3 ml), dried by passing through a phase separator, and concentrated in vacuo to give the title compound (471 mg, 1.435 mmol, 100% yield, 97% purity) as an orange oil. 1 H NMR (500MHz, DMSO-d6) δ8.13~8.10(m,1H), 7.81(dd,J=8.9,2.4Hz,1H), 7.42(d,J=8.8Hz,1H), 3.55~3.45( m,3H), 3.30~3.25(m,2H), 3.03~2.97(m,2H), 1.95~1.87(m,2H), 1.59~1.51(m,2H), 1.12(t,J=7.0Hz,3H).
[0505] Step 2: 2-(4-Ethoxypiperidin-1-yl)-5-(trifluoromethyl)aniline: 5% Pd / C (50% w / w water) Type 87L (50 mg, 0.012 mmol) in EtOH (0.5 ml) was added to a solution of the product from Step 1 above (228 mg, 0.695 mmol) in EtOH (3.0 ml) at room temperature. The reaction mixture was hydrogenated (4 bar) at room temperature for 18 hours. The catalyst was removed by filtration through a pad of Celite® and washed with EtOH (15 ml). The filtrate was concentrated in vacuo and azeotroped with MeOH (6 ml) to give the title compound (179 mg, 0.559 mmol, 80% yield, 90% purity) as an off-white solid. UPLC-MS (Method 1) m / z 289.3 (M+H) at 1.66 min + . 1 H NMR(500MHz,DMSO-d6)δ6.99(d,J=8.1Hz,1H), 6.95(d,J=2.2Hz,1H), 6.82(dd,J=8.2,1.6Hz,1H), 5.10(br s,2H), 3.48(q,J=7.0Hz,2H), 3.45~3.38(m,1H), 3.06~2.99(m,2H), 2.65~ 2.57(m,2H), 1.99~1.91(m,2H), 1.68~1.59(m,2H), 1.12(t,J=7.0Hz,3H).
[0506] Step 3: Methyl 3-(N-(2-(4-ethoxypiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoate: Pyridine (0.081 ml, 1.01 mmol) was added to a cloudy solution of the product from Step 2 above (81 mg, 0.252 mmol) and methyl 3-(chlorosulfonyl)-4-methoxybenzoate (80 mg, 0.302 mmol) in DCM (2.0 ml) at room temperature. The resulting clear solution was stirred at room temperature for 18 hours and then concentrated in vacuo. The crude product was purified by silica gel chromatography (10 g cartridge, 0-60% EtOAc / isohexane) to give the title compound (92.5 mg, 0.159 mmol, 63% yield, 89% purity) as a colorless oil. UPLC-MS (Method 1) m / z 517.4 (M+H) at 1.80 min. +, 515.2(MH) - .
[0507] Step 4: 3-(N-(2-(4-Ethoxypiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid: 1M LiOH(aq) (0.634 ml, 0.634 mmol) was added to a solution of the product from Step 3 above (92 mg, 0.159 mmol) in THF (1.3 ml) at room temperature. The reaction mixture was stirred at room temperature for 18 hours and then concentrated in vacuo. The residue was dissolved in water (3 ml) and washed with EtOAc (2 x 5 ml). The aqueous phase was acidified to pH 4-5 using 1M HCl and the product was extracted into EtOAc (3 x 5 ml). The combined organic phases were dried over MgSO4 and concentrated in vacuo to give the title compound (61 mg, 0.118 mmol, 74% yield, 97% purity) as an off-white solid. UPLC-MS (Method 1) m / z 503.3 (M+H) at 1.63 min + , 501.3(MH) - . 1 H NMR (500MHz, DMSO-d6) δ13.18 (br s, 1H), 8.87 (br s,1H), 8.36(d,J=2.2Hz,1H), 8.16(dd,J=8.7,2.2Hz,1H), 7.44(d,J=1.7Hz,1H), 7.36(dd,J=8.4,1.6Hz,1H), 7.34~7.30(m,2H), 3 .91(s,3H), 3.52~3.42(m,3H), 2.99~2.91(m,2H), 2.72~2.64(m,2H), 1.98~1.90(m,2H), 1.67~1.58(m,2H), 1.14(t,J=7.0Hz,3H). [Example 181]
[0508] 4-Methoxy-3-(N-(2-(4-methoxypiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid [ka]
[0509] Step 1: 4-Methoxy-1-(2-nitro-4-(trifluoromethyl)phenyl)piperidine: EtN (318 μl, 2.28 mmol) was added to a solution of 1-fluoro-2-nitro-4-(trifluoromethyl)benzene (128 μl, 0.912 mmol) and 4-methoxypiperidine (105 mg, 0.912 mmol) in DCM (3 ml), and the resulting solution was stirred at room temperature for 20 h. 1 M HCl (2 ml) was added, and the organic phase was dried by passing through a phase separator. The organic phase was concentrated in vacuo to give the title compound (277 mg, 0.912 mmol, 100% yield, 100% purity) as a pale orange oil. UPLC-MS (Method 1) m / z 1.305.6 (M+H) at 60 min. + .
[0510] Step 2: 2-(4-Methoxypiperidin-1-yl)-5-(trifluoromethyl)aniline: The product from Step 1 above (277 mg, 0.912 mmol) was dissolved in EtOH (14.2 ml) and hydrogenated in a Thales Nano H-cube® flow reactor (10% Pd / C, 30 × 4 mm, full hydrogen mode, 40 °C, flow rate 1 ml / min, 2-flow). The reaction mixture was concentrated in vacuo and azeotroped with MeOH (6 ml) to give the title compound (239 mg, 0.854 mmol, 94% yield, 98% purity) as a cream-colored solid. UPLC-MS (Method 2) m / z 275.3 (M+H) at 1.53 min. + , 273.3(MH) - .
[0511] Step 3: Methyl 4-methoxy-3-(N-(2-(4-methoxypiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoate: The product from Step 2 above (69.1 mg, 0.252 mmol) was dissolved in a mixture of DCM (1 mL) and pyridine (81 μL, 1.01 mmol) and treated with a solution of methyl 3-(chlorosulfonyl)-4-methoxybenzoate (80 mg, 0.302 mmol) in DCM (1 mL). The resulting solution was stirred at room temperature for 4 days. The crude product was directly purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to afford the title compound (52.8 mg, 0.103 mmol, 40.9% yield, 98% purity) as a white solid. UPLC-MS (Method 1) m / z 503.4 (M+H) at 1.71 min + (ES+);501.2(MH) - (ES-),
[0512] Step 4: 4-Methoxy-3-(N-(2-(4-methoxypiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid: The product from Step 3 above (50 mg, 0.100 mmol) was dissolved in THF (2 ml) and treated with 1.1 M LiOH(aq) (362 μl, 0.398 mmol). MeOH was added dropwise until the mixture went into solution and the reaction was stirred at 30° C. for 20 h. The reaction mixture was diluted with water (3 ml), concentrated in vacuo and the resulting aqueous solution was diluted with water (to ∼5 ml). The aqueous phase was washed with EtOAc (2 × 5 ml) and neutralized to ∼pH 6 with 1 M HCl. The resulting chunky suspension was sonicated to give a cloudy mixture. The cloudy mixture was concentrated in vacuo to ∼2 ml. The resulting precipitate was collected by filtration and washed with water (2 × 2 ml). The solid was suspended in MeCN (4 ml), concentrated in vacuo, and dried at 45° C. to give the title compound (38.8 mg, 0.078 mmol, 78% yield, 98% purity) as a white solid. UPLC-MS (Method 1) m / z 489.2 (M+H) at 1.53 min + , 487.1(MH) - . 1H NMR(500MHz,DMSO-d6)δ13.16(s,1H), 8.88(s,1H), 8.35(d,J=2.2Hz,1H), 8.15(dd,J=8.7,2.2Hz,1H), 7.43(d,J=2.0Hz,1H), 7.38~7 .28(m,3H), 3.91(s,3H), 3.35~3.28(m,1H), 3.27(s,3H), 2.98~2.90(m,2H), 2.71~2.62(m,2H), 1.99~1.90(m,2H), 1.67~1.57(m,2H). [Example 182]
[0513] 3-(N-(5-cyano-2-(piperidin-1-yl)phenyl)sulfamoyl)-4-methoxybenzoic acid [ka]
[0514] Step 1: 3-Nitro-4-(piperidin-1-yl)benzonitrile: A mixture of 4-fluoro-3-nitrobenzonitrile (300 mg, 1.81 mmol), piperidine (0.2 mL, 2.02 mmol), and EtN (0.65 mL, 4.66 mmol) in DCM (6 mL) was stirred at room temperature overnight. The mixture was washed with water (10 mL), passed through a phase separator, concentrated onto silica, and purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to give the title compound (400 mg, 1.73 mmol, 96% yield, 100% purity) as a pale orange solid. UPLC-MS (Method 2) m / z 232.1 (M+H) at 1.60 min + . 1 H NMR (500MHz, DMSO-d6) δ8.28(d,J=2.1Hz,1H), 7.84(dd,J=8.9,2.1Hz,1H), 7.34(d,J=8.9Hz,1H), 3.18~3.10(m,4H), 1.65~1.54(m,6H).
[0515] Step 2: 3-Amino-4-(piperidin-1-yl)benzonitrile: A solution of the product from Step 1 (398 mg, 1.72 mmol) in EtOH (35 mL) was hydrogenated in a Thales Nano H-cube® flow reactor (10% Pt / C, 30 × 4 mm, full hydrogen mode, 25 °C, flow rate 1 mL / min, 1 flow path). The mixture was concentrated onto silica and purified by silica gel chromatography (12 g cartridge, 0–50% EtOAc / isohexane) to give the title compound (118 mg, 0.542 mmol, 32% yield, 93% purity) as an amber oil. UPLC-MS (Method 2) m / z 202.2 (M+H) at 1.58 min. + . 1 H NMR (500MHz, DMSO-d6) δ6.96~6.95(m,3H), 5.07(s,2H), 2.79(t,J=5.1Hz,4H), 1.71~1.63(m,4H), 1.57~1.48(m,2H).
[0516] Step 3: Methyl 3-(N-(5-cyano-2-(piperidin-1-yl)phenyl)sulfamoyl)-4-methoxybenzoate: A mixture of the product from Step 2 above (118 mg, 0.542 mmol), methyl 3-(chlorosulfonyl)-4-methoxybenzoate (172 mg, 0.651 mmol), and pyridine (130 μl, 1.61 mmol) in DCM (5 mL) was stirred at room temperature over the weekend. The mixture was concentrated onto silica and purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to give the title compound (172 mg, 0.394 mmol, 73% yield, 98% purity) as a white solid. UPLC-MS (Method 2) m / z 430.2 (M+H) at 1.58 min + , 428.1(MH) - . 1H NMR(500MHz,DMSO-d6)δ8.94(s,1H), 8.33(d,J=2.3Hz,1H), 8.20(dd,J=8.7,2.3Hz,1H), 7.50(dd,J=8.5,2.0Hz,1H), 7.41~ 7.35(m,2H), 7.24(d,J=8.5Hz,1H), 3.94(s,3H), 3.86(s,3H), 2.82(t,J=5.3Hz,4H), 1.65~1.57(m,4H), 1.55~1.46(m,2H).
[0517] Step 4: 3-(N-(5-cyano-2-(piperidin-1-yl)phenyl)sulfamoyl)-4-methoxybenzoic acid: A mixture of the product from Step 3 above (170 mg, 0.390 mmol) and LiOH (40 mg, 1.67 mmol) in THF / HO (4:1, 4 ml) was stirred at room temperature for 1 h and then at 35 °C overnight. The mixture was diluted with HO (10 ml) and EtOAc (15 ml) and acidified to ∼pH 4 with 1 M HCl. The phases were separated and the aqueous solution was extracted with EtOAc (2 × 15 ml). The combined organic extracts were washed with brine (15 ml), passed through a phase separator and the solvent removed in vacuo. The residue was loaded onto silica and purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to give the title compound (105 mg, 0.243 mmol, 62% yield, 96% purity) as a white solid. UPLC-MS (Method 1) m / z 416.2 (M+H) at 1.47 min + , 413.7(MH) - . 1 H NMR(500MHz,DMSO-d6)δ13.18(s,1H), 8.88(s,1H), 8.33(d,J=2.2Hz,1H), 8.17(dd,J=8.7,2.2Hz,1H), 7.50(dd,J=8.3,2.0Hz,1H), 7.39 (d,J=2.0Hz,1H), 7.34(d,J=8.7Hz,1H), 7.24(d,J=8.3Hz,1H), 3.92(s,3H), 2.81(t,J=5.2Hz,4H), 1.67~1.56(m,4H), 1.56~1.45(m,2H). [Example 183]
[0518] 4-Ethyl-3-(N-(2-(3-hydroxyazetidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid [ka]
[0519] Step 1: Methyl 3-(chlorosulfonyl)-4-ethylbenzoate: Thionyl chloride (5 ml, 68.5 mmol) was added portionwise to the product from Example 1, Step 1, 3-((chlorosulfonyl)-4-ethylbenzoic acid) (0.888 g, 3.57 mmol) at room temperature. The mixture was heated to 75° C. for 1 h. The solution was cooled to room temperature and concentrated in vacuo. The residue was dissolved in DCM (5 ml) and treated with MeOH (0.144 ml, 3.57 mmol) followed by EtN (0.536 ml, 3.93 mmol) and stirred at room temperature overnight. The mixture was diluted with DCM (50 ml), washed with water (50 ml), dried over MgSO, filtered, and concentrated in vacuo to give the title compound (0.450 g, 1.37 mmol, 38% yield, 80% purity) as a light brown oil. 1 H NMR(500MHz,DMSO-d6)δ8.73(d,J=1.8Hz,1H), 8.32(dd,J=8.1,1.8Hz,1H), 7. 61(d,J=8.0Hz,1H), 3.99(s,3H), 3.28(q,J=7.3Hz,2H), 1.40(t,J=7.4Hz,3H).
[0520] Step 2: 1-(2-Nitro-4-(trifluoromethyl)phenyl)azetidin-3-ol: EtN (0.700 ml, 5.02 mmol) was added to a solution of 1-fluoro-2-nitro-4-(trifluoromethyl)benzene (0.201 ml, 1.44 mmol) and azetidin-3-ol hydrochloride (189 mg, 1.72 mmol) in DCM (6 ml) at room temperature. The clear solution was stirred at room temperature for 16 hours. The organic phase was washed with 1 M HCl (3 ml), and the organic phase was dried through a hydrophobic frit and concentrated in vacuo to give the title compound (461 mg, 1.39 mmol, 97% yield, 79% purity) as an orange oil. 1H NMR(500MHz,DMSO-d6)δ8.09~8.05(m,1H), 7.73(dd,J=9.0,2.3Hz,1H), 6.90(d,J=8.9Hz,1H), 5.79(d, J=6.3Hz,1H), 4.55~4.49(m,1H), 4.19(ddd,J=9.7,6.7,1.4Hz,2H), 3.77(ddd,J=9.7,4.1,1.3Hz,2H).
[0521] Step 3: 1-(2-amino-4-(trifluoromethyl)phenyl)azetidin-3-ol: The product from Step 2 above (455 mg, 1.37 mmol) was dissolved in EtOH (27.4 ml) and hydrogenated in a Thales Nano H-cube® flow reactor (10% Pd / C, 30 × 4 mm, full hydrogen mode, 40 °C, flow rate 1 ml / min, 1 flow path). The reaction mixture was concentrated in vacuo and azeotroped with MeOH (12 ml) to give the title compound (395 mg, 1.37 mmol, 100% yield, 81% purity) as a pale yellow oil. UPLC-MS (Method 1) m / z 233.3 (M+H) at 1.00 min + . 1 H NMR(500MHz,DMSO-d6)δ6.86(d,J=2.1Hz,1H), 6.83~6.79(m,1H), 6.50(d,J=8.1Hz,1H), 5.52(d,J=6.5Hz,1H), 4.74(br s, 2H), 4.46 (sextet, J=6.2Hz, 1H), 4.19~4.13 (m, 2H), 3.45~3.40 (m, 2H).
[0522] Step 4: Methyl 4-ethyl-3-(N-(2-(3-hydroxyazetidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoate: Pyridine (0.072 ml, 0.896 mmol) was added to a solution of the product from Step 3 above (65 mg, 0.224 mmol) and the product from Step 1 above (92 mg, 0.280 mmol) in DCM (2.0 ml) at room temperature. The resulting cloudy solution was stirred at room temperature for 21 hours. The reaction mixture was concentrated in vacuo, and the crude product was purified by silica gel chromatography (10 g cartridge, 0-65% EtOAc / isohexane) to give the title compound (51 mg, 0.102 mmol, 46% yield, 92% purity) as a red oil. UPLC-MS (Method 1) m / z 459.4 (M+H) at 0.66 min + , 457.2(MH) - .
[0523] Step 5: 4-Ethyl-3-(N-(2-(3-hydroxyazetidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid: 1M LiOH(aq) (0.409 ml, 0.409 mmol) was added to a solution of the product from Step 4 above (51 mg, 0.102 mmol) in THF (0.82 ml) at room temperature. The solution was stirred at room temperature for 17 hours and then concentrated in vacuo. The residue was dissolved in water (3 ml) and washed with EtOAc (5 ml). The aqueous phase was acidified to pH 4-5 using 1M HCl and the product was extracted into EtOAc (3 x 5 ml). The organic phases were combined, dried over MgSO and concentrated in vacuo. The crude product was purified by preparative HPLC (Waters, Acidic (0.1% formic acid), Acidic, Waters X-Select Prep-C18, 5 μm, 19 × 50 mm column, 35-65% MeCN in water) to give the title compound (7.3 mg, 0.016 mmol, 16% yield, 99% purity) as a white solid. UPLC-MS (Method 1) m / z 445.3 (M+H) at 1.32 min. + , 443.2(MH) - . 1H NMR(500MHz,DMSO-d6)δ13.24(br s,1H), 9.55(br s,1H), 8.25(d,J=1.8Hz,1H), 8.11(dd,J=8.0,1.5Hz,1H), 7.62(d,J=8.1Hz,1H), 7.31(br d,J=8.7Hz,1H), 6.51(d,J=8.6Hz,1H), 6.24(br s,1H), 5.63(br d,J=5.9Hz,1H), 4.58~4.48(m,1H), 4.40~4.33(m,2H), 3.82(dd,J=8.7,4.8Hz,2H), 2.94(q,J=7.4Hz,2H), 1.17(t,J=7.4Hz,3H). [Example 184]
[0524] 3-(N-(3-fluoro-2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid [ka]
[0525] Step 1: 1-(2-Fluoro-6-nitro-4-(trifluoromethyl)phenyl)piperidine: EtN (0.767 ml, 5.50 mmol) was added to a solution of 1,2-difluoro-3-nitro-5-(trifluoromethyl)benzene (500 mg, 2.20 mmol) and piperidine (0.261 ml, 2.64 mmol) in DCM (6 ml) at room temperature. The clear solution was stirred at room temperature for 23 hours. The organic phase was washed with 1 M HCl (3 ml), dried by passing through a phase separator, and concentrated in vacuo to give the title compound (676 mg, 2.20 mmol, 100% yield, 98% purity) as a brown oil. UPLC-MS (Method 1) m / z 293.5 (M+H) at 1.93 min + .
[0526] Step 2: 3-Fluoro-2-(piperidin-1-yl)-5-(trifluoromethyl)aniline: The product from Step 1 above (0.642 g, 2.20 mmol) was dissolved in EtOH (44 ml) and hydrogenated in a Thales Nano H-cube® flow reactor (10% Pd / C, 30 × 4 mm, full hydrogen mode, RT, flow rate 1 ml / min, 1 flow path). The crude product was concentrated in vacuo and azeotroped with MeOH (12 ml) to give the title compound (0.543 g, 1.97 mmol, 90% yield, 95% purity) as a pale yellow oil. UPLC-MS (Method 1) m / z 263.3 (M+H) at 1.89 min. + .
[0527] Step 3: Methyl 3-(N-(3-fluoro-2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoate: Pyridine (0.139 ml, 1.72 mmol) was added to a solution of the product from Step 2 above (0.15 g, 0.572 mmol) and methyl 3-(chlorosulfonyl)-4-methoxybenzoate (0.189 g, 0.715 mmol) in DCM (10 ml), and the solution was stirred at room temperature for 18 hours. The solution was concentrated in vacuo, and the crude product was purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to give the title compound (0.372 g, 0.546 mmol, 95% yield, 72% purity) as a white solid. UPLC-MS (Method 1) m / z 491.3 (M+H) at 1.96 min + , 489.2(MH) - .
[0528] Step 4: 3-(N-(3-Fluoro-2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid: 1M LiOH(aq) (3.28 ml, 3.28 mmol) was added to a solution of the product from Step 3 above (0.268 g, 0.547 mmol) in THF (12 ml) and MeOH (3 ml) and the solution was stirred at room temperature overnight. The solvent was removed in vacuo and the residue was dissolved in water (5 ml) and extracted with TBME (3 x 5 ml). The aqueous phase was acidified with conc. HCl and the product extracted into TBME (3 x 10 ml). The organic phases were combined and dried by passing through a phase separator. The solvent was removed in vacuo to give the title compound (0.184 g, 0.378 mmol, 69% yield, 98% purity) as an off-white solid. UPLC-MS (method 1) m / z 477.3 (M+H) at 1.81 min + , 474.9(MH) - . 1 H NMR(500MHz,DMSO-d6)δ13.19(s,1H), 8.99(s,1H), 8.38(d,J=2.2Hz,1H), 8.17(dd,J=8.7,2.2H z,1H), 7.37~7.31(m,3H), 3.94(s,3H), 2.91~2.81(m,4H), 1.69~1.62(m,4H), 1.58~1.51(m,2H).
[0529] The following examples were prepared in a similar manner to Example 184, substituting the appropriate starting materials and intermediates where necessary.
[0530] [Table 8] JPEG0007595355000131.jpg214170JPEG0007595355000132.jpg200170
[0531] [Example 200]
[0532] 3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-(trifluoromethyl)benzoic acid [ka]
[0533] Step 1: Methyl 3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-(trifluoromethyl)benzoate: A mixture of 2-(piperidin-1-yl)-5-(trifluoromethyl)aniline (75 mg, 0.307 mmol), methyl 3-(chlorosulfonyl)-4-(trifluoromethyl)benzoate (101 mg, 0.335 mmol), and pyridine (75 μL, 0.927 mmol) in DCM (4 mL) was stirred at room temperature overnight and then at 35° C. for 11 days. The mixture was concentrated onto silica and purified by silica gel chromatography (12 g cartridge, 0-50% EtOAc / isohexane) to give the title compound (91 mg, 0.178 mmol, 58.1% yield, 100% purity) as a pale yellow solid. UPLC-MS (method 1) m / z 511.2 (M+H) at 1.99 min + , 509.0(MH) - . 1 H NMR(500MHz,DMSO-d6)δ9.73(s,1H), 8.46(s,1H), 8.34(d,J=8.2Hz,1H), 8.19(d,J=8.2Hz,1H), 7.50(d,J=8.4 Hz,1H), 7.37(d,J=2.2Hz,1H), 7.26(dd,J=8.4,2.2Hz,1H), 3.89(s,3H), 2.71~2.65(m,4H), 1.48~1.36(m,6H).
[0534] Step 2: 3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-(trifluoromethyl)benzoic acid: A mixture of the product from Step 1 above (91 mg, 0.178 mmol) and LiOH (17 mg, 0.710 mmol) in THF / MeOH / water (4:1:1, 2.4 ml) was stirred at 35° C. overnight. The mixture was diluted with water (10 ml) and EtOAc (15 ml) and acidified to ∼pH 4 with 1 M HCl (aq). The phases were separated and the aqueous phase was extracted with EtOAc (2 x 15 ml). The organic extracts were combined, washed with brine (15 ml), dried by passing through a phase separator and the solvent removed in vacuo. The residue was triturated with isohexane / TBME (5:1) to give the title compound (33.4 mg, 0.066 mmol, 37.0% yield, 98% purity) as a beige solid. UPLC-MS (Method 1) m / z 497.2 (M+H) at 1.92 min + , 495.1(MH) - . 1 H NMR(500MHz,DMSO-d6)δ13.89(s,1H), 9.69(s,1H), 8.48(d,J=1.6Hz,1H), 8.32(dd,J=8.2,1.6Hz,1H), 8.16(d,J=8.2H) z,1H), 7.49(dd,J=8.5,2.2Hz,1H), 7.35(d,J=2.2Hz,1H), 7.26(d,J=8.5Hz,1H), 2.73~2.64(m,4H), 1.49~1.35(m,6H). [Example 201]
[0535] 4-Ethoxy-3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid [ka]
[0536] Step 1: Methyl 4-ethoxy-3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoate: A solution of 2-(piperidin-1-yl)-5-(trifluoromethyl)aniline (0.100 g, 0.409 mmol) in DCM (5 mL) and pyridine (0.199 mL, 2.46 mmol) was added to a solution of methyl 3-(chlorosulfonyl)-4-ethoxybenzoate (0.114 g, 0.409 mmol) in DCM (10 mL), and the solution was stirred at room temperature for 24 h. The solvent was removed in vacuo, and the crude product was purified by silica gel chromatography (40 g cartridge, 0–50% EtOAc / isohexane) to give the title compound (0.160 g, 0.326 mmol, 80% yield, 99% purity) as a cream-colored waxy solid. UPLC-MS (method 1) m / z 487.4 (M+H) at 1.93 min + , 485.2(MH) - .
[0537] Step 2: 4-Ethoxy-3-(N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid: 1M LiOH(aq) (0.024 g, 0.987 mmol) was added to a solution of the product from Step 1 (0.160 g, 0.329 mmol) in THF (5 ml) and the solution was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo to an aqueous solution. The pH was adjusted to pH 6 with 1M HCl(aq) to give a precipitate which was filtered and washed with water (10 ml) and isohexane (20 ml) to give the title compound (0.151 g, 0.304 mmol, 92% yield, 95% purity) as a white solid. UPLC-MS (Method 1) m / z 473.4 (M+H) at 1.78 min + , 471.2(MH) - . 1H NMR (500MHz, DMSO-d6) δ13.20 (br s, 1H), 8.55 (br s,1H), 8.40(d,J=2.2Hz,1H), 8.13(dd,J=8.7,2.2Hz,1H), 7.47(d,J=2.0Hz,1H), 7.39~7.34(m,1H), 7.32~7.30(m,2) H), 4.22(q,J=7.0Hz,2H), 2.76(t,J=5.3Hz,4H), 1.62(p,J=5.5Hz,4H), 1.52(p,J=6.3Hz,2H), 1.27(t,J=7.0Hz,3H). [Example 202]
[0538] 3-(N-(4,5-dichloro-2-(piperidin-1-yl)phenyl)sulfamoyl)-4-methoxybenzoic acid [ka]
[0539] Step 1: Methyl 3-(N-(4,5-dichloro-2-(piperidin-1-yl)phenyl)sulfamoyl)-4-methoxybenzoate: Pyridine (0.166 ml, 2.06 mmol) was added to a solution of 4,5-dichloro-2-(piperidin-1-yl)aniline (0.168 g, 0.685 mmol) and methyl 3-(chlorosulfonyl)-4-methoxybenzoate (0.227 g, 0.857 mmol) in DCM (10 ml). The solution was stirred at room temperature for 18 hours and then concentrated in vacuo. The crude product was purified by silica gel chromatography (12 g cartridge, 0–100% EtOAc / isohexane) to afford the title compound (0.257 g, 0.543 mmol, 79% yield, 81% purity) as a white solid. UPLC-MS (method 1) m / z 475.4 (M+H) at 1.75 min + , 472.8(MH) - .
[0540] Step 2: 3-(N-(4,5-Dichloro-2-(piperidin-1-yl)phenyl)sulfamoyl)-4-methoxybenzoic acid: 1M LiOH(aq) (3.26 ml, 3.26 mmol) was added to a solution of the product from Step 1 above (0.257 g, 0.543 mmol) in THF (13 ml) and MeOH (3 ml), and the solution was stirred at room temperature overnight. The solvent was removed in vacuo, and the residue was dissolved in water (5 ml) and washed with TBME (3 x 5 ml). The aqueous phase was acidified with conc. HCl and extracted with TBME (3 x 10 ml). The combined organic phases were dried by passing through a phase separator, and the solvent was removed in vacuo to give the title compound (0.229 g, 0.494 mmol, 91% yield, 97% purity) as an off-white solid. UPLC-MS (Method 1) m / z 459.3 / 461.3 (M+H) at 1.82 min + , 457.2 / 459.2(MH) - . 1 H NMR(500MHz,DMSO-d6)δ13.22(s,1H), 8.75(s,1H), 8.35(d,J=2.2Hz,1H), 8.17(dd,J=8.7,2.2Hz,1H), 7.42(s, 1H), 7.38(s,1H), 7.34(d,J=8.8Hz,1H), 3.94(s,3H), 2.70~2.64(m,4H), 1.67~1.56(m,4H), 1.56~1.42(m,2H). [Example 203]
[0541] 3-(N-(2-(4,4-difluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-ethylbenzoic acid [ka]
[0542] Step 1: 3-(Chlorosulfonyl)-4-ethylbenzoic acid: 4-Ethylbenzoic acid (7 g, 46.6 mmol) in chlorosulfonic acid (20 mL, 299 mmol) was heated at 100° C. for 5 hours. The mixture was cooled and carefully added to stirring ice-water (200 mL). The precipitated solid was collected by filtration, washed with water (100 mL), and evaporated to dryness in vacuo to give the title compound (10.9 g, 41.5 mmol, 89% yield, 95% purity) as a white solid. 1 H NMR(500MHz,DMSO-d6)δ13.65(br s,1H), 8.34(d,J=1.9Hz,1H), 7.82(dd,J=7.9,2.0Hz,1H), 7.32(d,J=7.9Hz,1H), 3.08(q,J=7.5Hz,2H), 1.18(t,J=7.5Hz,3H).
[0543] Step 2: Methyl 3-(chlorosulfonyl)-4-ethylbenzoate: Thionyl chloride (10 ml, 137 mmol) was added portionwise to the product from Step 1 above (4 g, 16.1 mmol) at room temperature. The mixture was heated to 75 °C for 2 hours, cooled to room temperature, concentrated in vacuo, and azeotroped with toluene. The solid was dissolved in DCM (10 ml), treated with MeOH (0.716 ml, 17.7 mmol) followed by EtN (2.41 ml, 17.7 mmol), and stirred at room temperature overnight. The mixture was diluted with DCM (50 ml), washed with water (50 ml), dried (MgSO), and concentrated in vacuo. The crude product was purified by silica gel chromatography (40 g cartridge, 0–50% EtOAc / isohexane) to afford the title compound (3.60 g, 13.02 mmol, 81% yield, 95% purity) as a white solid. 1 H NMR(500MHz,DMSO-d6)δ8.74(d,J=1.8Hz,1H), 8.32(dd,J=8.0,1.8Hz,1H), 7. 61(d,J=8.0Hz,1H), 3.99(s,3H), 3.28(q,J=7.5Hz,2H), 1.41(t,J=7.5Hz,3H).
[0544] Step 3: Methyl 3-(N-(2-(4,4-difluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-ethylbenzoate: Pyridine (0.069 ml, 0.856 mmol) was added to a solution of the product from Step 2 of Example 12 (0.08 g, 0.285 mmol) and the product from Step 2 above (0.094 g, 0.357 mmol) in DCM (10 ml), and the solution was stirred at room temperature for 18 hours. The solution was concentrated in vacuo, and the crude product was purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to give the title compound (0.137 g, 0.227 mmol, 80% yield, 84% purity) as a white solid. UPLC-MS (Method 1) m / z 507.4 (M+H) at 1.90 min + , 505.2(MH) - .
[0545] Step 4: 3-(N-(2-(4,4-Difluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-ethylbenzoic acid: 1M LiOH(aq) (1.35 ml, 1.35 mmol) was added to a solution of the product from Step 3 above (0.137 g, 0.225 mmol) in THF (6 ml) and MeOH (1.3 ml), and the solution was stirred at room temperature overnight. The solvent was removed in vacuo, and the residue was dissolved in water (5 ml) and washed with TBME (3 x 5 ml). The aqueous phase was acidified with conc. HCl and extracted with TBME (3 x 10 ml). The organic phases were combined, dried by passing through a phase separator, and the solvent was removed in vacuo to give the title compound (0.105 g, 0.209 mmol, 93% yield, 98% purity) as an off-white solid. UPLC-MS (method 1) m / z 493.3 (M+H) at 1.76 min + , 490.9(MH) - . 1H NMR(500MHz,DMSO-d6)δ13.31(s,1H), 9.85(s,1H), 8.37(d,J=1.8Hz,1H), 8.10(dd,J=8.0,1.8Hz,1H), 7.61(d,J=8.0Hz,1H), 7. 44(dd,J=8.5,2.1Hz,1H), 7.36~7.31(m,2H), 3.03(q,J=7.4Hz,2H), 2.89~2.80(m,4H), 2.13~2.00(m,4H), 1.18(t,J=7.4Hz,3H). [Example 204]
[0546] 3-(N-(2-(3,3-difluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-ethylbenzoic acid [ka]
[0547] Step 1: Methyl 3-(N-(2-(3,3-difluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-ethylbenzoate: Pyridine (0.052 ml, 0.642 mmol) was added to a solution of the product from Step 2 of Example 9 (60 mg, 0.214 mmol) and the product from Step 2 of Example 203 (70 mg, 0.268 mmol) in DCM (10 ml). The solution was stirred at room temperature for 18 hours and then concentrated in vacuo. The crude product was purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to give the title compound (0.057 g, 0.113 mmol, 52.6% yield, 100% purity) as a white solid. UPLC-MS (Method 1) m / z 507.7 (M+H) at 1.89 min + , 505.2(MH) - .
[0548] Step 2: 3-(N-(2-(3,3-Difluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-ethylbenzoic acid: 1M LiOH(aq) (0.675 ml, 0.675 mmol) was added to a solution of the product from Step 1 above (0.057 g, 0.113 mmol) in THF (8 ml) and MeOH (2 ml). The solution was stirred at room temperature overnight and then concentrated in vacuo. The residue was dissolved in water (5 ml) and washed with TBME (3 x 5 ml). The aqueous phase was acidified with conc. HCl and extracted with TBME (3 x 10 ml). The organic phases were combined, dried by passing through a phase separator, and concentrated in vacuo to give the title compound (0.056 g, 0.110 mmol, 98% yield, 97% purity) as an off-white solid. UPLC-MS (method 1) m / z 493.7 (M+H) at 1.74 min + , 491.1(MH) - . 1 H NMR(500MHz,DMSO-d6)δ13.30(s,1H), 9.30(s,1H), 8.35(d,J=1.8Hz,1H), 8.11(d d,J=8.0,1.8Hz,1H), 7.62(d,J=8.0Hz,1H), 7.45(dd,J=8.5,2.1Hz,1H), 7.33(d, J=8.5Hz,1H), 7.12(d,J=2.1Hz,1H), 3.21(t,J=11.4Hz,2H), 3.00(q,J=7.4Hz,2H ), 2.98~2.94(m,2H), 2.08~1.96(m,2H), 1.84~1.75(m,2H), 1.19(t,J=7.4Hz,3H). [Example 205]
[0549] 4-Ethyl-3-(N-(2-(4-fluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid [ka]
[0550] Step 1: 4-Fluoro-1-(2-nitro-4-(trifluoromethyl)phenyl)piperidine: EtN (500 μL, 3.59 mmol) was added to a solution of 1-fluoro-2-nitro-4-(trifluoromethyl)benzene (201 μL, 1.44 mmol) and 4-fluoropiperidine (192 mg, 1.87 mmol) in DCM (6 mL), and the resulting solution was stirred at room temperature for 3 days. 1 M HCl (aq) (2 mL) was added, and the organic phase was separated by passing through a phase separator. The organic phase was concentrated in vacuo to give the title compound (419 mg, 1.44 mmol, 100% yield, 100% purity) as a pale yellow viscous oil. UPLC-MS (Method 2) m / z 293.3 (M+H) at 1.62 min + .
[0551] Step 2: 2-(4-Fluoropiperidin-1-yl)-5-(trifluoromethyl)aniline: The product from Step 1 above (419 mg, 1.44 mmol) was dissolved in EtOH (28.8 ml), and the reaction mixture was hydrogenated in a Thales Nano H-cube® flow reactor (10% Pd / C, 30 × 4 mm, full hydrogen mode, 40 °C, flow rate 1 ml / min, 2-flow). The reaction mixture was concentrated in vacuo and azeotroped with MeOH (6 ml) to give the title compound (371 mg, 1.27 mmol, 89% yield, 90% purity) as a clear, viscous oil. UPLC-MS (Method 2) m / z 263.3 (M+H) at 1.59 min. + .
[0552] Step 3: Methyl 4-ethyl-3-(N-(2-(4-fluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoate: The product from Step 2 above (66.5 mg, 0.254 mmol) was dissolved in a mixture of DCM (1 mL) and pyridine (82 μL, 1.02 mmol) and treated with a suspension of the product from Step 2 of Example 203 (80 mg, 0.305 mmol) in DCM (1 mL). The resulting solution was stirred at room temperature for 20 hours. The reaction mixture was directly purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to afford the title compound (61 mg, 0.112 mmol, 44.3% yield, 90% purity) as a cream-colored solid. UPLC-MS (Method 1) m / z 489.3 (M+H) at 1.87 min + , 487.2(MH) - .
[0553] Step 4: 4-Ethyl-3-(N-(2-(4-fluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid: The product from Step 3 above (59 mg, 0.121 mmol) was dissolved in THF (2 ml) and treated with 1.1 M LiOH(aq) (439 μl, 0.483 mmol). MeOH was added dropwise to give a solution which was stirred at 30° C. for 20 hours. The reaction mixture was diluted with water (3 ml) and concentrated in vacuo, and the resulting aqueous solution was diluted with water (to ∼5 ml). The aqueous phase was washed with EtOAc (2 × 5 ml) and neutralized to ∼pH 6 with 1 M HCl. The chunky suspension was sonicated to give a cloudy solution which was concentrated in vacuo to ∼2 ml. The resulting precipitate was collected by filtration and washed with water (2 × 2 ml). The solid was suspended in MeCN (4 ml), concentrated in vacuo, and dried at 45° C. to give the title compound (38.4 mg, 0.078 mmol, 64.3% yield, 96% purity) as a white solid. UPLC-MS (Method 1) m / z 475.4 (M+H) at 1.74 min + , 473.2(MH) - . 1H NMR (500MHz, DMSO-d6) δ13.29 (br s, 1H), 9.68 (br s,1H), 8.34(d,J=1.8Hz,1H), 8.09(dd,J=8.0,1.8Hz,1H), 7.61(d,J=8.0Hz,1H), 7.46~7.40(m,1H), 7.31~7.24(m,2H), 4.85~4.70( m,1H), 3.03(q,J=7.4Hz,2H), 2.89(t,J=9.9Hz,2H), 2.74~2.67(m,2H), 2.00~1.87(m,2H), 1.85~1.73(m,2H), 1.19(t,J=7.4Hz,3H). [Example 206]
[0554] 3-(N-(2-(4-fluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid [ka]
[0555] Step 1: Methyl 3-(N-(2-(4-fluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoate: The product from Step 2 of Example 205 (66.1 mg, 0.252 mmol) was dissolved in a mixture of DCM (1 mL) and pyridine (81 μL, 1.01 mmol) and treated with a solution of methyl 3-(chlorosulfonyl)-4-methoxybenzoate (80 mg, 0.302 mmol) in DCM (1 mL). The resulting solution was stirred at room temperature for 20 h. The reaction mixture was directly purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to afford the title compound (88 mg, 0.161 mmol, 64.1% yield, 90% purity) as a cream-colored sticky solid. UPLC-MS (Method 1) m / z 491.4 (M+H) at 1.73 min + , 489.1(MH) - .
[0556] Step 2: 3-(N-(2-(4-Fluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid: The product from Step 1 above (86 mg, 0.175 mmol) was dissolved in THF (2 ml) and treated with 1.1 M LiOH(aq) (638 μl, 0.701 mmol). MeOH was added dropwise to give a solution which was stirred at 30° C. for 20 hours. The reaction mixture was diluted with water (3 ml) and concentrated in vacuo, and the resulting aqueous solution was diluted with water (to ∼5 ml). The aqueous phase was washed with EtOAc (2 × 5 ml) and neutralized to ∼pH 6 with 1 M HCl. The chunky suspension was sonicated to give a cloudy solution which was concentrated in vacuo to ∼2 ml. The resulting precipitate was collected by filtration and washed with water (2 × 2 ml). The solid was suspended in MeCN (4 ml), concentrated in vacuo, and dried at 45° C. to give the title compound (52.7 mg, 0.108 mmol, 61.8% yield, 98% purity) as a white solid. UPLC-MS (Method 1) m / z 477.3 (M+H) at 1.56 min + , 475.1(MH) - . 1 H NMR (500MHz, DMSO-d6) δ13.16 (br s, 1H), 9.00 (br s,1H), 8.35(d,J=2.2Hz,1H), 8.16(dd,J=8.7,2.2Hz,1H), 7.44(d,J=2.0Hz,1H), 7.40~7.29(m,3H), 4.93~ 4.75(m,1H), 3.90(s,3H), 2.94(t,J=9.8Hz,2H), 2.79~2.73(m,2H), 2.10~1.94(m,2H), 1.93~1.79(m,2H). [Example 207]
[0557] 4-Methoxy-3-(N-(5-(methylsulfonyl)-2-(piperidin-1-yl)phenyl)sulfamoyl)benzoic acid [ka]
[0558] Step 1: 1-(4-(methylsulfonyl)-2-nitrophenyl)piperidine: EtN (0.795 ml, 5.70 mmol) was added to a solution of 1-fluoro-4-(methylsulfonyl)-2-nitrobenzene (500 mg, 2.28 mmol) and piperidine (0.226 ml, 2.28 mmol) in DCM (6 ml) at room temperature. The clear solution was stirred at room temperature for 23 hours. The organic phase was washed with 1 M HCl (aq) (3 ml), dried by passing through a phase separator, and concentrated in vacuo to give the title compound (0.676 g, 2.28 mmol, 100% yield, 100% purity) as a brown oil. UPLC-MS (Method 1) m / z 285.2 (M+H) at 1.32 min + .
[0559] Step 2: 5-(methylsulfonyl)-2-(piperidin-1-yl)aniline: The product from Step 1 above (0.676 g, 2.38 mmol) was dissolved in EtOH (44 ml), and the reaction mixture was hydrogenated in a Thales Nano H-cube® flow reactor (10% Pd / C, 30 × 4 mm, full hydrogen mode, RT, flow rate 1 ml / min, 1 flow path). The reaction mixture was concentrated in vacuo and then azeotroped with MeOH (12 ml) to give the title compound (0.615 g, 2.370 mmol, 100% yield, 98% purity) as a pale yellow oil. UPLC-MS (Method 1) m / z 255.3 (M+H) at 1.20 min. + .
[0560] Step 3: Methyl 4-methoxy-3-(N-(5-(methylsulfonyl)-2-(piperidin-1-yl)phenyl)sulfamoyl)benzoate: Pyridine (0.143 ml, 1.77 mmol) was added to a solution of the product from Step 2 above (0.15 g, 0.590 mmol) and methyl 3-(chlorosulfonyl)-4-methoxybenzoate (0.195 g, 0.737 mmol) in DCM (10 ml). The resulting solution was stirred at room temperature for 18 hours. The solution was concentrated in vacuo, and the crude product was purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to give the title compound (0.201 g, 0.412 mmol, 69.9% yield, 99% purity) as a white solid. UPLC-MS (Method 1) m / z 483.3 (M+H) at 1.49 min. + , 481.0(MH) - .
[0561] Step 4: 4-Methoxy-3-(N-(5-(methylsulfonyl)-2-(piperidin-1-yl)phenyl)sulfamoyl)benzoic acid: 1M LiOH(aq) (2.47 ml, 2.47 mmol) was added to a solution of the product from Step 3 above (0.199 g, 0.412 mmol) in THF (10 ml) and MeOH (2.5 ml) and the solution was stirred at room temperature overnight. The solvent was removed in vacuo and the residue was dissolved in water (5 ml) and washed with TBME (3 x 5 ml). The aqueous phase was acidified with conc. HCl and extracted with TBME (3 x 10 ml). The organic phases were combined and dried by passing through a phase separator. The solvent was removed in vacuo to give the title compound (0.176 g, 0.372 mmol, 90% yield, 99% purity) as an off-white solid. UPLC-MS (method 1) m / z 469.4 (M+H) at 1.36 min + , 467.0(MH) - . 1H NMR(500MHz,DMSO-d6)δ13.17(s,1H), 8.82(s,1H), 8.35(d,J=2.2Hz,1H), 8.15(dd,J=8.7,2.2Hz,1H), 7.65(d,J=2.2Hz,1H), 7.55(dd,J=8.4 ,2.2Hz,1H), 7.34(d,J=8.4Hz,1H), 7.33(d,J=8.7Hz,1H), 3.94(s,3H) , 3.00(s,3H), 2.85~2.78(m,4H), 1.71~1.60(m,4H), 1.58~1.50(m,2H). [Example 208]
[0562] (R)-3-(N-(2-(3-fluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid [ka]
[0563] Step 1: (R)-3-Fluoro-1-(2-nitro-4-(trifluoromethyl)phenyl)piperidine: EtN (500 μl, 3.59 mmol) was added to a solution of 1-fluoro-2-nitro-4-(trifluoromethyl)benzene (300 mg, 1.44 mmol) and (R)-3-fluoropiperidine (250 mg, 2.42 mmol) in DCM (6 ml). The resulting solution was stirred at room temperature for 20 hours. 1 M HCl (aq) (2 ml) was added and the organic phase was separated by passing through a phase separator. The organic phase was concentrated in vacuo to give the title compound (488 mg, 1.44 mmol, 100% yield, 86% purity) as a pale orange viscous oil. UPLC-MS (Method 2) m / z 293.0 (M+H) at 1.59 min + .
[0564] Step 2: (R)-2-(3-fluoropiperidin-1-yl)-5-(trifluoromethyl)aniline: The product from Step 1 above (419 mg, 1.44 mmol) was dissolved in EtOH (28.8 ml), and the reaction mixture was hydrogenated in a Thales Nano H-cube® flow reactor (10% Pd / C, 30 × 4 mm, full hydrogen mode, 40 °C, flow rate 1 ml / min, 2-flow). The reaction mixture was concentrated in vacuo and azeotroped with MeOH (6 ml) to give the title compound (457 mg, 1.394 mmol, 97% yield, 80% purity) as a cream-colored gel. UPLC-MS (Method 2) m / z 263.3 (M+H) at 1.59 min. + .
[0565] Step 3: (R)-Methyl 3-(N-(2-(3-fluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoate: The product from Step 3 above (66.1 mg, 0.252 mmol) was dissolved in a mixture of DCM (1 mL) and pyridine (81 μL, 1.01 mmol) and treated with a solution of methyl 3-(chlorosulfonyl)-4-methoxybenzoate (80 mg, 0.302 mmol) in DCM (1 mL). The resulting solution was stirred at room temperature for 3 days. The reaction mixture was directly purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to afford the title compound (72.4 mg, 0.118 mmol, 46.9% yield, 80% purity) as an off-white solid. UPLC-MS (Method 1) m / z 491.3 (M+H) at 1.73 min + , 489.1(MH) - .
[0566] Step 4: (R)-3-(N-(2-(3-fluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid: The product from Step 3 above (69 mg, 0.141 mmol) was dissolved in THF (2 ml) and treated with 1.1 M LiOH(aq) (512 μl, 0.563 mmol). MeOH was added dropwise to give a solution which was stirred at 30° C. for 20 hours. The reaction mixture was diluted with water (3 ml), concentrated in vacuo and the resulting aqueous solution was diluted with water (to ∼5 ml). The aqueous phase was washed with EtOAc (2 × 5 ml) and neutralized to ∼pH 6 with 1 M HCl. The chunky suspension was sonicated to give a cloudy solution which was concentrated in vacuo to ∼2 ml. The precipitate was collected by filtration and washed with water (2 × 2 ml). The solid was suspended in MeCN (4 ml), concentrated in vacuo, and dried at 45° C. to give the title compound (55.2 mg, 0.110 mmol, 78% yield) as a white solid. UPLC-MS (Method 1) m / z 477.4 (M+H) at 1.57 min + , 475.1(MH) - . 1 H NMR (500MHz, DMSO-d6) δ13.19 (br s, 1H), 8.75 (br s,1H), 8.38(d,J=2.2Hz,1H), 8.16(dd,J=8.7,2.2Hz,1H), 7.44(s,1H), 7.38~7.33(m,2H), 7.31(d,J=8.8Hz,1H) ), 4.95~4.79(m,1H), 3.91(s,3H), 3.09~2.86(m,3H), 2.85~2.75(m,1H), 1.95~1.75(m,3H), 1.74~1.63(m,1H). [Example 209]
[0567] (S)-3-(N-(2-(3-fluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid [ka]
[0568] Step 1: (S)-3-Fluoro-1-(2-nitro-4-(trifluoromethyl)phenyl)piperidine: EtN (500 μL, 3.59 mmol) was added to a solution of 1-fluoro-2-nitro-4-(trifluoromethyl)benzene (300 mg, 1.44 mmol) and (S)-3-fluoropiperidine (250 mg, 2.42 mmol) in DCM (6 mL), and the resulting solution was stirred at room temperature for 20 hours. 1M HCl (aq) (2 mL) was added, and the organic phase was separated and concentrated in vacuo to give the title compound (461 mg, 1.44 mmol, 100% yield, 91% purity) as a pale orange viscous oil. UPLC-MS (Method 2) m / z 1.293.1 (M+H) at 60 min. + .
[0569] Step 2: (S)-2-(3-fluoropiperidin-1-yl)-5-(trifluoromethyl)aniline: The product from Step 1 above (419 mg, 1.44 mmol) was dissolved in EtOH (28.8 ml). The reaction mixture was hydrogenated in a Thales Nano H-cube® flow reactor (10% Pd / C, 30 × 4 mm, full hydrogen mode, 40 °C, flow rate 1 ml / min, 2 flows). The reaction mixture was concentrated in vacuo and azeotroped with MeOH (6 ml) to give the title compound (475 mg, 1.43 mmol, 100% yield, 79% purity) as a cream-colored gel. UPLC-MS (Method 2) m / z 263.3 (M+H) at 1.59 min. + .
[0570] Step 3: (S)-Methyl 3-(N-(2-(3-fluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoate: The product from Step 2 above (66.1 mg, 0.252 mmol) was dissolved in a mixture of DCM (1 mL) and pyridine (81 μL, 1.01 mmol) and treated with a solution of methyl 3-(chlorosulfonyl)-4-methoxybenzoate (80 mg, 0.302 mmol) in DCM (1 mL). The resulting solution was stirred at room temperature for 3 days. The reaction mixture was directly purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to afford the title compound (81.4 mg, 0.133 mmol, 52.7% yield, 80% purity) as an off-white solid. UPLC-MS (Method 1) m / z 491.4 (M+H) at 1.74 min. + , 489.3(MH) - .
[0571] Step 4: (S)-3-(N-(2-(3-fluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)-4-methoxybenzoic acid: The product from Step 3 above (78 mg, 0.159 mmol) was dissolved in THF (2 ml) and treated with 1.1 M LiOH(aq) (578 μl, 0.636 mmol). MeOH was added dropwise to give a solution which was stirred at 30° C. for 20 hours. The reaction mixture was diluted with water (3 ml) and concentrated in vacuo and the resulting aqueous solution was diluted with water (to ∼5 ml). This was washed with EtOAc (2 × 5 ml) and neutralized to ∼pH 6 with 1 M HCl. The chunky suspension was sonicated to give a cloudy solution which was concentrated in vacuo to ∼2 ml. The precipitate was collected by filtration and washed with water (2 × 2 ml). The solid was suspended in MeCN (4 ml), concentrated in vacuo, and dried at 45° C. to give the title compound (55.2 mg, 0.110 mmol, 69.2% yield, 95% purity) as a white solid. UPLC-MS (Method 1) m / z 477.3 (M+H) at 1.57 min + , 475.2(MH) - . 1H NMR (500MHz, DMSO-d6) δ13.18 (br s, 1H), 8.74 (br s,1H), 8.37(d,J=2.2Hz,1H), 8.15(dd,J=8.7,2.2Hz,1H), 7.44(s,1H), 7.39~7.27(m,3H), 4.95~4. 79(m,1H), 3.91(s,3H), 3.08~2.86(m,3H), 2.83~2.76(m,1H), 1.95~1.75(m,3H), 1.74~1.63(m,1H). [Example 210]
[0572] (S)-4-Ethyl-3-(N-(2-(3-fluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid [ka]
[0573] Step 1: (S)-Methyl 4-ethyl-3-(N-(2-(3-fluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoate: The product from Step 2 of Example 209 (67 mg, 0.255 mmol) was dissolved in a mixture of DCM (1 mL) and pyridine (83 μL, 1.02 mmol) and treated with a suspension of the product from Step 2 of Example 203 (124 mg, 0.307 mmol) in DCM (1 mL). The resulting solution was stirred at room temperature for 3 days. The reaction mixture was directly purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to afford the title compound (65.9 mg, 0.108 mmol, 42.2% yield, 80% purity) as an off-white solid. UPLC-MS (Method 1) m / z 489.4 (M+H) at 1.89 min + , 487.2(MH) - .
[0574] Step 2: (S)-4-Ethyl-3-(N-(2-(3-fluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid: The product from Step 1 above (63 mg, 0.129 mmol) was dissolved in THF (2 ml) and treated with 1.1 M LiOH(aq) (469 μl, 0.516 mmol). MeOH was added dropwise to give a solution which was stirred at 30° C. for 20 h. The reaction mixture was diluted with water (3 ml) and concentrated in vacuo, and the resulting aqueous solution was diluted with water (to ∼5 ml). The aqueous phase was washed with EtOAc (2 × 5 ml) and neutralized to ∼pH 6 with 1 M HCl. The chunky suspension was sonicated to give a cloudy solution which was concentrated in vacuo to ∼2 ml. The precipitate was collected by filtration and washed with water (2 × 2 ml). The solid was suspended in MeCN (4 ml), concentrated in vacuo, and dried at 45° C. to give the title compound (35.9 mg, 0.072 mmol, 55.7% yield) as a cream-colored solid. UPLC-MS (Method 1) m / z 475.3 (M+H) at 1.74 min + , 473.2(MH) - . 1 H NMR (500MHz, DMSO-d6) δ13.31 (br s, 1H), 9.36 (br s,1H), 8.36(d,J=1.8Hz,1H), 8.09(dd,J=8.0,1.8Hz,1H), 7.61(d,J=8.1 Hz,1H), 7.42(dd,J=8.4,2.1Hz,1H), 7.33~7.24(m,2H), 1.98~1.85(m,1H) , 3.13~2.97(m,3H), 2.89~2.79(m,2H), 2.71(td,J=8.1,4.0Hz,1H), 1.98~ 1.85(m,1H), 1.82~1.71(m,1H), 1.71~1.55(m,2H), 1.19(t,J=7.4Hz,3H). [Example 211]
[0575] (R)-4-Ethyl-3-(N-(2-(3-fluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid [ka]
[0576] Step 1: (R)-Methyl 4-ethyl-3-(N-(2-(3-fluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoate: The product from Step 2 of Example 208 (67 mg, 0.255 mmol) was dissolved in a mixture of DCM (1 mL) and pyridine (83 μL, 1.02 mmol) and treated with a suspension of the product from Step 2 of Example 203 (124 mg, 0.307 mmol) in DCM (1 mL). The resulting solution was stirred at room temperature for 3 days. The reaction mixture was directly purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to afford the title compound (76.7 mg, 0.126 mmol, 49.2% yield, 80% purity) as an off-white solid. UPLC-MS (Method 1) m / z 489.3 (M+H) at 1.89 min + , 487.2(MH) - .
[0577] Step 2: (R)-4-Ethyl-3-(N-(2-(3-fluoropiperidin-1-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid: The product from Step 1 above (74 mg, 0.151 mmol) was dissolved in THF (2 ml) and treated with 1.1 M LiOH(aq) (551 μl, 0.606 mmol). MeOH was added dropwise to give a solution which was stirred at 30° C. for 20 h. The reaction mixture was diluted with water (3 ml) and concentrated in vacuo, and the resulting aqueous solution was diluted with water (to ∼5 ml). The aqueous phase was washed with EtOAc (2 × 5 ml) and neutralized to ∼pH 6 with 1 M HCl. The chunky suspension was sonicated to give a cloudy solution which was concentrated in vacuo to ∼2 ml. The resulting precipitate was collected by filtration and washed with water (2 × 2 ml). The solid was suspended in MeCN (4 ml), concentrated in vacuo, and dried at 45° C. to give the title compound (43.5 mg, 0.087 mmol, 57.5% yield, 95% purity) as a cream-colored solid. UPLC-MS (Method 1) m / z 475.4 (M+H) at 1.74 min + , 473.2(MH) - . 1H NMR (500MHz, DMSO-d6) δ13.31 (br s, 1H), 9.36 (br s,1H), 8.36(d,J=1.8Hz,1H), 8.09(dd,J=8.0,1.8Hz,1H), 7.61(d,J=8.0Hz,1H), 7.45~7.38(m,1H), 7.33~7.25(m,2H), 4.84~4.68(m,1H) , 3.13~2.96(m,3H), 2.89~2.79(m,2H), 2.75~2.67(m,1H), 1.98~1.85(m,1H), 1.82~1.72(m,1H), 1.70~1.54(m,2H), 1.19(t,J=7.4Hz,3H). [Example 212]
[0578] 3-(N-(5-(difluoromethyl)-2-(piperidin-1-yl)phenyl)sulfamoyl)-4-methoxybenzoic acid [ka]
[0579] Synthesis of 3-(chlorosulfonyl)-4-methoxybenzoic acid 4-Methoxybenzoic acid (6.5 g, 42.7 mmol) was added portionwise to chlorosulfonic acid (30 mL, 448 mmol) at room temperature. The mixture was heated to 80° C. for 2 hours, then cooled to room temperature and carefully added to ice water (300 mL), followed by stirring for 1 hour. The solid was collected, washed with water (200 mL), and evaporated to dryness in vacuo to give the title compound (7.92 g, 30.0 mmol, 70.3% yield, 95% purity) as a white solid. 1 H NMR (500MHz, DMSO-d6) δ13.31(br s,1H), 8.30(d,J=2.3Hz,1H), 7.90(dd,J=8.6,2.4Hz,1H), 7.07(d,J=8.6Hz,1H), 3.83(s,3H).
[0580] Synthesis of 3-(N-(5-(difluoromethyl)-2-(piperidin-1-yl)phenyl)sulfamoyl)-4-methoxybenzoic acid Step 1: 1-(4-(difluoromethyl)-2-nitrophenyl)piperidine: EtN (547 μl, 3.92 mmol) was added to a solution of 4-(difluoromethyl)-1-fluoro-2-nitrobenzene (300 mg, 1.57 mmol) and piperidine (202 μl, 2.04 mmol) in DCM (6 ml), and the resulting solution was stirred at room temperature for 20 h. 1 M HCl (aq) (2 ml) was added, and the organic phase was separated by passing through a phase separator. The organic phase was concentrated in vacuo to give the title compound (402 mg, 1.57 mmol, 100% yield, 100% purity) as a yellow viscous oil. UPLC-MS (Method 1) m / z 257.3 (M+H) at 1.63 min + .
[0581] Step 2: 5-(Difluoromethyl)-2-(piperidin-1-yl)aniline: The product from Step 1 above (402 mg, 1.57 mmol) was dissolved in EtOH (14.4 ml). The reaction mixture was hydrogenated in a Thales Nano H-cube® flow reactor (10% Pd / C, 30 × 4 mm, full hydrogen mode, 40 °C, flow rate 1 ml / min, 2-flow). The reaction mixture was concentrated in vacuo and azeotroped with MeOH (6 ml) to give the title compound (324 mg, 1.403 mmol, 89% yield, 98% purity) as a pale yellow oil. UPLC-MS (Method 1) m / z 227.3 (M+H) at 1.58 min. + .
[0582] Step 3: 3-(N-(5-(Difluoromethyl)-2-(piperidin-1-yl)phenyl)sulfamoyl)-4-methoxybenzoic acid: The product from Step 2 above (60.2 mg, 0.266 mmol) was dissolved in a mixture of DCM (1 mL) and pyridine (86 μL, 1.06 mmol) and treated with a suspension of 3-(chlorosulfonyl)-4-methoxybenzoic acid (80 mg, 0.319 mmol) in DCM (1 mL). The resulting solution was stirred at room temperature for 20 hours. The reaction mixture was filtered and the filtrate was purified directly by silica gel chromatography (12 g cartridge, 100% isohexane followed by 0-100% 10% MeOH / isohexane in EtOAc). The crude product was purified by preparative HPLC (Waters, Acidic (0.1% formic acid), Acidic, Waters X-Select Prep-C18, 5 μm, 19 × 50 mm column, 35-65% MeCN in water) to give the title compound (18 mg, 0.040 mmol, 14.9% yield, 97% purity) as a white solid. UPLC-MS (Method 1) m / z 441.2 (M+H) at 1.57 min + , 439.1(MH) - . 1 H NMR (500MHz, DMSO-d6) δ13.15 (br s, 1H), 8.66 (br s,1H), 8.39(d,J=2.2Hz,1H), 8.14(dd,J=8.7,2.2Hz,1H), 7.42(s,1H), 7.30(d,J=8.9Hz,1H), 7.29(d,J=8.2Hz,1H),7. 18(d,J=8.2,1H), 6.89(t,J=55.9Hz,1H), 3.93(s,3H), 2.71(t,J=5.2Hz,4H), 1.67(p,J=5.5Hz,4H), 1.57~1.50(m,2H). [Example 213]
[0583] 3-(N-(5-(difluoromethyl)-2-(piperidin-1-yl)phenyl)sulfamoyl)-4-ethylbenzoic acid [ka]
[0584] Step 1: Methyl 3-(N-(5-(difluoromethyl)-2-(piperidin-1-yl)phenyl)sulfamoyl)-4-ethylbenzoate: The product of Step 2 of Example 212 (57.4 mg, 0.254 mmol) was dissolved in a mixture of DCM (1 mL) and pyridine (82 μL, 1.02 mmol) and treated with a suspension of the product of Step 2 of Example 203 (80 mg, 0.305 mmol) in DCM (1 mL). The resulting solution was stirred at room temperature for 20 hours. The reaction mixture was directly purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to afford the title compound (54 mg, 0.119 mmol, 47.0% yield, 100% purity) as a pale yellow solid. UPLC-MS (Method 1) m / z 453.4 (M+H) at 1.91 min. + , 451.1(MH) - .
[0585] Step 2: 3-(N-(5-(Difluoromethyl)-2-(piperidin-1-yl)phenyl)sulfamoyl)-4-ethylbenzoic acid: conc. HCl (2.2 ml, 72.4 mmol) was added to water (0.737 ml) and this solution was added to a solution of the product from Step 1 above (52 mg, 0.115 mmol) in dioxane (2.2 ml). The reaction mixture was heated at 50° C. for 2 days. The solution was concentrated in vacuo and the crude product was purified by silica gel chromatography (24 g cartridge, 0-100% 10% MeOH / pentane in EtOAc) to give the title compound (18 mg, 0.039 mmol, 33.9% yield, 95% purity) as a cream-colored solid. UPLC-MS (Method 1) m / z 439.4 (M+H) at 1.75 min + , 437.3(MH) - . 1H NMR (500MHz, DMSO-d6) δ13.28 (br s, 1H), 9.21 (br s,1H), 8.36(d,J=1.8Hz,1H), 8.07(dd,J=8.0,1.8Hz,1H), 7.59(d,J=8.1Hz,1H), 7.32~7.18(m,3H), 7.02~6.08 (m,1H), 3.03(q,J=7.4Hz,2H), 2.67~2.61(m,4H), 1.59~1.50(m,4H), 1.49~1.42(m,2H), 1.20(t,J=7.4Hz,3H). [Example 214]
[0586] 4-Methoxy-3-(N-(2-(piperidin-1-yl)-5-(1H-tetrazol-1-yl)phenyl)sulfamoyl)benzoic acid [ka]
[0587] Step 1: 1-(4-Fluoro-3-nitrophenyl)tetrazole: Trimethylsilyl azide (1.70 mL, 12.8 mmol) was added to 4-fluoro-3-nitroaniline (0.4 g, 2.56 mmol) and triethyl orthoformate (2.13 mL, 12.8 mmol) in acetic acid (9.97 mL) at 0 °C. The resulting mixture was stirred for 30 min, then heated to 80 °C over 1 h and stirred for 20 h. The solvent was removed in vacuo, and the crude product was purified by silica gel chromatography (12 g cartridge, 0–10% MeOH / DCM) to give the title compound (0.469 g, 2.220 mmol, 87% yield, 99% purity) as a white solid. UPLC-MS (Method 1) m / z 1.75 min, no ionization. 1 H NMR (500 MHz, CDCl) δ 9.16 (s, 1H), 8.50 (dd, J = 6.1, 2.8 Hz, 1H), 8.15–8.09 (m, 1H), 7.61 (apparent t, J = 9.4 Hz, 1H).
[0588] Step 2: 1-(2-Nitro-4-(1H-tetrazol-1-yl)phenyl)piperidine: EtN (0.781 ml, 5.61 mmol) was added to a solution of the product from Step 1 above (0.469 g, 2.24 mmol) and piperidine (0.266 ml, 2.69 mmol) in DCM (6 ml) at room temperature. The clear solution was stirred at room temperature for 23 hours. The organic phase was washed with 1 M HCl (aq) (3 ml), dried by passing through a phase separator, and concentrated in vacuo to give the title compound (0.609 g, 2.20 mmol, 98% yield, 99% purity) as a brown oil. UPLC-MS (Method 1) m / z 1.39 min. 1 H NMR(500MHz,CDCl3)δ8.98(s,1H), 8.12(d,J=2.7Hz,1H), 7.78(dd,J=9.0,2.7Hz,1 H), 7.27(d,J=9.0Hz,1H), 3.22~3.05(m,4H), 1.81~1.71(m,4H), 1.69~1.61(m,2H).
[0589] Step 3: 2-(piperidin-1-yl)-5-(1H-tetrazol-1-yl)aniline: The product from Step 2 (0.609 g, 2.22 mmol) was dissolved in EtOH (48 ml), and the reaction mixture was hydrogenated in a Thales Nano H-cube® flow reactor (10% Pd / C, 30 × 4 mm, full hydrogen mode, RT, flow rate 1 ml / min, 1 flow path). The reaction mixture was concentrated in vacuo and azeotroped with MeOH (12 ml) to give the title compound (0.531 g, 2.15 mmol, 97% yield, 99% purity) as a pale yellow oil. UPLC-MS (Method 1) m / z None 1.18 min. 1 H NMR(500MHz,DMSO-d6)δ9.91(s,1H), 7.14(d,J=2.5Hz,1H), 7.05(d,J=8.4Hz,1H), 6.98(dd ,J=8.3,2.6Hz,1H), 5.21(s,2H), 2.91~2.69(m,4H), 1.75~1.62(m,4H), 1.60~1.47(m,2H).
[0590] Step 4: Methyl 4-methoxy-3-(N-(2-(piperidin-1-yl)-5-(1H-tetrazol-1-yl)phenyl)sulfamoyl)benzoate: Pyridine (0.199 ml, 2.46 mmol) was added to a solution of the product from Step 3 above (200 mg, 0.819 mmol) and methyl 3-(chlorosulfonyl)-4-methoxybenzoate (260 mg, 0.982 mmol) in DCM (8 ml), and the solution was stirred at room temperature for 18 hours. The solution was concentrated in vacuo, and the crude product was purified by silica gel chromatography (12 g cartridge, 0-100% EtOAc / isohexane) to give the title compound (0.221 g, 0.468 mmol, 57.1% yield, 100% purity) as a white solid. UPLC-MS (Method 1) m / z 473.3 (M+H) at 1.52 min. + , 471.3(MH) - .
[0591] Step 5: 4-Methoxy-3-(N-(2-(piperidin-1-yl)-5-(1H-tetrazol-1-yl)phenyl)sulfamoyl)benzoic acid: 1M LiOH(aq) (2.81 ml, 2.81 mmol) was added to a solution of the product from Step 4 above (0.221 g, 0.468 mmol) in THF (11 ml) and MeOH (3 ml), and the solution was stirred at room temperature overnight. The solvent was removed in vacuo, and the residue was dissolved in water (5 ml) and washed with TBME (3 x 5 ml). The aqueous phase was acidified with conc. HCl and extracted with TBME (3 x 10 ml). The organic phases were combined, dried by passing through a phase separator, and the solvent was removed in vacuo to give the title compound (0.171 g, 0.369 mmol, 79% yield, 99% purity) as an off-white solid. UPLC-MS (method 1) m / z 1.459.3 (M+H) in 40 minutes + , 457.2(MH) - . 1H NMR(500MHz,DMSO-d6)δ13.16(s,1H), 9.95(s,1H), 8.83(s,1H), 8.41(d,J=2.2Hz,1H), 8.14(dd,J=8.7,2.2Hz,1H), 7.80(d,J=2.5Hz,1H), 7. 53(dd,J=8.6,2.5Hz,1H), 7.45(d,J=8.6Hz,1H), 7.33(d,J=8.8Hz,1H), 3.95(s,3H), 2.77~2.68(m,4H), 1.74~1.61(m,4H), 1.60~1.49(m,2H). [Example 215]
[0592] 3-(N-(5-cyano-2-(piperidin-1-yl)phenyl)sulfamoyl)-4-ethylb...
Claims
1. Formula (Ia) 【Chemistry 1】 (In the formula, The X-Y group is -NHSO 2 -or-SO 2 NH-; R 1 is H or alkyl; R 2 is selected from COOH and a tetrazolyl group; R 3 is selected from H, Cl and alkyl; R 4 is selected from H, Cl and F; R 5 is H, alkyl, alkynyl, alkenyl, haloalkyl, SO 2 - selected from alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R 6 is H; R 7 is CN, haloalkyl, Cl, F, SO 2 -Alkyl, SO 2 N.R. 13 R 14 , heteroaryl and alkyl, said heteroaryl group being optionally substituted with one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; R 8 is selected from H, alkyl, haloalkyl, and halo; R 9 is H, C 1 -C 3 - alkyl or halo; R 10 and R 11 together with the nitrogen to which they are attached form an azepanyl group, (a) the azepanyl group is substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, which may in turn be further substituted with one or more groups selected from halo, and alkyl, or (b) one or two carbons in the azepanyl group are replaced with a group selected from O, NH, S, and CO, the azepanyl group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, which may in turn be further substituted with one or more groups selected from halo and alkyl; or R 10 and R 11 taken together with the nitrogen to which they are attached form an azetidinyl, pyrrolidinyl, or piperidinyl group, (a) the azetidinyl, pyrrolidinyl, or piperidinyl group is substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl, and heteroaryl, which heteroaryl groups may in turn be further substituted with one or more groups selected from halo and alkyl, or (b) one or two carbons in the azetidinyl, pyrrolidinyl, or piperidinyl group are replaced with a group selected from NH, S, and CO; or R 10 and R 11 together with the nitrogen to which they are attached form an 8-, 9- or 10-membered bicyclic heterocycloalkyl group, where one or two carbons in the bicyclic heterocycloalkyl ring are optionally replaced with groups selected from O, NH, S and CO, said bicyclic heterocycloalkyl group being optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl; or R 10 and R 11 together with the nitrogen to which they are attached form a 6-12 membered bicyclic group containing spiro ring carbon atoms, in which one or two carbons are optionally replaced with a group selected from O, NH, S and CO, in which the bicyclic group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, or in which the bicyclic group is optionally fused to a 5 or 6 membered aryl or heteroaryl group; R 13 and R 14 are each independently H or alkyl, or a pharma- ceutically acceptable salt or hydrate thereof.
2. R 2 is COOH; X-Y is NH-SO 2 That is, R 5 is alkyl, alkynyl, alkenyl, haloalkyl, SO 2 - selected from alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R 7 is haloalkyl; A compound of formula (Ia) according to claim 1.
3. R 5 The compound of formula (Ia) according to claim 2, wherein is OMe.
4. R 7 But, CF 3 4. A compound of formula (Ia) according to claim 2 or 3, wherein
5. R 1 , R 3 , R 4 , R 6 , R 8 and R 9 The compound of formula (Ia) according to any one of claims 1 to 4, wherein all are H.
6. R 10 and R 11 together with the nitrogen to which they are attached, C 1-3 -Alkyl, CN, C 3-6 -Cycloalkyl, OH, C 1-3 -alkoxy, halo and CF 3 The compound of formula (Ia) according to any one of claims 1 to 5, which forms an azetidinyl group substituted with one or more groups selected from:
7. R 10 and R 11 together with the nitrogen to which they are attached, C 1-3 -Alkyl, CN, C 3-6 -Cycloalkyl, OH, C 1-3 -alkoxy, halo and CF 3 The compound of formula (Ia) according to any one of claims 1 to 5, which forms a pyrrolidinyl group substituted with one or more groups selected from:
8. R 10 and R 11 together with the nitrogen to which they are attached, C 1-3 -Alkyl, CN, C 3-6 -cycloalkyl, OH, C 1-3 -alkoxy, halo and CF 3 The compound of formula (Ia) according to any one of claims 1 to 5, which forms a piperidinyl group substituted with one or more groups selected from:
9. R 10 and R 11 together with the nitrogen to which they are attached form an 8-, 9- or 10-membered bicyclic heterocycloalkyl group, wherein one or two carbons in the bicyclic heterocycloalkyl ring are optionally replaced with a group selected from O, NH, S and CO, and wherein the bicyclic heterocycloalkyl group is optionally substituted with one or more groups selected from CN, alkyl, OH and halo; A compound of formula (Ia) according to any one of claims 1 to 5.
10. R 10 and R 11 together with the nitrogen to which they are attached form a piperidinyl group optionally substituted with one or more groups selected from alkyl, CN, OH and halo, wherein two non-adjacent ring carbons in said piperidinyl group are linked to each other via a two-carbon or three-carbon alkylene bridge; 10. A compound of formula (Ia) according to claim 9.
11. R 10 and R 11 together with the nitrogen to which they are attached form a 6-12 membered bicyclic group containing spiro ring carbon atoms, one carbon in the bicyclic group being optionally replaced by O, the bicyclic group being optionally substituted with one or more groups selected from CN, alkyl, halo and heteroaryl, or the bicyclic group being optionally fused to a 5 or 6 membered aryl or heteroaryl group; A compound of formula (Ia) according to any one of claims 1 to 5.
12. R 10 and R 11 together with the nitrogen to which they are attached form a 7-, 8- or 9-membered bicyclic group containing spiro ring carbon atoms, one carbon in the bicyclic group being replaced by O, and the bicyclic group being optionally substituted with one or more groups selected from CN, alkyl, halo and heteroaryl; 12. A compound of formula (Ia) according to claim 11.
13. N.R. 10 R 11 The following group: 【Chemistry 2】 or N.R. 10 R 11 The following group: 【Chemistry 3】 or N.R. 10 R 11 The following group: 【Chemistry 4】 Selected from: A compound of formula (Ia) according to any one of claims 1 to 5.
14. 【Chemical 5-1】 【Chemistry 5-2】 【Chemistry 5-3】 【Chemistry 5-4】 【Chemistry 5-5】 【Chemistry 5-6】 【Chemistry 5-7】 【Chemistry 5-8】 【Chemistry 5-9】 【Chemistry 5-10】 【Chemistry 5-11】 2. The compound of claim 1 selected from: and pharma- ceutically acceptable salts and hydrates thereof.
15. Formula (Id) 【Chemistry 6】 (In the formula, The X-Y group is -NHSO 2 -or-SO 2 NH-; R 1 is H or alkyl; R 2 is selected from COOH and a tetrazolyl group; R 3 is selected from H, Cl and alkyl; R 4 is selected from H, Cl and F; R 5 is an alkyl, alkenyl, alkynyl, haloalkyl, SO 2 - selected from alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R 6 is H; R 7 CN, SO 2 -Alkyl, SO 2 N.R. 13 R 14 or a heteroaryl group, said heteroaryl group being optionally substituted with one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl, and OH; R 8 is selected from H, alkyl, haloalkyl, and halo; R 9 is H, C 1 -C 3 - alkyl or halo; R 10 and R 11 together with the nitrogen to which they are attached form a 4-, 5-, 6- or 7-membered monocyclic heterocycloalkyl group, in which one or two carbons are optionally replaced with a group selected from O, NH, S and CO, which monocyclic heterocycloalkyl group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, which heteroaryl group may in turn be further substituted with one or more groups selected from halo and alkyl; or R 10 and R 11 together with the nitrogen to which they are attached form an 8-, 9- or 10-membered bicyclic heterocycloalkyl group, wherein one or two carbons in the bicyclic heterocycloalkyl ring are optionally replaced with groups selected from O, NH, S and CO, and wherein the bicyclic heterocycloalkyl group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl; or R 10 and R 11 together with the nitrogen to which they are attached form a 6-12 membered bicyclic group containing spiro ring carbon atoms, in which one or two carbons in the bicyclic group are optionally replaced with a group selected from O, NH, S and CO, said bicyclic group being optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, or said bicyclic group being optionally fused to a 5 or 6 membered aryl or heteroaryl group; R 13 and R 14 and each is H, or a pharma- ceutically acceptable salt or hydrate thereof.
16. R 10 and R 11 are taken together with the nitrogen to which they are attached to form a 6-membered monocyclic heterocycloalkyl group, one or two carbons in the monocyclic heterocycloalkyl group are optionally replaced with a group selected from O, NH, S and CO, the monocyclic heterocycloalkyl group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, the heteroaryl group in turn being optionally further substituted with one or more groups selected from halo and alkyl.
17. R 10 and R 11 together with the nitrogen to which they are attached form a piperidinyl group which may be substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, which heteroaryl groups may in turn be further substituted with one or more groups selected from halo and alkyl; 17. A compound according to claim 15 or 16.
18. R 10 and R 11 and together with the nitrogen to which they are attached form an unsubstituted piperidinyl group.
19. R 8 The compound according to any one of claims 15 to 18, wherein is selected from H, haloalkyl and Cl.
20. R 2 The compound according to any one of claims 15 to 19, wherein is COOH.
21. R 7 is a heteroaryl group selected from imidazolyl, pyrazolyl, pyrazinyl, pyrazidinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, tetrazolyl and triazolyl, each of which is optionally substituted with one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; The compound according to any one of claims 15 to 20.
22. R 7 is a heteroaryl group selected from 1H-pyrazol-5-yl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, oxazol-2-yl, 1H-1,2,3-triazol-4-yl, 1H-1,2,3-triazol-5-yl, thiazol-5-yl, 1H-1,2,3,4-tetrazol-4-yl, 2H-1,2,3,4-tetrazol-5-yl, isoxazol-4-yl, isoxazol-5-yl, isothiazol-5-yl, pyrazidin-3-yl, pyrazidin-4-yl, pyrazinyl and 1,3,4-oxadiazol-2-yl, each of which is optionally substituted by one or more substituents selected from Me, F, Cl, CN and MeO; 22. The compound of claim 21.
23. R 7 The compound according to any one of claims 15 to 20, wherein is CN.
24. The compound of formula (Id) 【Chemistry 7-1】 【Chemistry 7-2】 【Chemistry 7-3】 【Chemistry 7-4】 【Chemistry 7-5】 and pharma- ceutically acceptable salts and hydrates thereof.
25. Formula (Ib) 【Chemistry 8】 (In the formula, The X-Y group is -NHSO 2 -or-SO 2 NH-; R 1 is H or alkyl; R 2 is a tetrazolyl group; R 3 is selected from H, Cl and alkyl; R 4 is selected from H, Cl and F; R 5 is an alkyl, alkynyl, alkenyl, haloalkyl, SO 2 - selected from alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R 6 is H; R 7 is H, CN, haloalkyl, Cl, F, SO 2 -Alkyl, SO 2 N.R. 13 R 14 , heteroaryl and alkyl, said heteroaryl group being optionally substituted with one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; R 8 is selected from H, alkyl, haloalkyl, and halo; R 9 is H, C 1 -C 3 - alkyl or halo; R 10 and R 11 together with the nitrogen to which they are attached form a 4-, 5-, 6- or 7-membered monocyclic heterocycloalkyl group, in which one or two carbons are optionally replaced with a group selected from O, NH, S and CO, which monocyclic heterocycloalkyl group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, which heteroaryl group may in turn be further substituted with one or more groups selected from halo and alkyl; or R 10 and R 11 together with the nitrogen to which they are attached form an 8-, 9- or 10-membered bicyclic heterocycloalkyl group, wherein one or two carbons in the bicyclic heterocycloalkyl ring are optionally replaced with groups selected from O, NH, S and CO, and wherein the bicyclic heterocycloalkyl group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl; or R 10 and R 11 together with the nitrogen to which they are attached form a 6-12 membered bicyclic group containing spiro ring carbon atoms, in which one or two carbons are optionally replaced with a group selected from O, NH, S and CO, in which the bicyclic group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, or in which the bicyclic group is optionally fused to a 5 or 6 membered aryl or heteroaryl group; R 13 and R 14 are each independently H or alkyl, or a pharma- ceutically acceptable salt or hydrate thereof.
26. 【Chemical 9】 26. The compound of claim 25, wherein:
27. Formula (Ic) 【Chemistry 10】 (In the formula, X is SO 2 and Y is NH; R 1 is H or alkyl; R 2 is selected from COOH and a tetrazolyl group; R 3 is selected from H, Cl and alkyl; R 4 is selected from H, Cl and F; R 5 is H, alkyl, alkynyl, alkenyl, haloalkyl, SO 2 - selected from alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R 6 is H; R 7 is H, CN, haloalkyl, Cl, F, SO 2 -Alkyl, SO 2 N.R. 13 R 14 , heteroaryl and alkyl, said heteroaryl group being optionally substituted with one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; R 8 is selected from H, alkyl, haloalkyl, and halo; R 9 is H, C 1 -C 3 - alkyl or halo; R 10 is alkyl; R 11 is alkyl; or R 10 and R 11 together with the nitrogen to which they are attached form a 4-, 5-, 6- or 7-membered monocyclic heterocycloalkyl group, in which one or two carbons are optionally replaced with a group selected from O, NH, S and CO, which monocyclic heterocycloalkyl group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, which heteroaryl group may in turn be further substituted with one or more groups selected from halo and alkyl; or R 10 and R 11 together with the nitrogen to which they are attached form an 8-, 9- or 10-membered bicyclic heterocycloalkyl group, wherein one or two carbons in the bicyclic heterocycloalkyl ring are optionally replaced with groups selected from O, NH, S and CO, and wherein the bicyclic heterocycloalkyl group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl; or R 10 and R 11 together with the nitrogen to which they are attached form a 6-12 membered bicyclic group containing spiro ring carbon atoms, in which one or two carbons are optionally replaced with a group selected from O, NH, S and CO, in which the bicyclic group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, or in which the bicyclic group is optionally fused to a 5 or 6 membered aryl or heteroaryl group; R 13 and R 14 are each independently H or alkyl, or a pharma- ceutically acceptable salt or hydrate thereof.
28. 【Chemical 11】 and pharma- ceutically acceptable salts and hydrates thereof. The compound according to claim 1,
29. 【Chemical 12-1】 【Chemistry 12-2】 【Chemistry 12-3】 and pharma- ceutically acceptable salts and hydrates thereof.
30. A pharmaceutical composition comprising a compound according to any one of claims 1 to 29 in admixture with a pharma- ceutically acceptable diluent, excipient or carrier.
31. A compound according to any one of claims 1 to 29 for use in medicine.
32. 31. The pharmaceutical composition of claim 30, wherein the pharmaceutical composition is for use in the treatment or prevention of a disease selected from a proliferative disease, an immune disease, a viral disease and an inflammatory disease.
33. A compound of formula (I) in admixture with a pharma- ceutical acceptable diluent, excipient or carrier for use in the treatment or prophylaxis of a disease selected from a proliferative disease, an immune disease, a viral disease and an inflammatory disease in a subject. 【Chemistry 13】 (In the formula, The X-Y group is -NHSO 2 -or-SO 2 NH-; R 1 is H or alkyl; R 2 is selected from COOH and a tetrazolyl group; R 3 is selected from H, Cl and alkyl; R 4 is selected from H, Cl and F; R 5 is H, alkyl, alkynyl, alkenyl, haloalkyl, SO 2 - selected from alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R 6 is H; R 7 is H, CN, haloalkyl, Cl, F, SO 2 -Alkyl, SO 2 N.R. 13 R 14 , heteroaryl and alkyl, said heteroaryl group being optionally substituted with one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; R 8 is selected from H, alkyl, haloalkyl, and halo; R 9 is H, C 1 -C 3 - alkyl or halo; R 10 is alkyl; R 11 is alkyl; or R 10 and R 11 together with the nitrogen to which they are attached form a 4-, 5-, 6- or 7-membered monocyclic heterocycloalkyl group, in which one or two carbons are optionally replaced with a group selected from O, NH, S and CO, which monocyclic heterocycloalkyl group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, which heteroaryl group may in turn be further substituted with one or more groups selected from halo and alkyl; or R 10 and R 11 together with the nitrogen to which they are attached form an 8-, 9- or 10-membered bicyclic heterocycloalkyl group, wherein one or two carbons in the bicyclic heterocycloalkyl ring are optionally replaced with groups selected from O, NH, S and CO, and wherein the bicyclic heterocycloalkyl group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl; or R 10 and R 11 together with the nitrogen to which they are attached form a 6-12 membered bicyclic group containing spiro ring carbon atoms, in which one or two carbons are optionally replaced with a group selected from O, NH, S and CO, in which the bicyclic group is optionally substituted with one or more groups selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, or in which the bicyclic group is optionally fused to a 5 or 6 membered aryl or heteroaryl group; R 13 and R 14 are each independently H or alkyl, or a pharma- ceutically acceptable salt or hydrate thereof.
34. or a pharma- ceutically acceptable salt or hydrate thereof, 【Chemistry 14-1】 【Chemistry 14-2】 【Chemistry 14-3】 【Chemistry 14-4】 【Chemistry 14-5】 【Chemistry 14-6】 【Chemistry 14-7】 【Chemistry 14-8】 【Chemistry 14-9】 【Chemistry 14-10】 【Chemistry 14-11】 【Chemistry 14-12】 【Chemistry 14-13】 【Chemistry 14-14】 【Chemistry 14-15】 【Chemistry 14-16】 【Chemistry 14-17】 【Chemistry 14-18】 【Chemistry 14-19】 【Chemistry 14-20】 【Chemistry 14-21】 and pharma- ceutically acceptable salts and hydrates thereof.
35. The pharmaceutical composition according to any one of claims 32 to 34, wherein the disease is a proliferative disease and the pharmaceutical composition is for use in treating or preventing the proliferative disease.
36. 36. The pharmaceutical composition of claim 35, wherein the proliferative disease is cancer or leukemia.
37. the pharmaceutical composition kills cancer cells, reduces the number of proliferating cells in the cancer, reduces the volume or size of a tumor containing the cancer cells, and / or reduces the number of metastatic cancer cells; The pharmaceutical composition according to claim 35,
38. 38. The pharmaceutical composition of claim 37, wherein the pharmaceutical composition is used to prevent cancer.
39. 40. The pharmaceutical composition of claim 38, wherein the pharmaceutical composition induces an existing immune response in a subject to a neoantigen.
40. a pharmaceutical composition is used in a subject having or susceptible to developing cancer, said pharmaceutical composition comprising as a first compound a compound as defined in any of claims 1 to 29 or a compound comprised in a pharmaceutical composition as defined in claim 33 or 34, to stimulate a neoantigen-directed immune response in said subject, after which a second pharmaceutical composition comprising a second compound (which may be the same as or different from the compound of said pharmaceutical composition) is used to stimulate the same neoantigen as the first compound, thereby directing the immune response of said subject against said cancer; The pharmaceutical composition according to claim 39,
41. 41. The pharmaceutical composition of any one of claims 35 to 40, which is for a subject who has previously had cancer, has a family history of cancer, is at high risk of developing cancer, has a genetic predisposition to developing cancer, has been exposed to a carcinogen, and / or is in remission from cancer.
42. An in vitro method for producing an antigen-presenting cell that presents a neoantigen, the method comprising the step of inducing a neoantigen in the antigen-presenting cell by a compound described in any one of claims 1 to 29, 33 or 34.
43. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 29, or a compound contained in a pharmaceutical composition as defined in claim 33 or 34, for use in an in vivo method for producing an antigen-presenting cell that presents a neoantigen, said method comprising a step of inducing a neoantigen in said antigen-presenting cell by means of said pharmaceutical composition.
44. The method described in claim 42, wherein the antigen-presenting cell is a dendritic cell.
45. The pharmaceutical composition described in claim 43, wherein the antigen-presenting cell is a dendritic cell.
46. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 29, or a compound contained in a pharmaceutical composition as defined in claim 33 or 34, for use in a method for increasing the sensitivity of cancer cells to immunotherapy, wherein said pharmaceutical composition is used in combination with immunotherapy.
47. 47. The pharmaceutical composition of claim 46, wherein the subject has cancer and the compound increases the sensitivity of cancer cells to immunotherapy.
48. Immunotherapy is an immune checkpoint intervention.
48. A pharmaceutical composition according to claim 46 or 47.
49. 49. The pharmaceutical composition of claim 48, wherein the immune checkpoint intervention is an antibody checkpoint inhibitor.
50. The pharmaceutical composition of claim 49, wherein the antibody checkpoint inhibitor is an anti-PD-1 antibody, an anti-PD-L1 antibody, or an anti-CTLA4 antibody.
51. The pharmaceutical composition according to any one of claims 32 to 34, wherein the disease is an immune disease, and the pharmaceutical composition is for use in treating or preventing the disease.
52. 52. The pharmaceutical composition of claim 51, wherein the immune disease is a disease selected from ankylosing spondylitis, Behcet's disease, psoriasis, and scattershot retinochoroidopathy.
53. The pharmaceutical composition according to any one of claims 32 to 34, wherein the disease is an inflammatory disease, and the pharmaceutical composition is for use in treating or preventing the disease.
54. 54. The pharmaceutical composition of claim 53, wherein the inflammatory disease is an autoinflammatory disease.
55. The pharmaceutical composition according to any one of claims 32 to 34, wherein the disease is a viral disease, and the pharmaceutical composition is for use in treating or preventing an infectious viral disease selected from HIV, HPV, CMV and HCV.
56. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 29, or a compound contained in the pharmaceutical composition as defined in claim 33 or 34, for use in a method for increasing visibility of cancer cells to the immune system, wherein the disease is cancer, and the pharmaceutical composition increases the visibility of cancer cells to the immune system by altering the repertoire of antigens and neoantigens presented to the immune system.
57. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 29, or a compound contained in the pharmaceutical composition as defined in claim 33 or 34, for use in a method of increasing a CD8+ T cell response against cancer cells, wherein use of the pharmaceutical composition increases a CD8+ T cell response against cancer cells.
58. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 29, or a compound contained in a pharmaceutical composition as defined in claim 33 or 34, and a further active agent.
